{
  "Row_0_Col_Disease": {
    "original_text": "Non-Alcoholic Fatty Liver Disease",
    "annotated_entities": [
      {
        "text": "Liver",
        "label": "ORGAN",
        "start_char": 20,
        "end_char": 25,
        "color": "red"
      }
    ]
  },
  "Row_0_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_0_Col_Disease_Mechanism": {
    "original_text": "The provided research paper discusses the association between alterations in the gut microbiome and Non-Alcoholic Fatty Liver Disease (NAFLD) but does not delve into specific mechanisms or details regarding microbiome-induced immune modulation, metabolic disruptions, gut-organ crosstalk, or key bacterial species involved. \n\nThe excerpt mentions the reduction in microbial diversity and changes in the Firmicutes to Bacteroidetes ratio in obese individuals, implicating these alterations in the development of NAFLD. It also highlights the role of colonic bacteria in intestinal absorption and delivery to the liver via the portal vein. However, it lacks depth on specific pathways or cellular mechanisms, such as inflammatory mediators (e.g., TNF-\u03b1, IL-6) or any particular bacterial taxa that may contribute to disease progression.\n\nTherefore, since the necessary mechanistic information linking gut microbiome alterations to NAFLD is not sufficiently detailed in the provided text, I cannot generate a response that meets your criteria.",
    "annotated_entities": [
      {
        "text": "gut microbiome",
        "label": "ORGAN",
        "start_char": 81,
        "end_char": 95,
        "color": "purple"
      },
      {
        "text": "Non-Alcoholic",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 100,
        "end_char": 113,
        "color": "red"
      },
      {
        "text": "Liver",
        "label": "ORGAN",
        "start_char": 120,
        "end_char": 125,
        "color": "pink"
      },
      {
        "text": "Firmicutes",
        "label": "AMINO_ACID",
        "start_char": 403,
        "end_char": 413,
        "color": "blue"
      },
      {
        "text": "colonic bacteria",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 549,
        "end_char": 565,
        "color": "green"
      },
      {
        "text": "intestinal",
        "label": "ORGAN",
        "start_char": 569,
        "end_char": 579,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 611,
        "end_char": 616,
        "color": "pink"
      },
      {
        "text": "portal vein",
        "label": "TISSUE",
        "start_char": 625,
        "end_char": 636,
        "color": "green"
      },
      {
        "text": "cellular",
        "label": "CELL",
        "start_char": 686,
        "end_char": 694,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 899,
        "end_char": 902,
        "color": "orange"
      }
    ]
  },
  "Row_0_Col_Rifaximin Justification": {
    "original_text": "### Expert Analysis - Therapeutic Alignment and Repurposing Rationale for Rifaximin in Non-Alcoholic Fatty Liver Disease\n\n**1. Mechanistic Convergence**\n\nThe pathophysiological mechanisms implicated in Non-Alcoholic Fatty Liver Disease (NAFLD) involve alterations in the gut microbiome, characterized by reduced microbial diversity and an imbalanced Firmicutes-to-Bacteroidetes ratio. These changes contribute to dysregulated immune responses, characterized by elevated levels of pro-inflammatory cytokines such as TNF-\u03b1 and IL-6. These inflammatory mediators are central in the progression of NAFLD, promoting hepatic inflammation and fibrosis.\n\nRifaximin's mechanism of action includes:\n- **Reduction of Pro-Inflammatory Cytokines**: Rifaximin significantly lowers TNF-\u03b1, which is implicated in liver inflammation.\n- **Microbial Modulation**: It alters gut microbiota composition, selectively targeting ammonia-producing bacteria, which may indirectly contribute to the dysregulated immune environment seen in NAFLD.\n- **Impact on Gut-Brain Axis**: Rifaximin contributes to cognitive improvement through decreased systemic ammonia levels, which may be a factor in the systemic effects of NAFLD.\n\nThe mechanistic overlap is evident in that Rifaximin targets two critical pathways involved in NAFLD:\n- **Cytokine Modulation**: The substantial reduction of TNF-\u03b1 and other inflammatory markers by Rifaximin mirrors the inflammatory processes in NAFLD.\n- **Gut Microbiota Changes**: By promoting beneficial bacteria while suppressing pathogenic ones, Rifaximin helps restore a microbial balance that could be beneficial in the context of NAFLD, potentially affecting metabolic homeostasis.\n\nGiven these overlaps, Rifaximin presents a mechanism through which it could exert therapeutic effects against the inflammatory and microbiome-driven components of NAFLD. \n\n**2. Supporting Clinical or Preclinical Evidence**\n\nAlthough specific clinical studies linking Rifaximin directly to NAFLD outcomes are not detailed, its established effects on reducing ammonia levels and improving gut microbiota dynamically align with potential benefits for NAFLD. Rifaximin's impact in conditions like hepatic encephalopathy (HE) suggests that similar mechanisms could be leveraged in NAFLD, where systemic inflammation and altered gut health are evident.\n\nThe antimicrobial properties of Rifaximin and its ability to reduce levels of inflammation align with the potential to alleviate gut-derived factors that contribute to liver disease, illustrating a favorable response to Rifaximin in conditions of systemic inflammation stemming from gut dysbiosis.\n\n**3. Therapeutic Implications**\n\nRifaximin could offer partial therapeutic benefits for NAFLD through:\n- **Symptom Relief**: By improving gut health and reducing systemic inflammation, Rifaximin may alleviate some symptoms associated with NAFLD.\n- **Modulation of Gut-Brain Axis Dysfunction**: Its effects on neuroinflammation and cognitive function may also offer indirect benefits in patients with NAFLD suffering from stress-related gut disorders.\n\n**Limitations or Caveats**:\n- **Incomplete Pathway Targeting**: While Rifaximin addresses key inflammatory pathways, it may not fully target all pathogenetic pathways involved in NAFLD, necessitating combination therapy with agents that further address hepatic lipid accumulation and fibrosis.\n- **Need for Adjunct Therapies**: Patients with NAFLD may require lifestyle modifications and additional pharmacological agents targeting metabolic syndrome components for comprehensive management.\n\nIn conclusion, Rifaximin demonstrates a mechanistic and clinical rationale for potential repurposing in Non-Alcoholic Fatty Liver Disease, leveraging its antimicrobial, anti-inflammatory, and microbiota-modulating actions to address key pathological drivers associated with this condition.",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 74,
        "end_char": 83,
        "color": "teal"
      },
      {
        "text": "Non-Alcoholic Fatty Liver",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 87,
        "end_char": 112,
        "color": "blue"
      },
      {
        "text": "Non-Alcoholic Fatty Liver",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 202,
        "end_char": 227,
        "color": "blue"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 271,
        "end_char": 285,
        "color": "orange"
      },
      {
        "text": "TNF-\u03b1",
        "label": "CELL",
        "start_char": 515,
        "end_char": 520,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 611,
        "end_char": 618,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 647,
        "end_char": 656,
        "color": "teal"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 723,
        "end_char": 732,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 736,
        "end_char": 745,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 797,
        "end_char": 802,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 855,
        "end_char": 858,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1051,
        "end_char": 1060,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1241,
        "end_char": 1250,
        "color": "teal"
      },
      {
        "text": "TNF-\u03b1",
        "label": "CELL",
        "start_char": 1356,
        "end_char": 1361,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1396,
        "end_char": 1405,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1549,
        "end_char": 1558,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1711,
        "end_char": 1720,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1956,
        "end_char": 1965,
        "color": "teal"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2047,
        "end_char": 2054,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2076,
        "end_char": 2079,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2144,
        "end_char": 2153,
        "color": "teal"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 2182,
        "end_char": 2189,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2312,
        "end_char": 2315,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2369,
        "end_char": 2378,
        "color": "teal"
      },
      {
        "text": "gut-derived factors",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2466,
        "end_char": 2485,
        "color": "purple"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2505,
        "end_char": 2510,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2557,
        "end_char": 2566,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2620,
        "end_char": 2623,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2669,
        "end_char": 2678,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2774,
        "end_char": 2777,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2821,
        "end_char": 2830,
        "color": "teal"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3022,
        "end_char": 3030,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3072,
        "end_char": 3075,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3158,
        "end_char": 3167,
        "color": "teal"
      },
      {
        "text": "hepatic lipid",
        "label": "ORGAN",
        "start_char": 3341,
        "end_char": 3354,
        "color": "yellow"
      },
      {
        "text": "Patients",
        "label": "ORGANISM",
        "start_char": 3416,
        "end_char": 3424,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3596,
        "end_char": 3605,
        "color": "teal"
      },
      {
        "text": "Non-Alcoholic Fatty",
        "label": "ORGANISM",
        "start_char": 3685,
        "end_char": 3704,
        "color": "green"
      },
      {
        "text": "Liver",
        "label": "ORGAN",
        "start_char": 3705,
        "end_char": 3710,
        "color": "red"
      }
    ]
  },
  "Row_1_Col_Disease": {
    "original_text": "Male infertility",
    "annotated_entities": []
  },
  "Row_1_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_1_Col_Disease_Mechanism": {
    "original_text": "The research paper explores causal relationships between gut microbiota and male reproductive diseases, particularly male infertility, using Mendelian randomization (MR). It identifies specific gut bacteria associated with male infertility and abnormal spermatozoa, suggesting a significant connection between gut microbiome alterations and male reproductive health.\n\n### Key Mechanisms Linking Gut Microbiome Alterations to Male Infertility:\n\n1. **Microbiome Composition and Association with Fertility:**\n   - The study identifies **Eubacterium oxidoreducens** as being positively associated with an increased risk of male infertility (Odds Ratio [OR] 2.05), indicating it may contribute negatively to reproductive health.\n   - Conversely, the family **Bacteroidaceae** is negatively associated with male infertility (OR 0.34), suggesting a protective role. This signifies how certain gut microbiota can influence reproductive outcomes.\n\n2. **Influence on Sperm Quality:**\n   - The association of specific gut bacteria with abnormal spermatozoa was noted, with **Streptococcaceae** linked to a higher risk of sperm abnormalities (OR 2.54) and **Porphyromonadaceae** associated with a lower risk (OR 0.38). These findings suggest that microbial composition can directly affect sperm quality and fertility.\n\n3. **Immune Modulation and Inflammatory Pathways:**\n   - While the paper doesn\u2019t delineate specific immune pathways or mediators, it implies that gut microbiota may influence the immune environment and systemic inflammatory responses that are relevant to reproductive health.\n\n4. **Metabolic Changes:**\n   - The gut microbiota impacts metabolic pathways, influencing androgen metabolism and potentially affecting spermatogenesis. Changes in microbial metabolism could lead to the production or disruption of metabolites that directly affect male reproductive physiology.\n   - Additionally, some gut microbiota were noted to play roles in male fertility by modulating **serum levels of trimethylamine N-oxide (TMAO)**, which can lead to vascular inflammation and erectile dysfunction, suggesting a systemic effect stemming from gut microbiome alterations.\n\nOverall, the study highlights a **high correlation between gut flora and the likelihood of male reproductive diseases**, indicating that targeted microbial therapies could serve as potential interventions for male infertility. The findings propose that specific bacteria either promote or protect against infertility, and underline the need for further research into **mechanisms such as immune regulation and metabolic interactions** influenced by the gut microbiome that could impact male reproductive health.",
    "annotated_entities": [
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 57,
        "end_char": 60,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 194,
        "end_char": 197,
        "color": "red"
      },
      {
        "text": "spermatozoa",
        "label": "CELL",
        "start_char": 253,
        "end_char": 264,
        "color": "yellow"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 310,
        "end_char": 324,
        "color": "green"
      },
      {
        "text": "Gut Microbiome Alterations",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 395,
        "end_char": 421,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 886,
        "end_char": 889,
        "color": "red"
      },
      {
        "text": "Sperm",
        "label": "CELL",
        "start_char": 957,
        "end_char": 962,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1007,
        "end_char": 1010,
        "color": "red"
      },
      {
        "text": "spermatozoa",
        "label": "CELL",
        "start_char": 1034,
        "end_char": 1045,
        "color": "yellow"
      },
      {
        "text": "sperm",
        "label": "CELL",
        "start_char": 1110,
        "end_char": 1115,
        "color": "teal"
      },
      {
        "text": "sperm",
        "label": "CELL",
        "start_char": 1277,
        "end_char": 1282,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1453,
        "end_char": 1456,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1619,
        "end_char": 1622,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1902,
        "end_char": 1905,
        "color": "red"
      },
      {
        "text": "serum",
        "label": "ORGANISM_SUBSTANCE",
        "start_char": 1976,
        "end_char": 1981,
        "color": "orange"
      },
      {
        "text": "trimethylamine N-oxide",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1992,
        "end_char": 2014,
        "color": "red"
      },
      {
        "text": "TMAO",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2016,
        "end_char": 2020,
        "color": "pink"
      },
      {
        "text": "vascular",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 2043,
        "end_char": 2051,
        "color": "green"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 2134,
        "end_char": 2148,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2222,
        "end_char": 2225,
        "color": "red"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 2616,
        "end_char": 2630,
        "color": "green"
      }
    ]
  },
  "Row_1_Col_Rifaximin Justification": {
    "original_text": "### Expert Analysis - Therapeutic Alignment and Repurposing Rationale\n\n#### 1. Mechanistic Convergence\n\nThe intersection of Rifaximin's mechanisms and male infertility pathophysiology presents compelling potential for repurposing in this context.\n\n- **Influence on Microbiome Composition:**\n  Rifaximin modulates gut microbiota by selectively targeting ammonia-producing bacteria such as **Streptococcus salivarius** and enhancing beneficial species like **Lactobacillus** and **Ruminococcaceae**. This alteration in microbial diversity not only reduces pathogenic bacteria but also restores healthy microbial communities. Given that specific gut bacteria such as **Eubacterium oxidoreducens** are linked to increased infertility risk, and certain strains of **Bacteroidaceae** are protective, Rifaximin's ability to foster a healthier microbiome aligns directly with mechanisms that could improve male fertility outcomes.\n\n- **Immune Modulation:**\n  Rifaximin is known to reduce pro-inflammatory cytokines like TNF\u03b1, IL-1\u03b2, and IL-17, which are involved in systemic inflammation. In the context of male infertility, systemic inflammatory responses can adversely affect reproductive health. The decrease in these markers could potentially ameliorate adverse effects resulting from immune dysregulation and inflammation that contribute to infertility. If gut bacteria influence these inflammatory pathways, Rifaximin\u2019s impact on reducing inflammation represents a critical area of convergence.\n\n- **Metabolic Changes:**\n  Rifaximin has been shown to modulate metabolic pathways via its effects on gut microbiota. Altered gut microbiome function can affect androgen metabolism, which is crucial for spermatogenesis. By potentially influencing the levels of systemic metabolites, including trimethylamine N-oxide (TMAO), Rifaximin may help alleviate some reproductive dysfunctions associated with metabolic perturbations\u2014postulating a link between gut health and metabolic regulation of sexual health.\n\nIn summary, there is substantial mechanistic alignment between Rifaximin's modulation of gut microbiota, reduction of inflammatory markers, and the proposed inflammatory and metabolic pathways contributing to male infertility.\n\n#### 2. Supporting Clinical or Preclinical Evidence\n\nThe provided observations indicate that Rifaximin has beneficial effects in various gastrointestinal and hepatic disorders related to gut health, which may extend to male fertility:\n\n- Rifaximin's **reduction of inflammatory markers** such as TNF\u03b1, IL-1\u03b2, and IL-17 could help mitigate systemic inflammation that adversely affects fertility.\n- Its role in **modulating gut microbiota** suggests potential benefits in ameliorating conditions linked to male infertility, considering the identified correlations between specific gut bacteria composition and reproductive health.\n- The drug's effectiveness in **improving overall gut health** and metabolic processes may also suggest indirect benefits on spermatogenesis and associated functions.\n\nWhile direct studies on Rifaximin\u2019s impact on male infertility are not explicitly detailed, the promising results in gut-related health and inflammatory conditions provide a credible foundation for exploring this repurposing.\n\n#### 3. Therapeutic Implications\n\nBased on the available data, Rifaximin could offer a **partial therapeutic benefit** for male infertility:\n\n- **Symptom Relief:** By enhancing gut microbiome health and reducing systemic inflammation, Rifaximin may improve symptoms associated with infertility related to inflammatory and gut health issues.\n- **Modulation of Gut-Brain Axis Dysfunction:** Given its neuroprotective effects and reduction of neuroinflammation, Rifaximin could also positively impact mental well-being and cognitive aspects linked to the stress of infertility.\n- **Reduction in Systemic Inflammation:** The modulation of inflammatory cytokines strengthens the argument for its therapeutic potential in protecting against fertility-related inflammatory responses.\n\nHowever, potential **limitations or caveats** should be noted:\n\n- Rifaximin\u2019s targeted action may not address all underlying pathways or root causes of male infertility, indicating that it might be **incomplete** as a stand-alone therapy.\n- Further research is required to clearly delineate the exact mechanisms through which Rifaximin influences reproductive health, especially regarding long-term effects and effectiveness across diverse patient populations.\n\nIn conclusion, Rifaximin\u2019s established mechanistic overlap with the pathophysiological drivers of male infertility supports its potential repurposing for this condition. Its role in modifying gut health and systemic inflammation presents a promising avenue for alleviating some challenges associated with male reproductive health.",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 124,
        "end_char": 133,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 293,
        "end_char": 302,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 313,
        "end_char": 316,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 643,
        "end_char": 646,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 794,
        "end_char": 803,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 951,
        "end_char": 960,
        "color": "teal"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1029,
        "end_char": 1034,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1354,
        "end_char": 1357,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1415,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1521,
        "end_char": 1530,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1596,
        "end_char": 1599,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1620,
        "end_char": 1623,
        "color": "green"
      },
      {
        "text": "trimethylamine N-oxide",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1787,
        "end_char": 1809,
        "color": "green"
      },
      {
        "text": "TMAO",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1811,
        "end_char": 1815,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1818,
        "end_char": 1827,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1945,
        "end_char": 1948,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2063,
        "end_char": 2072,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2089,
        "end_char": 2092,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2321,
        "end_char": 2330,
        "color": "teal"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 2365,
        "end_char": 2381,
        "color": "red"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 2386,
        "end_char": 2393,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2415,
        "end_char": 2418,
        "color": "green"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2524,
        "end_char": 2528,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2541,
        "end_char": 2546,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2650,
        "end_char": 2653,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2807,
        "end_char": 2810,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2907,
        "end_char": 2910,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3049,
        "end_char": 3058,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3315,
        "end_char": 3324,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3429,
        "end_char": 3432,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3487,
        "end_char": 3496,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3574,
        "end_char": 3577,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3711,
        "end_char": 3720,
        "color": "teal"
      },
      {
        "text": "root",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 4167,
        "end_char": 4171,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4356,
        "end_char": 4365,
        "color": "teal"
      },
      {
        "text": "patient",
        "label": "ORGANISM",
        "start_char": 4470,
        "end_char": 4477,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4507,
        "end_char": 4516,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4684,
        "end_char": 4687,
        "color": "green"
      }
    ]
  },
  "Row_2_Col_Disease": {
    "original_text": "Myocardial Infarction",
    "annotated_entities": [
      {
        "text": "Myocardial",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 0,
        "end_char": 10,
        "color": "red"
      }
    ]
  },
  "Row_2_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_2_Col_Disease_Mechanism": {
    "original_text": "The research paper provides evidence linking gut microbiome alterations to myocardial infarction (MI) through multiple interconnected mechanisms involving immune modulation, metabolic disruptions, and the generation of specific microbial metabolites.\n\n### Key Mechanisms Linking Gut Microbiome Alterations to Myocardial Infarction\n\n1. **Microbiome-Induced Immune Modulation**:\n   - The gut microbiota influence inflammatory pathways associated with MI, particularly via changes in immune cell activity. For instance, bacterial DNA can activate macrophages through Toll-like receptors (TLR2 and TLR4), stimulating an immune response that reduces plaque stability in atherosclerosis. This activation can lead to chronic inflammation and destabilization of arterial plaques, which are critical in the development of myocardial infarction.\n\n2. **Metabolic Disruptions**:\n   - Gut microbiome composition affects the metabolism of various compounds, notably through the production of metabolites such as Trimethylamine N-oxide (TMAO). TMAO is implicated in increasing cardiovascular risk factors by enhancing platelet hyperreactivity and driving inflammatory responses in vascular tissues. The activation of heat shock protein 60 (HSP60) and the production of inflammatory mediators such as IL-1, TNF-\u03b1, and C-reactive protein via MAPK and NF-\u03baB signaling pathways contribute to vascular inflammation that underpins MI.\n   - Additionally, alterations in short-chain fatty acids (SCFAs), especially butyrate, are noted to play a role in plaque stability. Butyric acid can counteract atherosclerotic processes by reducing pro-inflammatory cytokines and inhibiting vascular smooth muscle cell proliferation.\n\n3. **Gut-Derived Metabolites**:\n   - The study emphasizes the detrimental role of lipopolysaccharides (LPS) in the context of gut permeability. When the intestinal barrier is compromised, LPS can enter the bloodstream, triggering systemic inflammation and affecting vascular integrity. The presence of LPS in circulation leads to the activation of cytokines that further exacerbate endothelial dysfunction.\n\n4. **Gut Microbial Composition**:\n   - Changes in the relative abundance of specific gut bacteria, such as a higher Firmicutes to Bacteroidetes ratio, have been correlated with an increased risk of cardiovascular diseases. Notably, the paper references Akkermansia spp. as beneficial bacteria that can lower plasma LPS levels, thus potentially reducing atherosclerosis risk.\n\n5. **Systemic Effects**: \n   - Dysbiosis in the gut microbiota not only affects local gut health but also has systemic implications. The increased intestinal permeability allows for gut-derived metabolites and endotoxins to exert effects on distant organs, which can influence cardiovascular health and contribute to MI pathology.\n\n### Summary\nThe gut microbiome influences myocardial infarction through immune modulation via TLR activation, metabolic disruptions mediated by harmful metabolites like TMAO and inflammatory components, and changes in gut microbial composition. The interplay of these mechanisms highlights the importance of gut health in the prevention and management of cardiovascular diseases.",
    "annotated_entities": [
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 45,
        "end_char": 48,
        "color": "green"
      },
      {
        "text": "myocardial",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 75,
        "end_char": 85,
        "color": "red"
      },
      {
        "text": "Gut Microbiome Alterations",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 279,
        "end_char": 305,
        "color": "orange"
      },
      {
        "text": "Myocardial",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 309,
        "end_char": 319,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 386,
        "end_char": 389,
        "color": "green"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 481,
        "end_char": 492,
        "color": "red"
      },
      {
        "text": "DNA",
        "label": "CELLULAR_COMPONENT",
        "start_char": 527,
        "end_char": 530,
        "color": "teal"
      },
      {
        "text": "macrophages",
        "label": "CELL",
        "start_char": 544,
        "end_char": 555,
        "color": "teal"
      },
      {
        "text": "Toll-like receptors",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 564,
        "end_char": 583,
        "color": "blue"
      },
      {
        "text": "TLR2",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 585,
        "end_char": 589,
        "color": "pink"
      },
      {
        "text": "TLR4",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 594,
        "end_char": 598,
        "color": "red"
      },
      {
        "text": "arterial plaques",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 754,
        "end_char": 770,
        "color": "red"
      },
      {
        "text": "myocardial",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 813,
        "end_char": 823,
        "color": "red"
      },
      {
        "text": "Trimethylamine N-oxide",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 998,
        "end_char": 1020,
        "color": "orange"
      },
      {
        "text": "TMAO",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1022,
        "end_char": 1026,
        "color": "green"
      },
      {
        "text": "platelet",
        "label": "CELL",
        "start_char": 1103,
        "end_char": 1111,
        "color": "orange"
      },
      {
        "text": "vascular tissues",
        "label": "TISSUE",
        "start_char": 1166,
        "end_char": 1182,
        "color": "yellow"
      },
      {
        "text": "heat shock protein 60",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1202,
        "end_char": 1223,
        "color": "teal"
      },
      {
        "text": "HSP60",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1225,
        "end_char": 1230,
        "color": "yellow"
      },
      {
        "text": "IL-1",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1285,
        "end_char": 1289,
        "color": "pink"
      },
      {
        "text": "C-reactive protein",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1302,
        "end_char": 1320,
        "color": "orange"
      },
      {
        "text": "MAPK",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1325,
        "end_char": 1329,
        "color": "yellow"
      },
      {
        "text": "vascular",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1373,
        "end_char": 1381,
        "color": "purple"
      },
      {
        "text": "short-chain fatty acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1448,
        "end_char": 1471,
        "color": "teal"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1473,
        "end_char": 1478,
        "color": "purple"
      },
      {
        "text": "butyrate",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1492,
        "end_char": 1500,
        "color": "green"
      },
      {
        "text": "Butyric acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1548,
        "end_char": 1560,
        "color": "blue"
      },
      {
        "text": "vascular smooth muscle cell",
        "label": "TISSUE",
        "start_char": 1656,
        "end_char": 1683,
        "color": "teal"
      },
      {
        "text": "lipopolysaccharides (",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1782,
        "end_char": 1803,
        "color": "orange"
      },
      {
        "text": "LPS",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1803,
        "end_char": 1806,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1826,
        "end_char": 1829,
        "color": "green"
      },
      {
        "text": "intestinal barrier",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1853,
        "end_char": 1871,
        "color": "blue"
      },
      {
        "text": "LPS",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1888,
        "end_char": 1891,
        "color": "purple"
      },
      {
        "text": "vascular",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1966,
        "end_char": 1974,
        "color": "purple"
      },
      {
        "text": "LPS",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2002,
        "end_char": 2005,
        "color": "purple"
      },
      {
        "text": "endothelial",
        "label": "CELL",
        "start_char": 2082,
        "end_char": 2093,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2193,
        "end_char": 2196,
        "color": "green"
      },
      {
        "text": "Firmicutes",
        "label": "AMINO_ACID",
        "start_char": 2224,
        "end_char": 2234,
        "color": "red"
      },
      {
        "text": "cardiovascular",
        "label": "ORGAN",
        "start_char": 2306,
        "end_char": 2320,
        "color": "purple"
      },
      {
        "text": "plasma LPS",
        "label": "ORGANISM_SUBSTANCE",
        "start_char": 2416,
        "end_char": 2426,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2532,
        "end_char": 2535,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2570,
        "end_char": 2573,
        "color": "green"
      },
      {
        "text": "intestinal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 2631,
        "end_char": 2641,
        "color": "green"
      },
      {
        "text": "gut-derived metabolites",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2666,
        "end_char": 2689,
        "color": "purple"
      },
      {
        "text": "endotoxins",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2694,
        "end_char": 2704,
        "color": "pink"
      },
      {
        "text": "organs",
        "label": "ORGAN",
        "start_char": 2733,
        "end_char": 2739,
        "color": "green"
      },
      {
        "text": "cardiovascular",
        "label": "TISSUE",
        "start_char": 2761,
        "end_char": 2775,
        "color": "purple"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 2832,
        "end_char": 2846,
        "color": "blue"
      },
      {
        "text": "myocardial",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 2858,
        "end_char": 2868,
        "color": "red"
      },
      {
        "text": "TLR",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2910,
        "end_char": 2913,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3034,
        "end_char": 3037,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3124,
        "end_char": 3127,
        "color": "green"
      },
      {
        "text": "cardiovascular",
        "label": "ORGAN",
        "start_char": 3171,
        "end_char": 3185,
        "color": "purple"
      }
    ]
  },
  "Row_2_Col_Rifaximin Justification": {
    "original_text": "### Expert Analysis - Therapeutic Alignment and Repurposing Rationale\n\n#### 1. Mechanistic Convergence\n\n**Microbiome-Induced Immune Modulation:**\n- **Involved Immune Cells:** The gut microbiota influences immune cell activity, particularly macrophages, through TLR2 and TLR4 activation. This activation can provoke a pro-inflammatory response.\n- **Specific Cytokines Elevated:** Key pro-inflammatory cytokines linked with this mechanism include TNF-\u03b1 and IL-1, which are implicated in plaque destabilization and cardiovascular risks.\n\n**Comparison with Rifaximin's Mechanisms:**\nRifaximin modulates immune responses by significantly reducing levels of **TNF-\u03b1**, along with other pro-inflammatory cytokines such as **IL-1\u03b2**. By downregulating these cytokines, Rifaximin potentially mitigates chronic inflammation associated with atherosclerosis and myocardial infarction. This overlap indicates a mechanistic alignment where Rifaximin\u2019s anti-inflammatory effects could counteract the dysregulation observed in MI.\n\n---\n\n**Metabolic Disruptions:**\n- **Key Metabolites:** The gut microbiome produces harmful metabolites like TMAO, which contributes to platelet hyperreactivity and vascular inflammation.\n- **Specific Pathways:** Activation of MAPK and NF-\u03baB signaling pathways leads to increased systemic inflammation, exacerbating MI progression.\n\n**Comparison with Rifaximin's Mechanisms:**\nRifaximin's ability to alter gut microbiota and suppress **pathogenic bacterial overgrowth** impacts the production of metabolites, including TMAO. Although specific studies directly relating Rifaximin use with TMAO reduction are necessary, its role in modulating gut bacterial composition suggests potential for decreased cardio-inflammatory mediators stemming from dysbiosis. Thus, Rifaximin could indirectly influence TMAO levels and related pathways.\n\n---\n\n**Gut-Derived Metabolites:**\n- **Pathways Affected:** The presence of LPS in circulation results from increased intestinal permeability, which activates systemic inflammation and endothelial dysfunction.\n\n**Comparison with Rifaximin's Mechanisms:**\nRifaximin enhances gut barrier function by reducing the bacterial load that produces detrimental metabolites. By modulating gut microbiota and reducing intestinal inflammation, Rifaximin may help stabilize gut permeability, which can lead to lower systemic levels of LPS and associated cardiovascular risks.\n\n---\n\n**Gut Microbial Composition:**\n- **Disrupted Patterns:** Changes in the Firmicutes to Bacteroidetes ratio and an increase in harmful bacteria correlate with MI risks.\n\n**Comparison with Rifaximin's Mechanisms:**\nRifaximin effectively alters gut microbial composition, promoting beneficial bacteria such as **Lactobacillus** and decreasing pathogenic strains. This modulation supports a healthier microbiome, which is crucial in reducing MI risk factors.\n\n#### Summary of Mechanistic Alignment:\nRifaximin appears to align well with mechanisms involved in MI, particularly through:\n- Reducing pro-inflammatory cytokines (TNF-\u03b1, IL-1\u03b2).\n- Modulating gut microbiota to enhance beneficial bacteria and reduce pathogenic ones.\n- Potentially influencing metabolic disruptions related to gut-derived inflammatory metabolites such as TMAO.\n\n---\n\n#### 2. Supporting Clinical or Preclinical Evidence\n\nRifaximin has demonstrated benefits in altering gut microbiota, reducing inflammatory markers, and improving cognitive and systemic symptoms, particularly in conditions like hepatic encephalopathy. Its ability to lower ammonia levels and modulate immune responses, as noted, supports the hypothesis of potential benefits in cardiovascular contexts, given the intertwined nature of gut health and cardiovascular integrity.\n\nWhile direct evidence linking Rifaximin to improved outcomes in MI specifically may be limited, the successful modulation of gut inflammation and beneficial microbiota supports its possible therapeutic role.\n\n---\n\n#### 3. Therapeutic Implications\n\nRifaximin could provide partial therapeutic benefits in myocardial infarction through:\n- **Symptom Relief:** By modulating gut-brain axis dysfunction and reducing systemic inflammation, it may help alleviate symptoms associated with myocardial infarction and improve overall patient health.\n- **Reduction in Systemic Inflammation:** Given its ability to lower inflammatory cytokines, Rifaximin can contribute to a more stable cardiovascular status in patients.\n\n**Limitations and Caveats:**\n- While Rifaximin may contribute positively, it may not address all pathways involved in MI, necessitating **adjunct therapies** for comprehensive management.\n- Individual variability in gut microbiota makes patient response to treatment with Rifaximin potentially heterogeneous.\n\n### Conclusion\n\nThe alignment between the mechanisms of Rifaximin and the pathophysiological drivers of myocardial infarction suggests that repurposing Rifaximin could emerge as a valuable adjunctive approach in MI treatment, particularly through its anti-inflammatory effects and modulation of the gut microbiome.",
    "annotated_entities": [
      {
        "text": "Immune Cells",
        "label": "CELL",
        "start_char": 159,
        "end_char": 171,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 179,
        "end_char": 182,
        "color": "purple"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 205,
        "end_char": 216,
        "color": "blue"
      },
      {
        "text": "TLR2",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 261,
        "end_char": 265,
        "color": "purple"
      },
      {
        "text": "TLR4",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 270,
        "end_char": 274,
        "color": "teal"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 357,
        "end_char": 366,
        "color": "green"
      },
      {
        "text": "TNF-\u03b1",
        "label": "CELL",
        "start_char": 445,
        "end_char": 450,
        "color": "pink"
      },
      {
        "text": "IL-1",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 455,
        "end_char": 459,
        "color": "green"
      },
      {
        "text": "cardiovascular",
        "label": "TISSUE",
        "start_char": 512,
        "end_char": 526,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 553,
        "end_char": 562,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 579,
        "end_char": 588,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 761,
        "end_char": 770,
        "color": "orange"
      },
      {
        "text": "myocardial",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 850,
        "end_char": 860,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 926,
        "end_char": 935,
        "color": "orange"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 1075,
        "end_char": 1089,
        "color": "teal"
      },
      {
        "text": "platelet",
        "label": "CELL",
        "start_char": 1151,
        "end_char": 1159,
        "color": "blue"
      },
      {
        "text": "vascular",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1180,
        "end_char": 1188,
        "color": "red"
      },
      {
        "text": "MAPK",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1242,
        "end_char": 1246,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1366,
        "end_char": 1375,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1392,
        "end_char": 1401,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1421,
        "end_char": 1424,
        "color": "purple"
      },
      {
        "text": "TMAO",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1534,
        "end_char": 1538,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1584,
        "end_char": 1593,
        "color": "orange"
      },
      {
        "text": "TMAO",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1603,
        "end_char": 1607,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1656,
        "end_char": 1659,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1776,
        "end_char": 1785,
        "color": "orange"
      },
      {
        "text": "TMAO",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1813,
        "end_char": 1817,
        "color": "yellow"
      },
      {
        "text": "LPS",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1923,
        "end_char": 1926,
        "color": "teal"
      },
      {
        "text": "intestinal",
        "label": "ORGAN",
        "start_char": 1965,
        "end_char": 1975,
        "color": "purple"
      },
      {
        "text": "endothelial",
        "label": "CELL",
        "start_char": 2032,
        "end_char": 2043,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2076,
        "end_char": 2085,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2102,
        "end_char": 2111,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2121,
        "end_char": 2124,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2226,
        "end_char": 2229,
        "color": "purple"
      },
      {
        "text": "intestinal",
        "label": "ORGAN",
        "start_char": 2254,
        "end_char": 2264,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2279,
        "end_char": 2288,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2308,
        "end_char": 2311,
        "color": "purple"
      },
      {
        "text": "LPS",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2369,
        "end_char": 2372,
        "color": "teal"
      },
      {
        "text": "cardiovascular",
        "label": "TISSUE",
        "start_char": 2388,
        "end_char": 2402,
        "color": "red"
      },
      {
        "text": "Firmicutes",
        "label": "AMINO_ACID",
        "start_char": 2488,
        "end_char": 2498,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2602,
        "end_char": 2611,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2628,
        "end_char": 2637,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2657,
        "end_char": 2660,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2910,
        "end_char": 2919,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3063,
        "end_char": 3066,
        "color": "purple"
      },
      {
        "text": "gut-derived inflammatory metabolites",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3196,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "TMAO",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3241,
        "end_char": 3245,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3306,
        "end_char": 3315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3354,
        "end_char": 3357,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3480,
        "end_char": 3487,
        "color": "red"
      },
      {
        "text": "cardiovascular",
        "label": "ORGAN",
        "start_char": 3630,
        "end_char": 3644,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3687,
        "end_char": 3690,
        "color": "purple"
      },
      {
        "text": "cardiovascular",
        "label": "ORGAN",
        "start_char": 3702,
        "end_char": 3716,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3759,
        "end_char": 3768,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3854,
        "end_char": 3857,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3977,
        "end_char": 3986,
        "color": "orange"
      },
      {
        "text": "myocardial",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 4033,
        "end_char": 4043,
        "color": "pink"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4100,
        "end_char": 4109,
        "color": "yellow"
      },
      {
        "text": "myocardial",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 4210,
        "end_char": 4220,
        "color": "pink"
      },
      {
        "text": "patient",
        "label": "ORGANISM",
        "start_char": 4252,
        "end_char": 4259,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4361,
        "end_char": 4370,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 4428,
        "end_char": 4436,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4476,
        "end_char": 4485,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4655,
        "end_char": 4658,
        "color": "purple"
      },
      {
        "text": "patient",
        "label": "ORGANISM",
        "start_char": 4676,
        "end_char": 4683,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4711,
        "end_char": 4720,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4805,
        "end_char": 4814,
        "color": "orange"
      },
      {
        "text": "myocardial",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 4853,
        "end_char": 4863,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4901,
        "end_char": 4910,
        "color": "orange"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 5048,
        "end_char": 5062,
        "color": "teal"
      }
    ]
  },
  "Row_3_Col_Disease": {
    "original_text": "Anxiety Disorders",
    "annotated_entities": []
  },
  "Row_3_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_3_Col_Disease_Mechanism": {
    "original_text": "The provided research paper elucidates several mechanisms that link gut microbiome alterations to anxiety disorders through the impact of the maternal microbiome on offspring behavior and neurodevelopment.\n\n1. **Influence of Maternal Microbiome on Offspring Behavior**: The study demonstrates that the maternal gut microbiome has a significant influence on behaviors associated with anxiety in offspring. Specifically, differences observed in anxiety-related phenotypes among offspring can be traced back to the gut microbiome of their mothers.\n\n2. **Gene Expression and DNA Methylation**: Genome-wide methylation analysis shows that the maternal microbiome influences methylation patterns of DNA in the hippocampus of the offspring. The study identifies 196 loci with differential methylation, with 176 of these showing conserved profiles between mother and offspring. This suggests that the microbiome can induce epigenetic changes that affect gene expression in neurodevelopmental processes relevant to anxiety disorders.\n\n3. **Metabolite Production and Biochemical Pathways**: The maternal microbiome's activity generates metabolites, such as bile acids, which can affect fetal development and CNS function. The research indicates that bile salt hydrolase (bsh) gene expression and specific bile acid composition correlate with adverse outcomes in offspring, pointing towards metabolic disruptions that could play a role in anxiety disorders.\n\n4. **Impact of Microbial Composition**: The study implies that variations in gut microbial composition (low vs. high phylogenetic diversity) influence anxiety-related behaviors and other phenotypic traits in offspring. It emphasizes that offspring raised by mothers with a high diversity microbiome exhibited different behavioral outcomes compared to those from mothers with a low diversity microbiome.\n\n5. **Neurodevelopmental Pathways**: Single-cell transcriptional analysis provides insights into altered expression of genes involved in neuropeptide signaling, which is closely related to satiety and potentially anxiety behaviors. This underscores the role of microbial-induced changes in gene expression patterns, affecting nervous system development and function.\n\nIn summary, alterations in the maternal gut microbiome impact offspring behavior through epigenetic mechanisms, metabolite production, and changes in gene expression in the hippocampus. These factors collectively inform the neurodevelopmental basis of anxiety disorders, highlighting the concept of fetal programming influenced by maternal microbial composition.",
    "annotated_entities": [
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 68,
        "end_char": 82,
        "color": "pink"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 512,
        "end_char": 526,
        "color": "pink"
      },
      {
        "text": "DNA",
        "label": "CELLULAR_COMPONENT",
        "start_char": 571,
        "end_char": 574,
        "color": "purple"
      },
      {
        "text": "DNA",
        "label": "CELLULAR_COMPONENT",
        "start_char": 693,
        "end_char": 696,
        "color": "purple"
      },
      {
        "text": "hippocampus",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 704,
        "end_char": 715,
        "color": "red"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1147,
        "end_char": 1151,
        "color": "red"
      },
      {
        "text": "fetal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1176,
        "end_char": 1181,
        "color": "teal"
      },
      {
        "text": "CNS",
        "label": "ANATOMICAL_SYSTEM",
        "start_char": 1198,
        "end_char": 1201,
        "color": "orange"
      },
      {
        "text": "bile salt hydrolase",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1240,
        "end_char": 1259,
        "color": "blue"
      },
      {
        "text": "bile acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1295,
        "end_char": 1304,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1525,
        "end_char": 1528,
        "color": "yellow"
      },
      {
        "text": "Single-cell",
        "label": "CELL",
        "start_char": 1888,
        "end_char": 1899,
        "color": "orange"
      },
      {
        "text": "neuropeptide",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1988,
        "end_char": 2000,
        "color": "blue"
      },
      {
        "text": "nervous system",
        "label": "TISSUE",
        "start_char": 2177,
        "end_char": 2191,
        "color": "green"
      },
      {
        "text": "fetal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 2518,
        "end_char": 2523,
        "color": "teal"
      }
    ]
  },
  "Row_3_Col_Rifaximin Justification": {
    "original_text": "### Expert Analysis \u2013 Therapeutic Alignment and Repurposing Rationale\n\n#### 1. Mechanistic Convergence\n\n**Anxiety Disorders Mechanism**:  \nThe pathophysiology of anxiety disorders, as outlined, involves several critical mechanisms, including:\n\n- **Maternal Microbiome Influence**: The maternal gut microbiota significantly impacts offspring behavior, particularly anxiety-related phenotypes. Specific microbes can alter the gut-brain axis, indicating that microbial composition directly influences emotional and behavioral outcomes.\n\n- **Epigenetic Changes**: The study shows that the maternal microbiome affects DNA methylation in the offspring's hippocampus, crucial for mood regulation, linking microbiota to anxiety through gene expression modifications.\n\n- **Altered Metabolite Production**: Microbial metabolites, specifically bile acids, correlate with anxiety pathways. The expression of genes related to bile salt hydrolase highlights a biochemical pathway that may influence the nervous system development.\n\n- **Neuropeptide Signaling**: Changes in gene expression in neuropeptide pathways can potentially alter satiety and anxiety behaviors, suggesting a neurodevelopmental pathway influenced by microbial-induced alterations.\n\n**Rifaximin's Mechanism**:  \nRifaximin exhibits several actions that could mechanistically align with these findings in anxiety disorders:\n\n- **Cytokine Modulation**: Rifaximin has been shown to reduce pro-inflammatory cytokines, particularly TNF\u03b1 and IL-1\u03b2, which are elevated in stress-induced and inflammatory states that can exacerbate anxiety symptoms.\n\n- **Gut Microbiota Modulation**: Rifaximin effectively alters gut microbiota composition, promoting beneficial bacteria that may positively impact mood and behavior through the gut-brain axis.\n\n- **Neuroinflammation Reduction**: By inhibiting the production of inflammatory markers, Rifaximin potentially reduces neuroinflammation, a factor implicated in the exacerbation of anxiety and stress-related disorders.\n\n**Mechanistic Overlap Assessment**:  \n- **Inflammatory Pathways**: Both the pathophysiology of anxiety disorders and Rifaximin's mechanism involve inflammatory pathways. Rifaximin's ability to decrease TNF\u03b1, IL-1\u03b2, and other inflammatory cytokines directly correlates with the upstream inflammatory processes that contribute to anxiety disorders.\n- **Microbial Composition**: The modulation of the gut microbiome by Rifaximin can directly support the microbial balance necessary for optimal neurodevelopment and emotional health, aligning with the observation that maternal and offspring gut microbiota influence anxiety-related behaviors.\n- **Epigenetic Implications**: While Rifaximin does not directly target epigenetic modifications, altering gut microbiota and reducing inflammation may indirectly affect gene expression changes critical for neurodevelopment.\n\nOverall, this mechanistic convergence suggests a potential alignment between Rifaximin\u2019s pharmacological effects and the pathophysiological drivers of anxiety disorders, primarily through immune modulation and gut microbiota influence.\n\n#### 2. Supporting Clinical or Preclinical Evidence\n\nThe provided data indicates that Rifaximin has notable effects relevant to anxiety disorders:\n\n- **Modulation of Microbiota**: Rifaximin successfully alters gut microbiota composition, enhancing beneficial bacteria like Lactobacillus and decreasing pathogenic species. This modulation is a pivotal factor in maintaining a balanced gut-brain axis, essential for emotional regulation.\n\n- **Reduction in Inflammatory Markers**: Rifaximin's capability to decrease systemic levels of pro-inflammatory cytokines such as TNF\u03b1 and IL-1\u03b2 could provide relief from the systemic inflammation that often accompanies anxiety disorders.\n\n- **Improvement in Cognitive Function**: Evidence supporting Rifaximin's effectiveness in improving cognitive function in hepatic encephalopathy patients indirectly suggests that it may also positively affect cognitive aspects of anxiety, particularly in conditions involving stress or inflammation.\n\n#### 3. Therapeutic Implications\n\n**Partial Therapeutic Benefit**:  \nRifaximin demonstrates potential for partial therapeutic benefit in anxiety disorders through:\n\n- **Symptom Relief**: By modulating the gut microbiome and reducing inflammatory responses, Rifaximin may alleviate anxiety symptoms indirectly linked to gut health.\n\n- **Gut-Brain Axis Modulation**: Its role in promoting a healthier gut environment can impact neurodevelopment and emotional health, providing an avenue for managing anxiety.\n\n- **Reduction of Systemic Inflammation**: With potential reductions in systemic inflammatory markers, Rifaximin may mitigate some underlying contributors to anxiety behaviors.\n\n**Limitations and Caveats**:  \n- Rifaximin may not fully encompass the complexities of anxiety disorders, as its effects primarily target microbial and inflammatory components but do not address other neurobiological or psychological factors contributing to anxiety.\n- The variability in patient response based on individual gut microbiota composition could limit its efficacy across diverse populations.\n- Therefore, while Rifaximin may offer symptom relief and modulate gut-brain interactions, it is crucial to consider it as an adjunct therapy combined with other modalities for comprehensive management of anxiety disorders.\n\nIn conclusion, the data supports a mechanistic and clinical rationale for exploring Rifaximin's repurposing potential in anxiety disorders, particularly through its anti-inflammatory and microbiota-modulating actions. The identified overlaps emphasize the likely benefits of such an intervention, especially as part of a multifaceted treatment strategy.",
    "annotated_entities": [
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 294,
        "end_char": 297,
        "color": "orange"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 424,
        "end_char": 433,
        "color": "teal"
      },
      {
        "text": "DNA",
        "label": "CELLULAR_COMPONENT",
        "start_char": 613,
        "end_char": 616,
        "color": "blue"
      },
      {
        "text": "bile acids",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 833,
        "end_char": 843,
        "color": "red"
      },
      {
        "text": "bile salt hydrolase",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 913,
        "end_char": 932,
        "color": "green"
      },
      {
        "text": "nervous system",
        "label": "TISSUE",
        "start_char": 989,
        "end_char": 1003,
        "color": "pink"
      },
      {
        "text": "Neuropeptide Signaling",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1022,
        "end_char": 1044,
        "color": "green"
      },
      {
        "text": "neuropeptide",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1078,
        "end_char": 1090,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1241,
        "end_char": 1250,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1268,
        "end_char": 1277,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1415,
        "color": "purple"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 1482,
        "end_char": 1486,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1631,
        "end_char": 1640,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1660,
        "end_char": 1663,
        "color": "orange"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1775,
        "end_char": 1784,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1881,
        "end_char": 1890,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2129,
        "end_char": 2138,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2182,
        "end_char": 2191,
        "color": "purple"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELLULAR_COMPONENT",
        "start_char": 2214,
        "end_char": 2218,
        "color": "teal"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 2410,
        "end_char": 2424,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2428,
        "end_char": 2437,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2600,
        "end_char": 2603,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2689,
        "end_char": 2698,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2759,
        "end_char": 2762,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2955,
        "end_char": 2964,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3088,
        "end_char": 3091,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3201,
        "end_char": 3210,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3295,
        "end_char": 3304,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3325,
        "end_char": 3328,
        "color": "orange"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3499,
        "end_char": 3508,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3593,
        "end_char": 3602,
        "color": "purple"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 3682,
        "end_char": 3686,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3853,
        "end_char": 3862,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3914,
        "end_char": 3921,
        "color": "yellow"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3937,
        "end_char": 3945,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4162,
        "end_char": 4171,
        "color": "purple"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 4298,
        "end_char": 4312,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4350,
        "end_char": 4359,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4412,
        "end_char": 4415,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4492,
        "end_char": 4495,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4703,
        "end_char": 4712,
        "color": "purple"
      },
      {
        "text": "patient",
        "label": "ORGANISM",
        "start_char": 5066,
        "end_char": 5073,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5103,
        "end_char": 5106,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5202,
        "end_char": 5211,
        "color": "purple"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 5250,
        "end_char": 5259,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5492,
        "end_char": 5501,
        "color": "purple"
      }
    ]
  },
  "Row_4_Col_Disease": {
    "original_text": "Traumatic Brain Injury",
    "annotated_entities": [
      {
        "text": "Brain",
        "label": "ORGAN",
        "start_char": 10,
        "end_char": 15,
        "color": "red"
      }
    ]
  },
  "Row_4_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_4_Col_Disease_Mechanism": {
    "original_text": "The provided research paper indicates several mechanisms linking gut microbiome alterations to traumatic brain injury (TBI):\n\n1. **Microbiome-Induced Immune Modulation**: The study discussed alterations in gut microbial composition in patients with TBI and noted that these changes could influence inflammatory pathways relevant to TBI. Notably, microbial diversity, assessed using indices such as Shannon and Simpson, was decreased in TBI patients compared to healthy controls, indicating a potential link to immune response modulation that could affect inflammation associated with TBI.\n\n2. **Metabolic Disruptions and Disease Pathophysiology**: The serum metabolome analysis indicated multiple metabolic functions were closely related to the gut microbiota. Specifically, the study found an enrichment in lipid-related metabolic pathways in the TBI group, particularly the synthesis and degradation of ketone bodies, suggesting that microbial metabolism may alter key metabolic pathways that have neuroprotective effects after TBI. \n\n3. **Gut Microbial Composition & Biomarkers**: The study utilized 16S rRNA gene sequencing to identify specific bacterial taxa that were different between TBI patients and healthy individuals. Alterations in microbial richness and diversity indices suggest that certain bacterial species may serve as biomarkers for disease progression or severity in TBI, influencing outcomes.\n\n4. **Gut-Organ Crosstalk**: The findings indicate that gut dysbiosis could potentially influence systemic effects impacting TBI recovery. The specific mechanisms of how gut-derived metabolites or bacterial endotoxins might affect other organs, such as the brain, were not explicitly detailed but are implied as an area of importance given the established brain-gut axis.\n\n5. **Key Bacterial Species & Their Roles**: While specific bacterial strains were not named in the excerpt, the overall alterations in the gut microbiome were related to the clinical severity of TBI, and the analysis identified differential OTUs (Operational Taxonomic Units) linked to various severities of TBI. This suggests certain bacterial strains may contribute to inflammation, metabolic changes, or other mechanistic pathways affecting TBI outcomes.\n\n6. **Biological Mechanism & Molecular Pathways**: The paper suggests that the changes in gut microbiota could mechanistically alter host physiology, potentially through the modulation of the serum metabolome which may reflect metabolic status post-TBI. The implication is that the gut microbiome affects host metabolism and immune responses, which are critical in the pathophysiology of TBI.\n\nIn summary, the study highlights the following key points and words: **microbial diversity**, **lipid-related metabolic pathways**, **synthesis and degradation of ketone bodies**, **gut dysbiosis**, **biomarkers for severity**, and **inflammatory responses**, emphasizing the interconnected roles of the gut microbiome in TBI mechanisms.",
    "annotated_entities": [
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 65,
        "end_char": 68,
        "color": "green"
      },
      {
        "text": "brain",
        "label": "ORGAN",
        "start_char": 105,
        "end_char": 110,
        "color": "red"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 119,
        "end_char": 122,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 206,
        "end_char": 209,
        "color": "green"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 235,
        "end_char": 243,
        "color": "yellow"
      },
      {
        "text": "TBI",
        "label": "CELL",
        "start_char": 249,
        "end_char": 252,
        "color": "red"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 332,
        "end_char": 335,
        "color": "red"
      },
      {
        "text": "TBI patients",
        "label": "CANCER",
        "start_char": 436,
        "end_char": 448,
        "color": "green"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 584,
        "end_char": 587,
        "color": "red"
      },
      {
        "text": "serum",
        "label": "ORGANISM_SUBSTANCE",
        "start_char": 652,
        "end_char": 657,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 745,
        "end_char": 748,
        "color": "green"
      },
      {
        "text": "TBI",
        "label": "CANCER",
        "start_char": 848,
        "end_char": 851,
        "color": "red"
      },
      {
        "text": "ketone",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 905,
        "end_char": 911,
        "color": "purple"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 1030,
        "end_char": 1033,
        "color": "red"
      },
      {
        "text": "TBI patients",
        "label": "CANCER",
        "start_char": 1192,
        "end_char": 1204,
        "color": "green"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 1388,
        "end_char": 1391,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1471,
        "end_char": 1474,
        "color": "green"
      },
      {
        "text": "TBI",
        "label": "CELL",
        "start_char": 1540,
        "end_char": 1543,
        "color": "red"
      },
      {
        "text": "gut-derived metabolites",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1585,
        "end_char": 1608,
        "color": "orange"
      },
      {
        "text": "organs",
        "label": "ORGAN",
        "start_char": 1652,
        "end_char": 1658,
        "color": "teal"
      },
      {
        "text": "brain",
        "label": "ORGAN",
        "start_char": 1672,
        "end_char": 1677,
        "color": "red"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 1927,
        "end_char": 1941,
        "color": "blue"
      },
      {
        "text": "TBI",
        "label": "CELL",
        "start_char": 1983,
        "end_char": 1986,
        "color": "red"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 2096,
        "end_char": 2099,
        "color": "red"
      },
      {
        "text": "TBI",
        "label": "CELL",
        "start_char": 2232,
        "end_char": 2235,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2336,
        "end_char": 2339,
        "color": "green"
      },
      {
        "text": "serum",
        "label": "ORGANISM_SUBSTANCE",
        "start_char": 2438,
        "end_char": 2443,
        "color": "pink"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 2528,
        "end_char": 2542,
        "color": "blue"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 2634,
        "end_char": 2637,
        "color": "red"
      },
      {
        "text": "ketone",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2803,
        "end_char": 2809,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2822,
        "end_char": 2825,
        "color": "green"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 2944,
        "end_char": 2958,
        "color": "blue"
      },
      {
        "text": "TBI",
        "label": "CANCER",
        "start_char": 2962,
        "end_char": 2965,
        "color": "red"
      }
    ]
  },
  "Row_4_Col_Rifaximin Justification": {
    "original_text": "### Expert Analysis - Therapeutic Alignment and Repurposing Rationale\n\n#### 1. Mechanistic Convergence\n\n**Mechanisms of Traumatic Brain Injury (TBI):**\n- **Microbiome-Induced Immune Modulation**: The research indicates decreased microbial diversity in TBI patients, which may influence pro-inflammatory pathways associated with TBI. Specifically, alterations in gut microbial composition could affect the activation and recruitment of immune cells that drive inflammation.\n  \n- **Inflammatory Responses**: Elevated pro-inflammatory cytokines (e.g., TNF\u03b1, IL-6) likely play a role in the pathophysiology of TBI. The diminished microbial diversity and presence of pathogenic species may contribute to higher systemic levels of these cytokines.\n\n- **Key Bacterial Species and Gut Dysbiosis**: The study highlights differential operational taxonomic units (OTUs) relating to TBI severity, suggesting a potential link between pathogenic bacteria and inflammatory responses that could worsen TBI outcomes.\n\nIn contrast, **Rifaximin's Mechanism of Action** involves:\n- **Modulation of Pro-Inflammatory Cytokines**: Rifaximin has been shown to significantly reduce levels of TNF\u03b1 and IL-1\u03b2, both of which are implicated in inflammatory responses within the TBI context. By suppressing these cytokines, Rifaximin may reduce inflammation that could contribute to secondary brain injury post-TBI.\n\n- **Gut Microbiota Modulation**: Rifaximin specifically targets ammonia-producing colonic bacteria, promoting the growth of beneficial species while suppressing pathogenic bacteria. This alteration in gut microbiota composition can relieve systemic inflammation, indirectly aiding in the recovery of TBI patients.\n\n**Mechanistic Alignment**: There is a direct overlap between Rifaximin's ability to modulate inflammatory pathways\u2014specifically through the reduction of TNF\u03b1 and IL-1\u03b2\u2014and the immune dysfunction observed in TBI. By promoting a healthier gut microbiome and reducing pro-inflammatory cytokines, Rifaximin can potentially mitigate the inflammatory contributions to TBI severity.\n\n#### 2. Supporting Clinical or Preclinical Evidence\n\nThe available data link Rifaximin to therapeutic benefits that could translate to TBI management:\n- **Reduction of Inflammatory Markers**: Rifaximin's demonstrated impact on decreasing cytokines such as TNF\u03b1 aligns with the need to address neuroinflammation in TBI. \n\n- **Modulation of Gut Microbiota**: Evidence indicates that Rifaximin improves gut microbial composition by enhancing beneficial genera such as Lactobacillus, which could counteract dysbiosis observed in TBI patients.\n\n- **Cognitive Improvement**: Rifaximin\u2019s effects on reducing systemic ammonia levels in hepatic encephalopathy suggest a potential cognitive benefit that could be mirrored in TBI patients experiencing cognitive decline due to neuroinflammation.\n\n#### 3. Therapeutic Implications\n\nGiven the outlined mechanisms of action and evidence:\n- **Partial Therapeutic Benefit**: Rifaximin could offer symptom relief and potentially modulate dysfunctions in the gut-brain axis by reducing inflammatory markers and promoting a healthier microbiome. This aligns well with the identified pathways involved in TBI.\n\n- **Limitations and Caveats**: One potential limitation is that while Rifaximin can address gut dysbiosis and systemic inflammation, it may not directly target all pathways involved in TBI pathology. Additional adjunct therapies may be necessary to comprehensively address cognitive impairments and facilitate full recovery in TBI patients. \n\n### Conclusion\n\nIn conclusion, there is a mechanistic alignment between Rifaximin's pharmacological effects and the pathophysiological drivers of Traumatic Brain Injury, particularly through its modulation of inflammatory responses and gut microbiota. This supports the viability of repurposing Rifaximin for clinical exploration in TBI, potentially benefiting patient outcomes through mitigating neuroinflammation and improving cognitive function. Key terms like **microbiome modulation**, **pro-inflammatory cytokine reduction**, and **systemic inflammation control** underscore this potential therapeutic pathway.",
    "annotated_entities": [
      {
        "text": "Brain",
        "label": "ORGAN",
        "start_char": 130,
        "end_char": 135,
        "color": "green"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 144,
        "end_char": 147,
        "color": "yellow"
      },
      {
        "text": "TBI patients",
        "label": "CANCER",
        "start_char": 252,
        "end_char": 264,
        "color": "pink"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 328,
        "end_char": 331,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 362,
        "end_char": 365,
        "color": "purple"
      },
      {
        "text": "immune cells",
        "label": "CELL",
        "start_char": 435,
        "end_char": 447,
        "color": "blue"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELLULAR_COMPONENT",
        "start_char": 549,
        "end_char": 553,
        "color": "red"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 606,
        "end_char": 609,
        "color": "yellow"
      },
      {
        "text": "Gut Dysbiosis",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 773,
        "end_char": 786,
        "color": "teal"
      },
      {
        "text": "TBI",
        "label": "CANCER",
        "start_char": 871,
        "end_char": 874,
        "color": "yellow"
      },
      {
        "text": "TBI",
        "label": "CELL",
        "start_char": 986,
        "end_char": 989,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1016,
        "end_char": 1025,
        "color": "teal"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1095,
        "end_char": 1104,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1108,
        "end_char": 1117,
        "color": "teal"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 1167,
        "end_char": 1171,
        "color": "red"
      },
      {
        "text": "TBI",
        "label": "CANCER",
        "start_char": 1249,
        "end_char": 1252,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1294,
        "end_char": 1303,
        "color": "teal"
      },
      {
        "text": "brain",
        "label": "ORGAN",
        "start_char": 1363,
        "end_char": 1368,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1420,
        "end_char": 1429,
        "color": "teal"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 1469,
        "end_char": 1476,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1588,
        "end_char": 1591,
        "color": "purple"
      },
      {
        "text": "TBI patients",
        "label": "CANCER",
        "start_char": 1687,
        "end_char": 1699,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1763,
        "end_char": 1772,
        "color": "teal"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 1855,
        "end_char": 1859,
        "color": "red"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 1909,
        "end_char": 1912,
        "color": "yellow"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 1939,
        "end_char": 1953,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1995,
        "end_char": 2004,
        "color": "teal"
      },
      {
        "text": "TBI",
        "label": "CELL",
        "start_char": 2064,
        "end_char": 2067,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2156,
        "end_char": 2165,
        "color": "teal"
      },
      {
        "text": "TBI",
        "label": "CANCER",
        "start_char": 2214,
        "end_char": 2217,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2271,
        "end_char": 2280,
        "color": "teal"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2335,
        "end_char": 2339,
        "color": "red"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 2393,
        "end_char": 2396,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota**:",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2418,
        "end_char": 2435,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2460,
        "end_char": 2469,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2479,
        "end_char": 2482,
        "color": "purple"
      },
      {
        "text": "Lactobacillus",
        "label": "CELLULAR_COMPONENT",
        "start_char": 2544,
        "end_char": 2557,
        "color": "orange"
      },
      {
        "text": "TBI patients",
        "label": "CANCER",
        "start_char": 2604,
        "end_char": 2616,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2648,
        "end_char": 2657,
        "color": "teal"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 2707,
        "end_char": 2714,
        "color": "green"
      },
      {
        "text": "TBI patients",
        "label": "CANCER",
        "start_char": 2794,
        "end_char": 2806,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2988,
        "end_char": 2997,
        "color": "teal"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3070,
        "end_char": 3079,
        "color": "red"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 3214,
        "end_char": 3217,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3290,
        "end_char": 3299,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3312,
        "end_char": 3315,
        "color": "purple"
      },
      {
        "text": "TBI",
        "label": "CANCER",
        "start_char": 3405,
        "end_char": 3408,
        "color": "yellow"
      },
      {
        "text": "TBI patients",
        "label": "CANCER",
        "start_char": 3547,
        "end_char": 3559,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3635,
        "end_char": 3644,
        "color": "teal"
      },
      {
        "text": "Brain",
        "label": "ORGAN",
        "start_char": 3719,
        "end_char": 3724,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3799,
        "end_char": 3802,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3858,
        "end_char": 3867,
        "color": "teal"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 3896,
        "end_char": 3899,
        "color": "yellow"
      },
      {
        "text": "patient",
        "label": "ORGANISM",
        "start_char": 3924,
        "end_char": 3931,
        "color": "purple"
      }
    ]
  },
  "Row_5_Col_Disease": {
    "original_text": "Mucormycosis",
    "annotated_entities": []
  },
  "Row_5_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_5_Col_Disease_Mechanism": {
    "original_text": "The research paper explores the mechanism linking gut microbiome alterations to the increased incidence of Mucormycosis during the COVID-19 pandemic. Here are the key points regarding this connection:\n\n1. **Dysbiosis and Immune Suppression**: The paper emphasizes that the indiscriminate use of steroids and antibiotics during the COVID-19 pandemic has led to dysbiosis of the gut microbiome. Dysbiosis refers to an imbalance in the microbial communities, which can disrupt normal immune functions. This dysbiosis contributes to immune suppression, thereby increasing susceptibility to opportunistic infections such as Mucormycosis.\n\n2. **Alteration of Gut Barrier Function**: The excessive use of systemic glucocorticoids (such as steroids) is noted to impair the gut epithelial barrier. This impairment can result in a \"leaky gut,\" allowing toxins and pathogens to enter the bloodstream, which can further compromise the immune response and provide an environment conducive to fungal growth.\n\n3. **Impact on Immune Responses**: The interaction of gut bacteria with the host immune system is highlighted, where gut-associated lymphoid tissue plays a crucial role in defending against infections. For instance, beneficial gut bacteria, such as those in the Bacteroides genus, help in the maturation of intestinal mucosal immunity. Disruption of these microbial populations can hinder the immune response, making the host more vulnerable to infections like Mucormycosis.\n\n4. **Inflammatory Cytokine Regulation**: The paper discusses how steroids downregulate the expression of pro-inflammatory cytokines (e.g., TNF-\u03b1, IL-6) released by macrophages. This downregulation leads to a reduced inflammatory response, which is typically critical for fighting infections, including fungal infections.\n\n5. **Gut-Lung Axis and Cross-Talk**: There's an assertion that the gut microbiota interacts with pulmonary microorganisms via the \"gut-lung axis,\" which can influence immune responses and the host\u2019s vulnerability to respiratory infections. This suggests that alterations in gut microbiota may have systemic effects that impact susceptibility to infectious diseases, including Mucormycosis.\n\n6. **Role of Nasal Microbiome**: The paper mentions that the nasal microbiome is crucial for local immune responses. Imbalances in nasal microbial communities due to practices like repeated steaming could lead to a suppression of local immunity, further facilitating fungal infections.\n\n7. **Environmental and Self-Medication Factors**: The research identifies external factors such as environmental conditions and self-medication trends that exacerbate dysbiosis and, consequently, the risk of Mucormycosis.\n\nOverall, the interconnectedness of gut microbiome health, immune system modulation, and Mucormycosis susceptibility is backed by the observations presented in the paper. The key words which make the gut microbiome effect possible include **dysbiosis**, **immune suppression**, **gut epithelial barrier**, **inflammatory cytokines**, **gut-lung axis**, and **nasal microbiome**.",
    "annotated_entities": [
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 50,
        "end_char": 53,
        "color": "green"
      },
      {
        "text": "COVID-19",
        "label": "CELLULAR_COMPONENT",
        "start_char": 131,
        "end_char": 139,
        "color": "red"
      },
      {
        "text": "steroids",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 295,
        "end_char": 303,
        "color": "orange"
      },
      {
        "text": "COVID-19",
        "label": "CELLULAR_COMPONENT",
        "start_char": 331,
        "end_char": 339,
        "color": "red"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 377,
        "end_char": 391,
        "color": "purple"
      },
      {
        "text": "Gut Barrier",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 653,
        "end_char": 664,
        "color": "blue"
      },
      {
        "text": "steroids",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 732,
        "end_char": 740,
        "color": "orange"
      },
      {
        "text": "gut epithelial barrier",
        "label": "CELL",
        "start_char": 765,
        "end_char": 787,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1049,
        "end_char": 1052,
        "color": "green"
      },
      {
        "text": "gut-associated lymphoid tissue",
        "label": "CELL",
        "start_char": 1112,
        "end_char": 1142,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1222,
        "end_char": 1225,
        "color": "green"
      },
      {
        "text": "intestinal mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1320,
        "color": "yellow"
      },
      {
        "text": "steroids",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1536,
        "end_char": 1544,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1860,
        "end_char": 1863,
        "color": "green"
      },
      {
        "text": "pulmonary",
        "label": "ORGAN",
        "start_char": 1890,
        "end_char": 1899,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2067,
        "end_char": 2070,
        "color": "green"
      },
      {
        "text": "Nasal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2197,
        "end_char": 2202,
        "color": "red"
      },
      {
        "text": "nasal microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 2245,
        "end_char": 2261,
        "color": "green"
      },
      {
        "text": "nasal",
        "label": "ORGAN",
        "start_char": 2315,
        "end_char": 2320,
        "color": "red"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 2729,
        "end_char": 2743,
        "color": "purple"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 2893,
        "end_char": 2907,
        "color": "purple"
      },
      {
        "text": "gut epithelial barrier",
        "label": "CELL",
        "start_char": 2973,
        "end_char": 2995,
        "color": "orange"
      },
      {
        "text": "nasal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3052,
        "end_char": 3057,
        "color": "red"
      }
    ]
  },
  "Row_5_Col_Rifaximin Justification": {
    "original_text": "**Expert Analysis - Therapeutic Alignment and Repurposing Rationale for Rifaximin in Mucormycosis**\n\n**1. Mechanistic Convergence**\n\nRifaximin exerts its effects primarily in the gastrointestinal tract through mechanisms that could potentially align with the pathophysiology of Mucormycosis, particularly under conditions of dysbiosis and immune suppression.\n\n- **Dysbiosis and Immune Suppression**: Rifaximin targets ammonia-producing bacteria and modulates gut microbiota, reducing specific pathogenic strains while enhancing beneficial species. Key beneficial genera, like Lactobacillus and Ruminococcaceae, are increased post-treatment, which may help stabilize the gut microbiome and reduce the risk of opportunistic infections. Rifaximin's ability to rectify dysbiosis could counteract the gut microbiome alteration seen in patients with Mucormycosis, primarily due to steroid usage that fosters microbial imbalances.\n\n- **Alteration of Gut Barrier Function**: Impaired gut epithelial barrier function, as described in Mucormycosis pathology, can lead to increased gut permeability and subsequent systemic inflammation. Rifaximin's modulation of gut microbiota can potentially enhance barrier function, assisting in maintaining gut integrity and preventing translocation of pathogens, thus indirectly mitigating risk factors for Mucormycosis.\n\n- **Impact on Immune Responses**: Rifaximin's influence on immune modulation is notable. The drug reduces pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-17. In the context of Mucormycosis, where immune suppression is a key driver, Rifaximin's capacity to downregulate these cytokines could enhance immune responses, increasing the host's ability to fend off infections.\n\n- **Inflammatory Cytokine Regulation**: The downregulation of TNF-\u03b1 and IL-6 by Rifaximin aligns with the mechanisms involved in Mucormycosis, where reduced inflammatory responses may compromise the host\u2019s ability to combat fungal pathogens. By inhibiting these pro-inflammatory signals, Rifaximin could theoretically restore a more balanced immune response, aiding the fight against Mucormycosis.\n\nIn summary, there is direct mechanistic overlap; Rifaximin modulates gut dysbiosis and alters pro-inflammatory cytokine levels, both of which are crucial pathways in the pathogenesis of Mucormycosis. This alignment suggests that Rifaximin may not only mitigate some of the risk factors associated with Mucormycosis but potentially bolster the immune response against fungal pathogens.\n\n**2. Supporting Clinical or Preclinical Evidence**\n\nWhile direct clinical evidence linking Rifaximin to Mucormycosis treatment is not outlined, the existing knowledge about Rifaximin\u2019s effects on the gut microbiota, ammonia levels, and systemic inflammation supports a rationale for its use in this context. Evidence indicating that Rifaximin can reduce levels of pathogenic bacteria, enhance beneficial microbiota, and decrease systemic inflammatory markers reinforces its potential role in improving outcomes in at-risk populations.\n\nThe modulation of gut microbial populations may lead to overall enhanced immunity, allowing the body to better contend with opportunistic infections such as Mucormycosis, particularly in patients who have undergone systemic steroid treatment.\n\n**3. Therapeutic Implications**\n\nGiven the findings, Rifaximin could offer several therapeutic benefits for patients at risk of Mucormycosis:\n\n- **Symptom Relief**: Rifaximin may alleviate symptoms associated with dysbiosis and gut-related issues, contributing to a more robust intestinal environment which could be protective against infections.\n\n- **Modulation of Gut-Brain Axis Dysfunction**: By improving gut health and reducing systemic inflammation, Rifaximin might positively influence gut-brain communication, which could be beneficial in patients experiencing cognitive dysfunction often observed in compromised states.\n\n- **Reduction in Systemic Inflammation**: Through its effects on pro-inflammatory cytokines, Rifaximin presents a potential avenue for reducing systemic inflammation, which is notably beneficial for patients at increased risk of opportunistic infections.\n\nNonetheless, limitations should be acknowledged. Rifaximin may not provide complete coverage of microbial targets or fully restore optimal immune function on its own. Therefore, combining Rifaximin with other antifungal agents or therapies targeting specific fungal pathogens may be necessary to achieve comprehensive treatment.\n\nIn conclusion, the evidence supports a mechanistic rationale for repurposing Rifaximin in addressing Mucormycosis, highlighting key therapeutic benefits while recognizing the need for adjunct strategies to achieve optimal outcomes. Key points supporting this approach include **dysbiosis mitigation**, **immune modulation**, **anti-inflammatory cytokine regulation**, and potential enhancement of **gut barrier integrity**.",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 72,
        "end_char": 81,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 133,
        "end_char": 142,
        "color": "orange"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 179,
        "end_char": 201,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 400,
        "end_char": 409,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 459,
        "end_char": 462,
        "color": "orange"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 670,
        "end_char": 684,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 734,
        "end_char": 743,
        "color": "orange"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 796,
        "end_char": 810,
        "color": "yellow"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 830,
        "end_char": 838,
        "color": "blue"
      },
      {
        "text": "Gut Barrier",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 943,
        "end_char": 954,
        "color": "purple"
      },
      {
        "text": "gut epithelial barrier",
        "label": "CELL",
        "start_char": 976,
        "end_char": 998,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1071,
        "end_char": 1074,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1126,
        "end_char": 1135,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1152,
        "end_char": 1155,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1234,
        "end_char": 1237,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1384,
        "end_char": 1393,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 1491,
        "end_char": 1495,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1589,
        "end_char": 1598,
        "color": "orange"
      },
      {
        "text": "TNF-\u03b1",
        "label": "CELL",
        "start_char": 1791,
        "end_char": 1796,
        "color": "purple"
      },
      {
        "text": "IL-6",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1801,
        "end_char": 1805,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1809,
        "end_char": 1818,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2017,
        "end_char": 2026,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2177,
        "end_char": 2186,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2197,
        "end_char": 2200,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2357,
        "end_char": 2366,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2605,
        "end_char": 2614,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2687,
        "end_char": 2696,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2714,
        "end_char": 2717,
        "color": "orange"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2730,
        "end_char": 2737,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2847,
        "end_char": 2856,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3068,
        "end_char": 3071,
        "color": "orange"
      },
      {
        "text": "body",
        "label": "TISSUE",
        "start_char": 3146,
        "end_char": 3150,
        "color": "green"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3237,
        "end_char": 3245,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3347,
        "end_char": 3356,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3402,
        "end_char": 3410,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3459,
        "end_char": 3468,
        "color": "orange"
      },
      {
        "text": "intestinal",
        "label": "ORGAN",
        "start_char": 3572,
        "end_char": 3582,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3703,
        "end_char": 3706,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3750,
        "end_char": 3759,
        "color": "orange"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3787,
        "end_char": 3796,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3841,
        "end_char": 3849,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4017,
        "end_char": 4026,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 4123,
        "end_char": 4131,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4229,
        "end_char": 4238,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4368,
        "end_char": 4377,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4587,
        "end_char": 4596,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4909,
        "end_char": 4912,
        "color": "orange"
      }
    ]
  },
  "Row_6_Col_Disease": {
    "original_text": "Irritable Bowel Syndrome",
    "annotated_entities": [
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 10,
        "end_char": 15,
        "color": "red"
      }
    ]
  },
  "Row_6_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_6_Col_Disease_Mechanism": {
    "original_text": "The provided research paper offers insight into the mechanisms linking gut microbiome alterations to Irritable Bowel Syndrome (IBS) through the interplay between enterochromaffin (EC) cells and the gut microbiota, specifically focusing on the role of serotonin and microbial metabolites. Here are the key mechanisms highlighted in the text:\n\n### Mechanisms Linking Gut Microbiome to IBS\n\n1. **Gut Microbiota Dysbiosis**:\n   - **Altered Composition**: IBS patients exhibit a significant alteration in their gut microbiota profile, characterized by a **reduction in commensal bacteria** like *Bifidobacterium* and *Lactobacillus*, and an **increase in pathogenic bacteria** such as *Enterobacter*, along with an overrepresentation of methanogenic bacteria (*Methanobravibacter smithii*).\n   - **Impact on Symptoms**: This dysbiosis is associated with symptom severity in IBS patients, indicating a clear link between microbial diversity and gastrointestinal health.\n\n2. **Serotonin Dynamics**:\n   - **EC Cells and Serotonin Production**: EC cells are the primary producers of serotonin in the gut. Gut microbiota can influence the **serotonin signaling** pathways, affecting gut neurohormonal and immune regulation. Microbiota-derived metabolites can modulate the function of EC cells, thereby impacting serotonin production.\n   - **Interplay with Gut Microbiota**: Certain indigenous gut bacteria promote serotonin biosynthesis from colonic EC cells, which in turn influences gut motility and gut-brain communication.\n\n3. **Microbial Metabolites**:\n   - **Short-Chain Fatty Acids (SCFAs)**: Produced from the fermentation of dietary fibers by gut microbiota, SCFAs are crucial for maintaining EC cell function. They activate G protein-coupled receptors (GPCRs) like FFAR2 on EC cells, enhancing serotonin production.\n   - **Bile Acids**: Dysbiosis alters the bile acid pool, which in turn affects gut microbiota diversity and serotonergic signaling. Increased bile acids have been linked to altered gut motility and can promote secretion through EC cell activation.\n\n4. **Visceral Hypersensitivity**:\n   - Microbial alterations and the subsequent changes in serotonin signaling may lead to **visceral hypersensitivity**, a hallmark of IBS, characterized by heightened sensitivity to visceral pain signals. \n\n5. **Immune Modulation and Barrier Function**:\n   - Gut microbiota dysbiosis is implicated in **immune dysregulation**, which can breach the intestinal barrier. This condition allows for the passage of food antigens and pathogens that activate an immune response, contributing to inflammation and gastrointestinal symptoms in IBS.\n\n6. **Interaction with Other Pathways**:\n   - **Tryptophan Metabolism**: Gut microbiota influence tryptophan metabolism pathways, crucial for serotonin production, potentially leading to altered systemic serotonergic pathways, affecting mood and gut function.\n   - **Aryl Hydrocarbon Receptor (AhR) Interaction**: Serotonin activates AhR in intestinal epithelial cells, contributing to gut motility and immune response, which is relevant for understanding the complex gut-brain axis in IBS pathology.\n\n### Key Points Summarized:\n- **Dysbiosis** leads to increased pathogenic bacteria like *Enterobacter* and altered SCFA and bile acid profiles.\n- **Serotonin production** by EC cells is influenced by gut microbial signaling, impacting **gut motility** and visceral sensation.\n- **Alterations in immune response** and intestinal barrier integrity due to dysbiosis contribute to IBS symptomatology.\n- **Pathways include SCFAs**, bile acids, tryptophan metabolites, and AhR interactions, creating a broad network of gut-brain and gut-microbiome communication.\n\nThese mechanisms underline the critical role of the gut microbiome in influencing the physiology and pathology associated with IBS, laying groundwork for potential therapeutic targets aimed at restoring gut microbiota balance and enhancing EC cell function.",
    "annotated_entities": [
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 71,
        "end_char": 74,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 111,
        "end_char": 116,
        "color": "purple"
      },
      {
        "text": "enterochromaffin",
        "label": "CELL",
        "start_char": 162,
        "end_char": 178,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 198,
        "end_char": 201,
        "color": "teal"
      },
      {
        "text": "serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 251,
        "end_char": 260,
        "color": "blue"
      },
      {
        "text": "IBS\n\n1",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 383,
        "end_char": 389,
        "color": "blue"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 393,
        "end_char": 407,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 506,
        "end_char": 509,
        "color": "teal"
      },
      {
        "text": "Bifidobacterium",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 591,
        "end_char": 606,
        "color": "green"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 869,
        "end_char": 881,
        "color": "purple"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 939,
        "end_char": 955,
        "color": "orange"
      },
      {
        "text": "Serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 970,
        "end_char": 979,
        "color": "blue"
      },
      {
        "text": "EC Cells",
        "label": "CELL",
        "start_char": 999,
        "end_char": 1007,
        "color": "red"
      },
      {
        "text": "Serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1012,
        "end_char": 1021,
        "color": "blue"
      },
      {
        "text": "EC cells",
        "label": "CELL",
        "start_char": 1036,
        "end_char": 1044,
        "color": "red"
      },
      {
        "text": "serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1074,
        "end_char": 1083,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1091,
        "end_char": 1094,
        "color": "teal"
      },
      {
        "text": "serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1131,
        "end_char": 1140,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1173,
        "end_char": 1176,
        "color": "teal"
      },
      {
        "text": "EC cells",
        "label": "CELL",
        "start_char": 1274,
        "end_char": 1282,
        "color": "red"
      },
      {
        "text": "serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1302,
        "end_char": 1311,
        "color": "blue"
      },
      {
        "text": "Gut",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1346,
        "end_char": 1349,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1383,
        "end_char": 1386,
        "color": "teal"
      },
      {
        "text": "serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1404,
        "end_char": 1413,
        "color": "blue"
      },
      {
        "text": "colonic EC cells",
        "label": "CELL",
        "start_char": 1432,
        "end_char": 1448,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1475,
        "end_char": 1478,
        "color": "teal"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1492,
        "end_char": 1501,
        "color": "red"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1580,
        "end_char": 1585,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1642,
        "end_char": 1645,
        "color": "teal"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1658,
        "end_char": 1663,
        "color": "red"
      },
      {
        "text": "EC cell",
        "label": "CELL",
        "start_char": 1692,
        "end_char": 1699,
        "color": "yellow"
      },
      {
        "text": "G protein-coupled receptors",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1724,
        "end_char": 1751,
        "color": "blue"
      },
      {
        "text": "EC cells",
        "label": "CELL",
        "start_char": 1774,
        "end_char": 1782,
        "color": "red"
      },
      {
        "text": "serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1794,
        "end_char": 1803,
        "color": "blue"
      },
      {
        "text": "bile acid",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 1858,
        "end_char": 1867,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1896,
        "end_char": 1899,
        "color": "teal"
      },
      {
        "text": "bile acids",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1959,
        "end_char": 1969,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1998,
        "end_char": 2001,
        "color": "teal"
      },
      {
        "text": "EC cell",
        "label": "CELL",
        "start_char": 2045,
        "end_char": 2052,
        "color": "yellow"
      },
      {
        "text": "serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2157,
        "end_char": 2166,
        "color": "blue"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 2191,
        "end_char": 2199,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 2282,
        "end_char": 2290,
        "color": "purple"
      },
      {
        "text": "intestinal",
        "label": "ORGAN",
        "start_char": 2448,
        "end_char": 2458,
        "color": "teal"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2604,
        "end_char": 2620,
        "color": "orange"
      },
      {
        "text": "Tryptophan",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2686,
        "end_char": 2696,
        "color": "orange"
      },
      {
        "text": "Gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2711,
        "end_char": 2714,
        "color": "teal"
      },
      {
        "text": "serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2780,
        "end_char": 2789,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2884,
        "end_char": 2887,
        "color": "teal"
      },
      {
        "text": "Serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2952,
        "end_char": 2961,
        "color": "blue"
      },
      {
        "text": "AhR",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2972,
        "end_char": 2975,
        "color": "red"
      },
      {
        "text": "intestinal epithelial cells",
        "label": "CELL",
        "start_char": 2979,
        "end_char": 3006,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3024,
        "end_char": 3027,
        "color": "teal"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3106,
        "end_char": 3115,
        "color": "red"
      },
      {
        "text": "IBS pathology",
        "label": "CANCER",
        "start_char": 3124,
        "end_char": 3137,
        "color": "orange"
      },
      {
        "text": "SCFA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3254,
        "end_char": 3258,
        "color": "pink"
      },
      {
        "text": "bile acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3263,
        "end_char": 3272,
        "color": "blue"
      },
      {
        "text": "Serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3287,
        "end_char": 3296,
        "color": "blue"
      },
      {
        "text": "EC cells",
        "label": "CELL",
        "start_char": 3313,
        "end_char": 3321,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3339,
        "end_char": 3342,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3376,
        "end_char": 3379,
        "color": "teal"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 3395,
        "end_char": 3403,
        "color": "purple"
      },
      {
        "text": "intestinal",
        "label": "IMMATERIAL_ANATOMICAL_ENTITY",
        "start_char": 3456,
        "end_char": 3466,
        "color": "teal"
      },
      {
        "text": "IBS",
        "label": "CANCER",
        "start_char": 3516,
        "end_char": 3519,
        "color": "green"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3557,
        "end_char": 3562,
        "color": "red"
      },
      {
        "text": "bile acids",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3566,
        "end_char": 3576,
        "color": "orange"
      },
      {
        "text": "AhR",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3606,
        "end_char": 3609,
        "color": "red"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3652,
        "end_char": 3661,
        "color": "red"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 3749,
        "end_char": 3763,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3900,
        "end_char": 3903,
        "color": "teal"
      },
      {
        "text": "EC cell",
        "label": "CELL",
        "start_char": 3937,
        "end_char": 3944,
        "color": "yellow"
      }
    ]
  },
  "Row_6_Col_Rifaximin Justification": {
    "original_text": "### Expert Analysis - Therapeutic Alignment and Repurposing Rationale for Rifaximin in Irritable Bowel Syndrome\n\n1. **Mechanistic Convergence**\n\n   **Gut Microbiota Dysbiosis**\n   - **Disruption**: IBS patients exhibit significant dysbiosis, with decreased levels of beneficial bacteria like *Bifidobacterium* and *Lactobacillus*, and increased pathogenic bacteria such as *Enterobacter*, as well as an overrepresentation of methanogens like *Methanobravibacter smithii*.\n   - **Rifaximin's Role**: Rifaximin selectively targets pathogenic bacteria while promoting the growth of beneficial species, such as *Ruminococcus gnavus* and *Lactobacillus*. By reducing ammonia-producing colonic bacteria and restoring microbial balance, Rifaximin addresses the dysbiosis observed in IBS, making its actions directly relevant to one of the disease's primary mechanisms.\n\n   **Serotonin Dynamics**\n   - **Disruption**: Gut microbiota influences EC cells, which produce serotonin. This dysregulation can contribute to altered gut motility and hypersensitivity.\n   - **Rifaximin's Role**: By modulating the gut microbiota through its antibacterial effects, Rifaximin may indirectly influence serotonin signaling pathways, optimizing serotonin production from EC cells. Although Rifaximin's direct modulation of serotonin dynamics isn't explicitly documented, its effects on gut microbial profiles suggest a plausible indirect impact.\n\n   **Visceral Hypersensitivity**\n   - **Disruption**: Altered gut microbiota leads to heightened visceral sensitivity, a hallmark of IBS symptoms.\n   - **Rifaximin's Role**: By restoring microbiota balance and reducing inflammatory cytokine levels such as TNF-\u03b1 and IL-1\u03b2, Rifaximin has the potential to ameliorate visceral hypersensitivity by modulating the neuroinflammatory environment in the gut.\n\n   **Immune Modulation and Barrier Function**\n   - **Disruption**: Dysbiosis may cause immune dysregulation and barrier dysfunction, leading to inflammation in IBS.\n   - **Rifaximin's Role**: Rifaximin's ability to reduce pro-inflammatory cytokines (e.g., TNF-\u03b1, IL-1\u03b2, IL-17) aligns with the need to mitigate inflammation and restore barrier integrity in IBS. This action reflects a mechanistic overlap with pathways implicated in IBS pathophysiology.\n\n   In summary, there is significant **mechanistic alignment** between Rifaximin\u2019s pharmacologic effects\u2014including modulation of inflammatory cytokines and restoration of microbiota balance\u2014and the pathophysiological mechanisms driving IBS. Rifaximin's modulation of gut dysbiosis and inflammation positions it as a viable candidate for treating IBS.\n\n2. **Supporting Clinical or Preclinical Evidence**\n   - Clinical evidence suggests Rifaximin effectively alters gut microbiota profiles, promoting beneficial species while reducing pathogenic groups in patients with IBS. This microbial modulation is linked to symptom relief, particularly in IBS with predominant bloating and discomfort.\n   - Observations of Rifaximin\u2019s ability to reduce ammonia levels in conditions like hepatic encephalopathy suggest the drug can impact systemic inflammation\u2014a feature relevant to IBS because of its links to visceral hypersensitivity and cognitive symptoms.\n\n3. **Therapeutic Implications**\n   - Rifaximin could provide **therapeutic benefits** for IBS through:\n     - **Symptom relief**: Improvement in abdominal discomfort and bloating associated with dysbiosis.\n     - **Modulation of gut-brain axis dysfunction**: By altering gut microbiota and potentially influencing serotonin dynamics, Rifaximin may positively affect both GI and cognitive functions.\n     - **Reduction in systemic inflammation**: Lowering pro-inflammatory cytokines could further alleviate IBS symptoms that are exacerbated by systemic inflammation.\n   \n   **Limitations**: Although Rifaximin shows promise, its effectiveness may vary based on individual gut microbiota compositions, potentially necessitating adjunct therapies for non-responders. Furthermore, while it addresses several mechanisms involved in IBS, it may not fully target every aspect of the disease's multifactorial nature, indicating the importance of comprehensive management strategies.\n\nIn conclusion, Rifaximin presents a robust opportunity for repurposing in the treatment of IBS due to its favorable impact on gut microbiota, inflammatory pathways, and symptomatology, suggesting a substantial potential for therapeutic benefit within this context.",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 74,
        "end_char": 83,
        "color": "yellow"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 97,
        "end_char": 102,
        "color": "orange"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 150,
        "end_char": 164,
        "color": "green"
      },
      {
        "text": "Bifidobacterium",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 293,
        "end_char": 308,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 479,
        "end_char": 488,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 499,
        "end_char": 508,
        "color": "yellow"
      },
      {
        "text": "Ruminococcus",
        "label": "CELL",
        "start_char": 608,
        "end_char": 620,
        "color": "pink"
      },
      {
        "text": "colonic bacteria",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 680,
        "end_char": 696,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 730,
        "end_char": 739,
        "color": "yellow"
      },
      {
        "text": "Serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 868,
        "end_char": 877,
        "color": "green"
      },
      {
        "text": "Gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 910,
        "end_char": 913,
        "color": "red"
      },
      {
        "text": "EC cells",
        "label": "CELL",
        "start_char": 936,
        "end_char": 944,
        "color": "teal"
      },
      {
        "text": "serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 960,
        "end_char": 969,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1016,
        "end_char": 1019,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1058,
        "end_char": 1067,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1096,
        "end_char": 1099,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1146,
        "end_char": 1155,
        "color": "yellow"
      },
      {
        "text": "serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1181,
        "end_char": 1190,
        "color": "green"
      },
      {
        "text": "serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1222,
        "end_char": 1231,
        "color": "green"
      },
      {
        "text": "EC cells",
        "label": "CELL",
        "start_char": 1248,
        "end_char": 1256,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1267,
        "end_char": 1276,
        "color": "yellow"
      },
      {
        "text": "serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1300,
        "end_char": 1309,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1363,
        "end_char": 1366,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1486,
        "end_char": 1489,
        "color": "red"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 1521,
        "end_char": 1529,
        "color": "orange"
      },
      {
        "text": "IBS",
        "label": "CANCER",
        "start_char": 1557,
        "end_char": 1560,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1578,
        "end_char": 1587,
        "color": "yellow"
      },
      {
        "text": "TNF-\u03b1",
        "label": "CELL",
        "start_char": 1680,
        "end_char": 1685,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1697,
        "end_char": 1706,
        "color": "yellow"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 1739,
        "end_char": 1747,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1820,
        "end_char": 1823,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1998,
        "end_char": 2007,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2018,
        "end_char": 2027,
        "color": "yellow"
      },
      {
        "text": "IBS",
        "label": "CANCER",
        "start_char": 2258,
        "end_char": 2261,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2350,
        "end_char": 2359,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2520,
        "end_char": 2529,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2546,
        "end_char": 2549,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2714,
        "end_char": 2723,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2743,
        "end_char": 2746,
        "color": "red"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 2833,
        "end_char": 2841,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2990,
        "end_char": 2999,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3020,
        "end_char": 3027,
        "color": "green"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3054,
        "end_char": 3061,
        "color": "orange"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 3177,
        "end_char": 3185,
        "color": "orange"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3373,
        "end_char": 3382,
        "color": "red"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3457,
        "end_char": 3466,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3499,
        "end_char": 3502,
        "color": "red"
      },
      {
        "text": "serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3542,
        "end_char": 3551,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3562,
        "end_char": 3571,
        "color": "yellow"
      },
      {
        "text": "GI",
        "label": "CANCER",
        "start_char": 3599,
        "end_char": 3601,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3827,
        "end_char": 3836,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3899,
        "end_char": 3902,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4219,
        "end_char": 4228,
        "color": "yellow"
      },
      {
        "text": "IBS",
        "label": "CELL",
        "start_char": 4295,
        "end_char": 4298,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4330,
        "end_char": 4333,
        "color": "red"
      }
    ]
  },
  "Row_7_Col_Disease": {
    "original_text": "Asthma",
    "annotated_entities": []
  },
  "Row_7_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its [green[systemic levels decrease following rifaximin treatment, correlating with improved cognitive function]].\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin [blue[reduces TNF\u03b1 levels]], which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to  [blue[reduce IL-1\u03b2 levels]] in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation.  [blue[Rifaximin\u2019s ability to reduce IL-17]] is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to  [blue[modulate INF\u03b3 production]], potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin  [blue[promotes the production of IL-10]], an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can [red[increase the levels of SCFAs]]. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "red"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "red"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "green"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "red"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "orange"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "red"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "red"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1644,
        "end_char": 1646,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1694,
        "end_char": 1703,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1788,
        "end_char": 1797,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1944,
        "end_char": 1947,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2013,
        "end_char": 2022,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2143,
        "end_char": 2146,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2192,
        "end_char": 2201,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2205,
        "end_char": 2209,
        "color": "green"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2211,
        "end_char": 2238,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2241,
        "end_char": 2250,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2341,
        "end_char": 2346,
        "color": "purple"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2382,
        "end_char": 2386,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2412,
        "end_char": 2415,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2433,
        "end_char": 2438,
        "color": "purple"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2461,
        "end_char": 2479,
        "color": "orange"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2531,
        "end_char": 2542,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2573,
        "end_char": 2582,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2686,
        "end_char": 2689,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2694,
        "end_char": 2699,
        "color": "purple"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2703,
        "end_char": 2708,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2727,
        "end_char": 2732,
        "color": "yellow"
      },
      {
        "text": "IL-17]]",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2838,
        "end_char": 2845,
        "color": "pink"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2872,
        "end_char": 2878,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2935,
        "end_char": 2940,
        "color": "purple"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2954,
        "end_char": 2958,
        "color": "green"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2960,
        "end_char": 2978,
        "color": "blue"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 3022,
        "end_char": 3028,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3046,
        "end_char": 3055,
        "color": "red"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3090,
        "end_char": 3094,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3161,
        "end_char": 3164,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3169,
        "end_char": 3174,
        "color": "purple"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3192,
        "end_char": 3200,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3214,
        "end_char": 3219,
        "color": "purple"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3247,
        "end_char": 3256,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3267,
        "end_char": 3276,
        "color": "red"
      },
      {
        "text": "IL-10]]",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3311,
        "end_char": 3318,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3448,
        "end_char": 3451,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3478,
        "end_char": 3487,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3531,
        "end_char": 3534,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3577,
        "end_char": 3582,
        "color": "orange"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3592,
        "end_char": 3597,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3774,
        "end_char": 3783,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3812,
        "end_char": 3815,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3849,
        "end_char": 3856,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4004,
        "end_char": 4007,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4009,
        "end_char": 4018,
        "color": "red"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4118,
        "end_char": 4136,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4159,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4224,
        "end_char": 4228,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4379,
        "end_char": 4382,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4443,
        "end_char": 4453,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4455,
        "end_char": 4503,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4505,
        "end_char": 4509,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4519,
        "end_char": 4528,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4691,
        "end_char": 4700,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4747,
        "end_char": 4750,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4847,
        "end_char": 4854,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5027,
        "end_char": 5036,
        "color": "red"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5118,
        "end_char": 5134,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5139,
        "end_char": 5146,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5190,
        "end_char": 5199,
        "color": "red"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5303,
        "end_char": 5311,
        "color": "yellow"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5340,
        "end_char": 5345,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5362,
        "end_char": 5371,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5383,
        "end_char": 5386,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5495,
        "end_char": 5507,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5533,
        "end_char": 5541,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5546,
        "end_char": 5555,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5625,
        "end_char": 5634,
        "color": "red"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5676,
        "end_char": 5691,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5732,
        "end_char": 5735,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5812,
        "end_char": 5821,
        "color": "red"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5831,
        "end_char": 5838,
        "color": "teal"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5853,
        "end_char": 5861,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5961,
        "end_char": 5964,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5988,
        "end_char": 5997,
        "color": "red"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6186,
        "end_char": 6190,
        "color": "green"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6199,
        "end_char": 6204,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6210,
        "end_char": 6214,
        "color": "green"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6238,
        "end_char": 6245,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6263,
        "end_char": 6266,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6368,
        "end_char": 6375,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6422,
        "end_char": 6425,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6481,
        "end_char": 6484,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6553,
        "end_char": 6562,
        "color": "red"
      }
    ]
  },
  "Row_7_Col_Disease_Mechanism": {
    "original_text": "The research paper discusses the connections between gut microbiome alterations and asthma through the lens of epithelial barrier dysfunction and immune modulation. Here are the key mechanistic insights presented:\n\n1. **Microbiota Changes Affecting Epithelial Function**: The text highlights that the host's metabolism, epithelial barrier integrity, and immune homeostasis were significantly linked to microbiota. Changes in the [green[gut microbiome (dysbiosis) can provoke local inflammation]], leading to [green[progressive epithelial barrier damage and a type 2 immune expulsion response]]. Dysbiosis facilitates translocation of pathogens and environmental allergens into inter- and subepithelial spaces, which initiates inflammatory responses associated with asthma.\n\n2. **Type 2 Immune Response**: The development of an inflammatory response is characterized by [blue[activation of IL-13 and other type 2 cytokines, promoting the expulsion response linked to asthma pathogenesis]]. Specifically, IL-13 has been noted to alter claudin expression and induce tight junction (TJ) protein aggregation, resulting in barrier leakiness.\n\n3. **Microbial Translocation and Immune Activation**: Following epithelial damage, microbiota translocate beneath the epithelium, triggering immune system stimulation. The active immune response involving eosinophils, Th2 cells, and production of IgE contributes to chronic lung inflammation characteristic of asthma.\n\n4. **Importance of Regulatory Microbes**: The paper mentions that beneficial microbiota can aid in preserving and healing the epithelial barrier. An imbalance in microbial composition can lead to a predominance of pathogenic bacteria, such as Staphylococcus aureus, which has been linked to the severity of asthma exacerbations.\n\n5. **Impact of Environmental Factors**: Environmental exposures, including pollutants and household chemicals, can damage epithelial barriers and precipitate dysbiosis. The subsequent inflammatory environment in barrier-defective tissues can initiate type 2 immune responses against both commensals and opportunistic pathogens.\n\n6. **Metabolites and Immune Regulation**: Gut bacteria produce metabolites, such as short-chain fatty acids (SCFAs), which are hinted at as having anti-inflammatory properties. [red[Lower levels of SCFA-producing bacteria have been associated with increased asthma severity]].\n\nThe overarching mechanism linking gut microbiome alterations to asthma involves the disruption of epithelial barrier integrity, leading to immune dysregulation characterized by enhanced type 2 inflammation. The interplay between microbial dysbiosis, environmental factors, and the consequent immune responses underpins the pathogenesis of asthma. \n\nKey points that elucidate this relationship include:\n- **Microbial Dysbiosis**: Loss of microbial diversity and increase in pathogenic bacteria.\n- **Epithelial Barrier Dysfunction**: Increased permeability allows allergens and pathogens to invade tissues.\n- **Type 2 Cytokine Activation**: IL-13 and others lead to inflammation and exacerbation of asthma symptoms.\n- **Regulatory Microbiota**: Essential for maintaining health and preventing exacerbations.\n- **Metabolite Production**: [red[SCFAs and other microbial metabolites modulate inflammation and host immune responses]].\n\nThrough these mechanisms, alterations in the gut microbiome are closely linked to the development and exacerbation of asthma.",
    "annotated_entities": [
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 53,
        "end_char": 67,
        "color": "pink"
      },
      {
        "text": "lens",
        "label": "TISSUE",
        "start_char": 103,
        "end_char": 107,
        "color": "blue"
      },
      {
        "text": "epithelial",
        "label": "TISSUE",
        "start_char": 111,
        "end_char": 121,
        "color": "purple"
      },
      {
        "text": "Epithelial",
        "label": "TISSUE",
        "start_char": 249,
        "end_char": 259,
        "color": "purple"
      },
      {
        "text": "epithelial",
        "label": "TISSUE",
        "start_char": 320,
        "end_char": 330,
        "color": "purple"
      },
      {
        "text": "epithelial",
        "label": "TISSUE",
        "start_char": 527,
        "end_char": 537,
        "color": "purple"
      },
      {
        "text": "subepithelial",
        "label": "TISSUE",
        "start_char": 688,
        "end_char": 701,
        "color": "yellow"
      },
      {
        "text": "IL-13",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 889,
        "end_char": 894,
        "color": "green"
      },
      {
        "text": "IL-13",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1003,
        "end_char": 1008,
        "color": "green"
      },
      {
        "text": "claudin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1033,
        "end_char": 1040,
        "color": "green"
      },
      {
        "text": "epithelial",
        "label": "TISSUE",
        "start_char": 1201,
        "end_char": 1211,
        "color": "purple"
      },
      {
        "text": "epithelium",
        "label": "TISSUE",
        "start_char": 1255,
        "end_char": 1265,
        "color": "teal"
      },
      {
        "text": "eosinophils",
        "label": "CELL",
        "start_char": 1342,
        "end_char": 1353,
        "color": "blue"
      },
      {
        "text": "Th2 cells",
        "label": "CELL",
        "start_char": 1355,
        "end_char": 1364,
        "color": "pink"
      },
      {
        "text": "IgE",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1384,
        "end_char": 1387,
        "color": "red"
      },
      {
        "text": "lung",
        "label": "ORGAN",
        "start_char": 1411,
        "end_char": 1415,
        "color": "orange"
      },
      {
        "text": "epithelial",
        "label": "TISSUE",
        "start_char": 1582,
        "end_char": 1592,
        "color": "purple"
      },
      {
        "text": "epithelial",
        "label": "TISSUE",
        "start_char": 1908,
        "end_char": 1918,
        "color": "purple"
      },
      {
        "text": "barrier-defective tissues",
        "label": "TISSUE",
        "start_char": 1998,
        "end_char": 2023,
        "color": "red"
      },
      {
        "text": "short-chain fatty acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2199,
        "end_char": 2222,
        "color": "teal"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2224,
        "end_char": 2229,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2427,
        "end_char": 2430,
        "color": "yellow"
      },
      {
        "text": "epithelial",
        "label": "TISSUE",
        "start_char": 2491,
        "end_char": 2501,
        "color": "purple"
      },
      {
        "text": "tissues",
        "label": "TISSUE",
        "start_char": 2989,
        "end_char": 2996,
        "color": "red"
      },
      {
        "text": "IL-13",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3032,
        "end_char": 3037,
        "color": "green"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 3368,
        "end_char": 3382,
        "color": "pink"
      }
    ]
  },
  "Row_7_Col_Rifaximin Justification": {
    "original_text": "**Evaluation of Rifaximin's Repurposing Potential for Asthma**\n\n### 1. Mechanistic Convergence\n\nRifaximin's mechanism of action demonstrates several aspects that have direct relevance to the pathophysiology of asthma:\n\n- **Epithelial Barrier Dysfunction**: Rifaximin exhibits antimicrobial effects by inhibiting bacteria associated with dysbiosis. By targeting [green[ammonia-producing bacteria and promoting beneficial genera]], Rifaximin may enhance the integrity of the epithelial barrier in the gut, which is crucial since asthma is exacerbated by epithelial barrier damage (increased permeability). \n    - **Specifics**: Dysbiosis in asthma leads to microbial translocation and inflammation. Rifaximin's modulation of gut microbiota may aid in preventing the translocation of pathogenic bacteria into the systemic circulation and lungs.\n\n- **Type 2 Cytokine Activation**: Asthma is characterized by an activated type 2 immune response, especially elevated levels of IL-13 and other cytokines that contribute to chronic inflammation. Rifaximin [blue[reduces levels of pro-inflammatory cytokines like TNF\u03b1 and IL-1\u03b2]], which can cotransmit inflammatory signals that activate eosinophils and Th2 cells.\n    - **Specifics**: In inflammatory conditions, reduced levels of TNF\u03b1 through Rifaximin\u2019s actions may disrupt the pathways leading to IL-13 elevation, potentially lessening the inflammatory response characteristic of asthma.\n\n- **Regulatory Microbiota Influence**: Rifaximin promotes [red[beneficial bacteria like Lactobacillus and Ruminococcaceae while suppressing harmful bacteria]] (e.g., Staphylococcus aureus), directly supporting immune homeostasis and reducing potential triggers for asthma exacerbations due to dysbiosis.\n    - **Specifics**: The balance of microbial composition influenced by Rifaximin may help prevent pathways leading to chronic lung inflammation, thereby aligning with the concept of regulatory microbiota in the gut linked to asthma pathology.\n\nThus, there is direct mechanistic alignment between Rifaximin's pharmacological effects in modulating microbiota and cytokine profiles with the pathophysiological drivers of asthma. Its actions may offer therapeutic benefits in restoring mucosal integrity and regulating immune responses implicated in asthma, indicating a viable avenue for repurposing.\n\n### 2. Supporting Clinical or Preclinical Evidence\n\nThe current data provide insights into Rifaximin's therapeutic efficacy in various conditions linked to gut health. Improvements noted in gastrointestinal disorders due to its ability to modulate microbiota and decrease inflammation warrant consideration for asthma management.\n\n- **Modulation of Microbiota**: Rifaximin has been documented to induce increases in beneficial bacteria and reduce pathogenic strains. Since asthma pathogenesis is linked to altered gut microbiota, these findings support a potential benefit in mitigating the immune dysregulation associated with asthma exacerbations.\n\n- **Reduction of Inflammatory Markers**: The [blue[reduction of TNF\u03b1, IL-1\u03b2]], and other pro-inflammatory cytokines by Rifaximin could parallel beneficial effects in an [blue[asthmatic context, offering symptom relief through its anti-inflammatory actions]].\n\nClinical observations of symptom improvements in gastrointestinal dysfunctions could also infer positive effects when considering asthma, particularly regarding the impact of gut-brain axis modulation on overall inflammatory burden.\n\n### 3. Therapeutic Implications\n\nRifaximin presents a promising partial therapeutic benefit for asthma due to its multifaceted effects:\n\n- **Symptom Relief**: By reducing dysbiosis, Rifaximin may alleviate the chronic inflammation and heightened immune response associated with asthma, potentially leading to symptom relief.\n  \n- **Modulation of the Gut-Brain Axis**: Given the role of gut health in overall immune function and the connection to lung health, Rifaximin\u2019s influence on the gut may contribute indirectly to lung health through improved systemic inflammatory profiles.\n  \n- **Reduction in Systemic Inflammation**: Rifaximin's ability to [blue[lower levels of inflammatory cytokines]] could provide an avenue for reducing systemic inflammation associated with asthma.\n\nHowever, several **limitations** and caveats must be acknowledged:\n- **Incomplete Pathway Targeting**: Rifaximin primarily acts within the gut and may not address all aspects of asthma pathophysiology. Its efficacy may depend on the individual's specific asthma profile and underlying microbial population variability.\n- **Scope of Symptom Improvement**: While it may alleviate certain symptoms, Rifaximin might not be a standalone treatment. Its use could be beneficial as an adjunct therapy rather than a primary intervention.\n\nIn conclusion, Rifaximin shows promise as a repurposable agent for asthma, particularly due to its well-supported mechanisms related to gut modulation and anti-inflammatory effects. Further exploration in this domain could yield valuable insights into its role in asthma management.",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 16,
        "end_char": 25,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 96,
        "end_char": 105,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 257,
        "end_char": 266,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 430,
        "end_char": 439,
        "color": "blue"
      },
      {
        "text": "epithelial",
        "label": "TISSUE",
        "start_char": 473,
        "end_char": 483,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 499,
        "end_char": 502,
        "color": "purple"
      },
      {
        "text": "epithelial",
        "label": "TISSUE",
        "start_char": 552,
        "end_char": 562,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 697,
        "end_char": 706,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 723,
        "end_char": 726,
        "color": "purple"
      },
      {
        "text": "lungs",
        "label": "ORGAN",
        "start_char": 835,
        "end_char": 840,
        "color": "red"
      },
      {
        "text": "IL-13",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 971,
        "end_char": 976,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1038,
        "end_char": 1047,
        "color": "blue"
      },
      {
        "text": "eosinophils",
        "label": "CELL",
        "start_char": 1178,
        "end_char": 1189,
        "color": "green"
      },
      {
        "text": "Th2 cells",
        "label": "CELL",
        "start_char": 1194,
        "end_char": 1203,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 1272,
        "end_char": 1276,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1285,
        "end_char": 1294,
        "color": "blue"
      },
      {
        "text": "IL-13",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1341,
        "end_char": 1346,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1472,
        "end_char": 1481,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1809,
        "end_char": 1818,
        "color": "blue"
      },
      {
        "text": "lung",
        "label": "ORGAN",
        "start_char": 1864,
        "end_char": 1868,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1949,
        "end_char": 1952,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2034,
        "end_char": 2043,
        "color": "blue"
      },
      {
        "text": "mucosal",
        "label": "ORGAN",
        "start_char": 2220,
        "end_char": 2227,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2428,
        "end_char": 2437,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2493,
        "end_char": 2496,
        "color": "purple"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 2527,
        "end_char": 2543,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2700,
        "end_char": 2709,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2851,
        "end_char": 2854,
        "color": "purple"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELLULAR_COMPONENT",
        "start_char": 3052,
        "end_char": 3056,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3107,
        "end_char": 3116,
        "color": "blue"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 3297,
        "end_char": 3313,
        "color": "orange"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3423,
        "end_char": 3432,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3515,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3664,
        "end_char": 3673,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3868,
        "end_char": 3871,
        "color": "purple"
      },
      {
        "text": "lung",
        "label": "ORGAN",
        "start_char": 3928,
        "end_char": 3932,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3941,
        "end_char": 3950,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3970,
        "end_char": 3973,
        "color": "purple"
      },
      {
        "text": "lung",
        "label": "ORGAN",
        "start_char": 4003,
        "end_char": 4007,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4109,
        "end_char": 4118,
        "color": "blue"
      },
      {
        "text": "blue[lower",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4133,
        "end_char": 4143,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4366,
        "end_char": 4375,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4402,
        "end_char": 4405,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4659,
        "end_char": 4668,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4808,
        "end_char": 4817,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4929,
        "end_char": 4932,
        "color": "purple"
      }
    ]
  },
  "Row_8_Col_Disease": {
    "original_text": "spondyloarthritis",
    "annotated_entities": []
  },
  "Row_8_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_8_Col_Disease_Mechanism": {
    "original_text": "The provided research paper primarily investigates the role of D-amino acids (D-aa) in modulating gut microbiome composition, particularly focusing on their effects on Proteobacteria, which include known pathogenic species. Here is a summary of the mechanisms that link gut microbiome alterations to conditions relevant to spondyloarthritis, particularly through the lens of inflammatory bowel disease (IBD):\n\n1. **Microbial Composition and Dysbiosis**: The study indicates that patients with ulcerative colitis (UC) exhibit a lower ratio of D-aa to L-aa in their feces compared to healthy controls, suggesting a dysbiosis characterized by an overrepresentation of pathogenic bacteria, particularly Proteobacteria. This dysbiosis is believed to be associated with inflammatory diseases, including spondyloarthritis.\n\n2. **Inhibition of Pathogenic Proteobacteria**: D-aa supplementation, particularly with D-alanine, has been shown to inhibit the growth of pathogenic bacteria such as *Escherichia coli* and *Klebsiella pneumoniae*. This inhibition is mediated by a decrease in the expression of the *ftsZ gene*, which is crucial for bacterial cell division. Thus, the direct action of D-aa on these bacteria reduces their population, potentially alleviating the inflammatory processes linked to their presence.\n\n3. **Influence on Immune Modulation**: While the study does not explicitly detail immune modulation related to spondyloarthritis, it provides a hint that the suppression of Proteobacteria via D-aa could influence inflammatory and immune pathways. The modulation of the microbiome may, therefore, result in altered interactions with the host immune system, potentially affecting cytokine production (though specific cytokines like TNF-\u03b1 and IL-6 are not directly referenced).\n\n4. **Prevention of Epithelial Barrier Disruption**: The paper details how D-aa can inhibit pathogenic bacterial invasion into intestinal epithelial cells through mechanisms that prevent pore formation induced by K. pneumoniae. This preservation of epithelial integrity may prevent systemic inflammation and promote gut health, which is crucial in the context of diseases like spondyloarthritis, where gut permeability is often altered.\n\n5. **Therapeutic Potential**: The findings suggest that manipulation of the gut microbiome with D-aa could open therapeutic avenues for managing IBD and its associated comorbidities, including spondyloarthritis, by targeting the bacterial populations that drive inflammation.\n\nIn summary, the mechanism linking gut microbiome alterations to spondyloarthritis, as revealed in this study, involves the modulation of pathogenic gut bacteria through D-aa supplementation, which in turn may influence local and systemic inflammatory responses. The findings highlight the importance of maintaining a balanced gut microbiome to potentially prevent the onset or exacerbation of spondyloarthritis and related inflammatory conditions.",
    "annotated_entities": [
      {
        "text": "D-amino acids",
        "label": "AMINO_ACID",
        "start_char": 63,
        "end_char": 76,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 98,
        "end_char": 101,
        "color": "red"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 270,
        "end_char": 284,
        "color": "green"
      },
      {
        "text": "lens",
        "label": "TISSUE",
        "start_char": 367,
        "end_char": 371,
        "color": "yellow"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 388,
        "end_char": 393,
        "color": "red"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 479,
        "end_char": 487,
        "color": "pink"
      },
      {
        "text": "ulcerative colitis",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 493,
        "end_char": 511,
        "color": "green"
      },
      {
        "text": "UC",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 513,
        "end_char": 515,
        "color": "red"
      },
      {
        "text": "L-aa",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 550,
        "end_char": 554,
        "color": "teal"
      },
      {
        "text": "D-alanine",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 905,
        "end_char": 914,
        "color": "blue"
      },
      {
        "text": "Escherichia coli",
        "label": "ORGANISM",
        "start_char": 985,
        "end_char": 1001,
        "color": "yellow"
      },
      {
        "text": "ftsZ",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1100,
        "end_char": 1104,
        "color": "pink"
      },
      {
        "text": "cell",
        "label": "CELL",
        "start_char": 1143,
        "end_char": 1147,
        "color": "green"
      },
      {
        "text": "IL-6",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1752,
        "end_char": 1756,
        "color": "blue"
      },
      {
        "text": "Epithelial",
        "label": "TISSUE",
        "start_char": 1807,
        "end_char": 1817,
        "color": "teal"
      },
      {
        "text": "intestinal epithelial cells",
        "label": "CELL",
        "start_char": 1914,
        "end_char": 1941,
        "color": "orange"
      },
      {
        "text": "K. pneumoniae",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2000,
        "end_char": 2013,
        "color": "purple"
      },
      {
        "text": "epithelial",
        "label": "TISSUE",
        "start_char": 2036,
        "end_char": 2046,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2103,
        "end_char": 2106,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2189,
        "end_char": 2192,
        "color": "red"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 2301,
        "end_char": 2315,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2536,
        "end_char": 2539,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2650,
        "end_char": 2653,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2828,
        "end_char": 2831,
        "color": "red"
      }
    ]
  },
  "Row_8_Col_Rifaximin Justification": {
    "original_text": "### Expert Analysis - Therapeutic Alignment and Repurposing Rationale\n\n#### 1. Mechanistic Convergence\n\n**Mechanistic Alignment:**\n\n- **Microbial Composition and Dysbiosis:** The reviewed research indicates that spondyloarthritis is associated with a dysbiotic gut microbiome characterized by an overrepresentation of pathogenic Proteobacteria. Rifaximin, by targeting and reducing pathogenic bacteria through its bactericidal action, may stabilize gut flora and benefit patients experiencing dysbiosis.\n\n- **Inhibition of Pathogenic Bacteria:** D-amino acids (particularly D-alanine) inhibit growth of specific pathogenic bacteria such as *E. coli* and *K. pneumoniae*, which are implicated in inflammatory processes. Rifaximin acts similarly by binding to bacterial RNA polymerase, thereby suppressing the growth of these bacteria in the gastrointestinal tract.\n\n- **Influence on Immune Modulation:** Although the study does not elaborate extensively on immune modulation specific to spondyloarthritis, it suggests that the suppression of Proteobacteria can modify immune pathways. Rifaximin has been shown to reduce pro-inflammatory cytokines such as TNF\u03b1 and IL-1\u03b2, which are central to the inflammatory response. This presents a crucial overlap in modulo  inflammatory pathways influenced by gut microbiota and the immune system.\n\n- **Prevention of Epithelial Barrier Disruption:** D-amino acids can inhibit bacterial invasion, preserving the integrity of the intestinal epithelial barrier. Rifaximin enhances gut barrier function through the modulation of cytokines and reduction of inflammatory mediators, thus preventing systemic inflammation that could exacerbate spondyloarthritis.\n\n**Overall Assessment:** \nRifaximin presents a **direct mechanistic alignment** with the pathophysiological drivers of spondyloarthritis by targeting inflammatory pathways and gut microbiota composition. Its ability to suppress pathogens and modulate key pro-inflammatory cytokines like TNF\u03b1 and IL-1\u03b2 may provide beneficial effects for managing spondyloarthritis.\n\n#### 2. Supporting Clinical or Preclinical Evidence\n\nThe therapeutic benefits of Rifaximin in gastrointestinal conditions suggest it has the potential to yield similar effects in spondyloarthritis:\n\n- **Reduction of Inflammatory Markers:** Rifaximin is documented to reduce systemic levels of inflammatory cytokines such as TNF\u03b1 and IL-1\u03b2, paralleling the inflammatory profile seen in spondyloarthritis. While direct evidence in spondyloarthritis patients is lacking, the overarching implications of Rifaximin's effects on immune modulation and gut health support a rationale for exploration in this context.\n\n- **Microbiota Modulation:** Rifaximin successfully alters the gut microbiota, increasing beneficial bacteria while reducing pathogenic strains. Its potential to restore a balanced microbiome could alleviate dysbiosis, a hallmark of both IBD and spondyloarthritis. Increased Lactobacillus and Ruminococcaceae populations could further facilitate gut health and reduce systemic inflammation.\n\n- **Improvement in Neurological Function:** While primarily focused on HE, Rifaximin's neuroprotective effects through the reduction in neuroinflammation and systemic toxins may also have implications for alleviating symptoms associated with spondyloarthritis, particularly if gut-to-brain signaling mechanisms are involved.\n\n#### 3. Therapeutic Implications\n\nBased on the available data, Rifaximin could offer **partial therapeutic benefits** for spondyloarthritis in several ways:\n\n- **Symptom Relief:** By reducing intestinal inflammation and modulating gut microbiota, Rifaximin could provide symptom relief for patients suffering from inflammatory bowel-related components of spondyloarthritis.\n\n- **Modulation of Gut-Brain Axis Dysfunction:** Rifaximin's action on gut permeability and its anti-inflammatory properties may improve communication along the gut-brain axis, potentially alleviating some neurological symptoms seen in spondyloarthritis patients.\n\n- **Reduction in Systemic Inflammation:** Its role in diminishing pro-inflammatory cytokines suggests that long-term use may contribute to decreased systemic inflammation, which is a critical factor in the progression of spondyloarthritis.\n\n**Limitations and Caveats:** While Rifaximin has shown promising attributes that align well with the pathophysiology of spondyloarthritis, careful consideration should be given to the following:\n\n- **Incomplete Pathway Targeting:** Rifaximin may not directly influence all inflammatory pathways associated with spondyloarthritis. Its primary actions focus on the microbiome and certain inflammatory mediators, which may leave other aspects of the disease unaddressed.\n\n- **Scope of Symptom Improvement:** Patients may experience varying degrees of response based on individual gut microbiota composition, necessitating further research to identify potential biomarkers predictive of Rifaximin\u2019s efficacy.\n\n- **Need for Adjunct Therapies:** Rifaximin may be most beneficial as part of a combination therapy approach, targeting multiple mechanisms of spondyloarthritis to optimize patient outcomes.\n\nIn conclusion, Rifaximin holds a **strategic potential** for repurposing in spondyloarthritis treatment, supported by its relevant mechanisms of action and existing clinical observations, meriting further investigation in this domain.",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 345,
        "end_char": 354,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 449,
        "end_char": 452,
        "color": "yellow"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 471,
        "end_char": 479,
        "color": "teal"
      },
      {
        "text": "D-amino acids",
        "label": "AMINO_ACID",
        "start_char": 546,
        "end_char": 559,
        "color": "green"
      },
      {
        "text": "D-alanine",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 574,
        "end_char": 583,
        "color": "red"
      },
      {
        "text": "E. coli",
        "label": "CELL",
        "start_char": 641,
        "end_char": 648,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 719,
        "end_char": 728,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 840,
        "end_char": 862,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1084,
        "end_char": 1093,
        "color": "yellow"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 1154,
        "end_char": 1158,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1297,
        "end_char": 1300,
        "color": "yellow"
      },
      {
        "text": "Epithelial",
        "label": "TISSUE",
        "start_char": 1354,
        "end_char": 1364,
        "color": "orange"
      },
      {
        "text": "D-amino acids",
        "label": "CELLULAR_COMPONENT",
        "start_char": 1387,
        "end_char": 1400,
        "color": "green"
      },
      {
        "text": "intestinal epithelial",
        "label": "TISSUE",
        "start_char": 1465,
        "end_char": 1486,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1496,
        "end_char": 1505,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1515,
        "end_char": 1518,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1718,
        "end_char": 1727,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1868,
        "end_char": 1871,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2139,
        "end_char": 2148,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2152,
        "end_char": 2168,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2298,
        "end_char": 2307,
        "color": "yellow"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2382,
        "end_char": 2386,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 2505,
        "end_char": 2513,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2558,
        "end_char": 2567,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2603,
        "end_char": 2606,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2697,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2731,
        "end_char": 2734,
        "color": "yellow"
      },
      {
        "text": "Lactobacillus",
        "label": "CELLULAR_COMPONENT",
        "start_char": 2943,
        "end_char": 2956,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3014,
        "end_char": 3017,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3135,
        "end_char": 3144,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3449,
        "end_char": 3458,
        "color": "yellow"
      },
      {
        "text": "intestinal",
        "label": "ORGAN",
        "start_char": 3578,
        "end_char": 3588,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3617,
        "end_char": 3620,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3633,
        "end_char": 3642,
        "color": "yellow"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3676,
        "end_char": 3684,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3809,
        "end_char": 3818,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3831,
        "end_char": 3834,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3921,
        "end_char": 3930,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 4014,
        "end_char": 4022,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4301,
        "end_char": 4310,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4498,
        "end_char": 4507,
        "color": "yellow"
      },
      {
        "text": "Patients",
        "label": "ORGANISM",
        "start_char": 4771,
        "end_char": 4779,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4843,
        "end_char": 4846,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4949,
        "end_char": 4958,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5006,
        "end_char": 5015,
        "color": "yellow"
      },
      {
        "text": "patient",
        "label": "ORGANISM",
        "start_char": 5145,
        "end_char": 5152,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5179,
        "end_char": 5188,
        "color": "yellow"
      }
    ]
  },
  "Row_9_Col_Disease": {
    "original_text": "Dysbiosis",
    "annotated_entities": []
  },
  "Row_9_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_9_Col_Disease_Mechanism": {
    "original_text": "The provided research paper does contain relevant insights regarding the link between gut microbiome alterations and dysbiosis, particularly in the context of traumatic brain injury (TBI).\n\n### Mechanistic Insights Linking Gut Microbiome Alterations to Dysbiosis:\n\n1. **Microbial Composition Changes Post-TBI**:\n   - Dysbiosis is characterized by a shift in microbial populations, where pathogenic bacteria outnumber beneficial nonpathogenic bacteria. The paper notes that significant changes in the gut microbiota occur as early as 2 to 24 hours after TBI, with specific taxa being affected. For example, there is a documented decrease in *Ruminococcus flavieciens* and an increase in *Eubacterium ventriosum* and *Marvinbryantia formatexigens*. This indicates a shift in the Firmicutes/Bacteroidetes ratio which is commonly associated with dysbiotic states.\n\n2. **Impact of Stress Responses on Microbiota**:\n   - The paper discusses how a surge in sympathetic nervous system (SNS) activation following TBI may be responsible for the observed alterations in gut microbiota. This implies that systemic stress responses can significantly influence microbial balance, leading to dysbiosis.\n\n3. **Immune Modulation**:\n   - While specific immune pathways are not elaborated in depth, the relationship between gut microbiota and immune responses is hinted at regarding gut-derived metabolites and inflammation. Elevated levels of inflammatory mediators such as tumor necrosis factor alpha (TNF-\u03b1) following TBI suggest that gut inflammation may be a consequence of, or contributor to, dysbiosis.\n\n4. **Gut-Brain Axis**:\n   - The paper emphasizes the role of the vagus nerve and the brain-gut axis in communicating changes in gut microbiota to the central nervous system. Changes in gut microbial composition can lead to alterations in vagal afferent signaling, which may further influence both GI function and broader neurophysiological responses. This connection suggests that microbial alterations can affect neuroinflammation and cognitive function, hence contributing to the systemic effects of dysbiosis.\n\n5. **Consequences of Dysbiosis**:\n   - Dysbiosis is linked with undesired health outcomes, particularly concerning gastrointestinal dysfunctions that can lead to chronic conditions. The paper identifies increased intestinal permeability and altered gut signaling as potential pathways for persistent dysbiosis following TBI.\n\nIn summary, key points to note include:\n- **Alteration of specific gut bacterial taxa** (e.g., decrease in *Ruminococcus flavieciens*).\n- **Increased sympathetic nervous system activation** contributing to microbiome changes.\n- Alterations in gut-derived immune mediators (like TNF-\u03b1) linked to gut inflammation and dysbiosis.\n- The **vagus nerve** as a critical mediator of gut-brain signaling, impacting overall health outcomes following TBI.\n\nThese insights highlight the multifaceted mechanisms through which gut microbiome alterations can lead to dysbiosis in the context of traumatic brain injuries.",
    "annotated_entities": [
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 86,
        "end_char": 100,
        "color": "purple"
      },
      {
        "text": "brain",
        "label": "ORGAN",
        "start_char": 169,
        "end_char": 174,
        "color": "red"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 183,
        "end_char": 186,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiome Alterations",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 223,
        "end_char": 249,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 500,
        "end_char": 503,
        "color": "orange"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 553,
        "end_char": 556,
        "color": "yellow"
      },
      {
        "text": "Ruminococcus",
        "label": "CELL",
        "start_char": 641,
        "end_char": 653,
        "color": "orange"
      },
      {
        "text": "sympathetic nervous system",
        "label": "CANCER",
        "start_char": 950,
        "end_char": 976,
        "color": "teal"
      },
      {
        "text": "SNS",
        "label": "ANATOMICAL_SYSTEM",
        "start_char": 978,
        "end_char": 981,
        "color": "purple"
      },
      {
        "text": "TBI",
        "label": "CANCER",
        "start_char": 1004,
        "end_char": 1007,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1059,
        "end_char": 1062,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1305,
        "end_char": 1308,
        "color": "orange"
      },
      {
        "text": "gut-derived metabolites",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1364,
        "end_char": 1387,
        "color": "red"
      },
      {
        "text": "tumor necrosis factor alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1456,
        "end_char": 1483,
        "color": "pink"
      },
      {
        "text": "TBI",
        "label": "CANCER",
        "start_char": 1502,
        "end_char": 1505,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1519,
        "end_char": 1522,
        "color": "orange"
      },
      {
        "text": "vagus nerve",
        "label": "TISSUE",
        "start_char": 1657,
        "end_char": 1668,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1720,
        "end_char": 1723,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1777,
        "end_char": 1780,
        "color": "orange"
      },
      {
        "text": "vagal afferent",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1830,
        "end_char": 1844,
        "color": "red"
      },
      {
        "text": "GI",
        "label": "CANCER",
        "start_char": 1889,
        "end_char": 1891,
        "color": "blue"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 2221,
        "end_char": 2237,
        "color": "green"
      },
      {
        "text": "intestinal",
        "label": "ORGAN",
        "start_char": 2319,
        "end_char": 2329,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2355,
        "end_char": 2358,
        "color": "orange"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 2426,
        "end_char": 2429,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2499,
        "end_char": 2502,
        "color": "orange"
      },
      {
        "text": "Ruminococcus",
        "label": "CELL",
        "start_char": 2540,
        "end_char": 2552,
        "color": "orange"
      },
      {
        "text": "sympathetic nervous system",
        "label": "CANCER",
        "start_char": 2582,
        "end_char": 2608,
        "color": "teal"
      },
      {
        "text": "microbiome",
        "label": "CANCER",
        "start_char": 2638,
        "end_char": 2648,
        "color": "blue"
      },
      {
        "text": "gut-derived immune",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2675,
        "end_char": 2693,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2727,
        "end_char": 2730,
        "color": "orange"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2807,
        "end_char": 2816,
        "color": "yellow"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 2872,
        "end_char": 2875,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2945,
        "end_char": 2948,
        "color": "orange"
      },
      {
        "text": "brain",
        "label": "ORGAN",
        "start_char": 3022,
        "end_char": 3027,
        "color": "red"
      }
    ]
  },
  "Row_9_Col_Rifaximin Justification": {
    "original_text": "## Expert Analysis - Therapeutic Alignment and Repurposing Rationale for Rifaximin in Dysbiosis\n\n### 1. Mechanistic Convergence\n\n#### Key Mechanisms in Dysbiosis:\n- **Microbial Composition Changes**: Following traumatic brain injury (TBI), notable dysbiosis occurs with specific alterations, such as a decrease in *Ruminococcus flavieciens* and an increase in *Eubacterium ventriosum* and *Marvinbryantia formatexigens*. This highlights a disruption of the Firmicutes/Bacteroidetes ratio, which is often indicative of a dysbiotic state.\n  \n- **Sympathetic Nervous System (SNS) Activation**: TBI induces a surge in SNS activity, which significantly impacts gut microbiota composition, potentially contributing to dysbiosis.\n\n- **Immune Modulation**: Elevated inflammatory mediators, including TNF-\u03b1, point to gut inflammation as both a contributor to and consequence of dysbiosis. Dysregulated immune responses, including pro-inflammatory cytokines, play a critical role in sustaining dysbiotic conditions.\n\n- **Gut-Brain Axis Interaction**: The vagus nerve facilitates communication between the gut and the central nervous system (CNS), which implies that alterations in gut microbiota can influence neuroinflammatory processes and cognitive function.\n\n#### Rifaximin\u2019s Mechanisms:\nRifaximin\u2019s diverse mechanisms provide a potential therapeutic fit for addressing these dysbiotic pathways:\n\n- **Antimicrobial Action**: By directly suppressing specific pathogenic bacteria, particularly ammonia-producing strains linked to HE and SIBO, Rifaximin can help restore beneficial microbial populations.\n\n- **Cytokine Modulation**: Rifaximin has been shown to reduce levels of pro-inflammatory cytokines such as TNF-\u03b1 and IL-1\u03b2, both of which are elevated during dysbiotic states linked to TBI. This action could directly counteract the inflammation contributing to dysbiosis.\n\n- **Gut Microbiota Modulation**: Rifaximin positively impacts the gut microbiome by increasing populations of beneficial bacteria like Lactobacillus and Ruminococcaceae, which can help restore the balance disrupted in dysbiotic states.\n\n- **Impact on Gut-Brain Axis**: The improvements in gut microbiota and reduction in inflammatory markers may potentially lead to enhancements in vagal signaling, affecting neuroinflammation and cognitive function positively.\n\n#### Critical Assessment:\nThere is a clear mechanistic overlap between the pathophysiological drivers of dysbiosis and Rifaximin\u2019s actions. Specifically:\n\n- The reduction of TNF-\u03b1 and other inflammatory cytokines by Rifaximin addresses the inflammatory imbalance observed in dysbiosis.\n- Rifaximin\u2019s ability to modulate gut microbiota can directly counter the microbial shifts noted post-TBI, such as restoring the populations of beneficial bacteria.\n- Rifaximin\u2019s role in the gut-brain axis may also aid in mitigating cognitive dysfunction related to dysbiosis, a consistent consequence observed following TBI.\n\n### 2. Supporting Clinical or Preclinical Evidence\nRifaximin has demonstrated significant therapeutic effects in relevant clinical applications:\n\n- In **Hepatic Encephalopathy (HE)**, Rifaximin\u2019s ability to reduce ammonia-producing bacteria correlates with decreased systemic ammonia levels, leading to cognitive improvement. This mechanistic insight aligns well with the cognitive dysfunction stemming from dysbiosis, indicating a potential benefit in similar contexts.\n\n- In **Irritable Bowel Syndrome (IBS)**, Rifaximin\u2019s modulation of gut microbiota and reduction of pathogenic bacteria have been shown to alleviate gastrointestinal symptoms, suggesting that Rifaximin can positively influence dysbiotic states related to gastrointestinal dysfunction.\n\n- Preclinical observations indicate that Rifaximin helps prevent mucosal inflammation and visceral hypersensitivity, which can be relevant in managing stress-induced gut disorders, thereby providing further evidence of its role in addressing dysbiosis-related symptoms.\n\n### 3. Therapeutic Implications\nBased on the existing data, Rifaximin is well-poised to offer therapeutic benefits in dysbiosis, including:\n\n- **Symptom Relief**: Modulating gut microbiota and inflammatory markers can lead to reductions in gastrointestinal symptoms related to dysbiosis, such as bloating and abdominal discomfort.\n\n- **Gut-Brain Axis Modulation**: By restoring microbial balance and reducing systemic inflammation, Rifaximin may improve cognitive function and reduce neuroinflammation\u2014a critical need in individuals with dysbiosis post-TBI.\n\n- **Reduction in Systemic Inflammation**: Rifaximin's effects on cytokine profiles could contribute to overall systemic anti-inflammatory states, which is vital for improving long-term outcomes in dysbiosis.\n\n#### Limitations and Caveats\nWhile Rifaximin presents a promising therapeutic option, considerations include:\n\n- **Scope of Action**: Rifaximin mainly targets certain bacterial populations, thus its effectiveness may vary based on the individual's baseline microbiota composition.\n- **Adjunctive Therapies**: An integrative approach might be necessary for comprehensive symptom management, particularly in complex cases with multi-organ involvement or severe dysbiosis.\n\nIn conclusion, Rifaximin\u2019s established mechanistic actions\u2014particularly its effects on microbial modulation and inflammatory pathways\u2014combined with evidence of clinical success in related conditions, support its potential as a repurposed treatment for dysbiosis. These perspectives substantiate Rifaximin's role as a modulator of the gut microbiome, a reducer of systemic inflammation, and potentially a significant player in improving gut-brain axis dysfunction.",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 73,
        "end_char": 82,
        "color": "orange"
      },
      {
        "text": "brain",
        "label": "ORGAN",
        "start_char": 220,
        "end_char": 225,
        "color": "blue"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 234,
        "end_char": 237,
        "color": "pink"
      },
      {
        "text": "Ruminococcus",
        "label": "CELL",
        "start_char": 315,
        "end_char": 327,
        "color": "purple"
      },
      {
        "text": "Sympathetic Nervous System",
        "label": "CELL",
        "start_char": 544,
        "end_char": 570,
        "color": "yellow"
      },
      {
        "text": "SNS",
        "label": "ANATOMICAL_SYSTEM",
        "start_char": 572,
        "end_char": 575,
        "color": "teal"
      },
      {
        "text": "SNS",
        "label": "CANCER",
        "start_char": 614,
        "end_char": 617,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 656,
        "end_char": 659,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 808,
        "end_char": 811,
        "color": "teal"
      },
      {
        "text": "vagus nerve",
        "label": "TISSUE",
        "start_char": 1045,
        "end_char": 1056,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1095,
        "end_char": 1098,
        "color": "teal"
      },
      {
        "text": "CNS",
        "label": "ANATOMICAL_SYSTEM",
        "start_char": 1131,
        "end_char": 1134,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1171,
        "end_char": 1174,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1258,
        "end_char": 1267,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1282,
        "end_char": 1291,
        "color": "orange"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1522,
        "end_char": 1524,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1535,
        "end_char": 1544,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1624,
        "end_char": 1633,
        "color": "orange"
      },
      {
        "text": "TNF-\u03b1",
        "label": "CELL",
        "start_char": 1704,
        "end_char": 1709,
        "color": "red"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 1782,
        "end_char": 1785,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1903,
        "end_char": 1912,
        "color": "orange"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 1936,
        "end_char": 1950,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2159,
        "end_char": 2162,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2452,
        "end_char": 2461,
        "color": "orange"
      },
      {
        "text": "TNF-\u03b1",
        "label": "CELL",
        "start_char": 2507,
        "end_char": 2512,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2549,
        "end_char": 2558,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2653,
        "end_char": 2656,
        "color": "teal"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2810,
        "end_char": 2819,
        "color": "pink"
      },
      {
        "text": "TBI",
        "label": "CELLULAR_COMPONENT",
        "start_char": 2940,
        "end_char": 2943,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2997,
        "end_char": 3006,
        "color": "orange"
      },
      {
        "text": "Hepatic",
        "label": "ORGAN",
        "start_char": 3099,
        "end_char": 3106,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3130,
        "end_char": 3139,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3459,
        "end_char": 3468,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3485,
        "end_char": 3488,
        "color": "teal"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3566,
        "end_char": 3582,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3609,
        "end_char": 3618,
        "color": "orange"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3672,
        "end_char": 3688,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3744,
        "end_char": 3753,
        "color": "orange"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 3768,
        "end_char": 3775,
        "color": "blue"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 3793,
        "end_char": 3801,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3869,
        "end_char": 3872,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4034,
        "end_char": 4043,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4148,
        "end_char": 4151,
        "color": "teal"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4214,
        "end_char": 4230,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4270,
        "end_char": 4278,
        "color": "green"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4283,
        "end_char": 4292,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4406,
        "end_char": 4415,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4575,
        "end_char": 4584,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4777,
        "end_char": 4786,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4876,
        "end_char": 4885,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5228,
        "end_char": 5237,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5508,
        "end_char": 5517,
        "color": "orange"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 5547,
        "end_char": 5561,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 5649,
        "end_char": 5658,
        "color": "pink"
      }
    ]
  },
  "Row_10_Col_Disease": {
    "original_text": "Barrett\u2019s Esophagus",
    "annotated_entities": [
      {
        "text": "Barrett\u2019s Esophagus",
        "label": "CANCER",
        "start_char": 0,
        "end_char": 19,
        "color": "red"
      }
    ]
  },
  "Row_10_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_10_Col_Disease_Mechanism": {
    "original_text": "The research paper titled \"Insights Into the Oral Microbiome and Barrett\u2019s Esophagus Early Detection: A Narrative Review\" establishes a link between alterations in the gut microbiome, particularly in the esophagus and oral cavity, and Barrett's Esophagus (BE) through several mechanisms:\n\n1. **Microbiome-Induced Immune Modulation**:\n   - Dysbiosis, or microbial imbalance, can induce inflammation and associated carcinogenesis in BE. The study suggests that changes in microbiota may stimulate immune responses through pathogen pattern recognition receptors like Toll-like receptors (TLRs). \n   - Specifically, the dominance of Gram-negative bacteria in patients with BE can lead to chronic inflammation via the activation of the NF-\u03baB signaling pathway. The lipopolysaccharides (LPS) from Gram-negative microbes bind TLR4, leading to downstream activation of pro-inflammatory cytokines, which play a role in persistent innate immune responses within the esophagus.\n\n2. **Metabolic Disruptions and Disease Pathophysiology**:\n   - The shifts in microbial populations from a Gram-positive (e.g., Streptococcus) to a Gram-negative composition (e.g., Veillonella, Prevotella) signify a transition from a \"health-associated\" microbiome to a \"disease-associated\" one. This change is linked to metabolic alterations that can foster conditions conducive to BE.\n   - The text notes the potential for Gram-negative bacteria to reduce dietary nitrates to nitrites, subsequently promoting the formation of carcinogenic N-nitroso compounds within the acidic environment of the esophagus.\n\n3. **Gut Microbial Composition & Biomarkers**:\n   - The narrative identifies specific bacterial taxa, such as reduced levels of Streptococcus and increased Enterobacteriaceae, as significant markers associated with patients who have BE, particularly those progressing to esophageal adenocarcinoma. These findings suggest that the composition and abundance of microbial taxa could correlate with the severity and progression of BE.\n\n4. **Key Bacterial Species & Their Roles**:\n   - The analysis highlights that while Streptococcus is typically abundant in healthy esophageal microbiota, patients with BE tend to exhibit a decreased presence of this genus, which could contribute to disease progression. The transformation to a microbiome dominated by Gram-negative bacteria is noted as a significant marker of disease progression.\n\nIn conclusion, the alterations in the gut microbiome linked to Barrett's Esophagus relate to immune modulation through inflammatory signaling pathways, metabolic disruptions involving important metabolites like nitrites, and specific changes in microbial composition that provide potential biomarkers for the disease. These mechanistic insights emphasize the complex interplay between gut microbiota and the pathophysiology of Barrett's Esophagus.",
    "annotated_entities": [
      {
        "text": "Oral",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 45,
        "end_char": 49,
        "color": "blue"
      },
      {
        "text": "Barrett\u2019s Esophagus",
        "label": "CANCER",
        "start_char": 65,
        "end_char": 84,
        "color": "green"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 168,
        "end_char": 182,
        "color": "pink"
      },
      {
        "text": "esophagus",
        "label": "ORGAN",
        "start_char": 204,
        "end_char": 213,
        "color": "teal"
      },
      {
        "text": "oral",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 218,
        "end_char": 222,
        "color": "blue"
      },
      {
        "text": "Barrett's Esophagus",
        "label": "CANCER",
        "start_char": 235,
        "end_char": 254,
        "color": "red"
      },
      {
        "text": "BE",
        "label": "CANCER",
        "start_char": 256,
        "end_char": 258,
        "color": "blue"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 655,
        "end_char": 663,
        "color": "orange"
      },
      {
        "text": "BE",
        "label": "CANCER",
        "start_char": 669,
        "end_char": 671,
        "color": "blue"
      },
      {
        "text": "LPS",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 781,
        "end_char": 784,
        "color": "red"
      },
      {
        "text": "TLR4",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 819,
        "end_char": 823,
        "color": "purple"
      },
      {
        "text": "esophagus",
        "label": "ORGAN",
        "start_char": 956,
        "end_char": 965,
        "color": "teal"
      },
      {
        "text": "BE",
        "label": "CANCER",
        "start_char": 1350,
        "end_char": 1352,
        "color": "blue"
      },
      {
        "text": "esophagus",
        "label": "ORGAN",
        "start_char": 1565,
        "end_char": 1574,
        "color": "teal"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 1792,
        "end_char": 1800,
        "color": "orange"
      },
      {
        "text": "esophageal adenocarcinoma",
        "label": "CANCER",
        "start_char": 1848,
        "end_char": 1873,
        "color": "purple"
      },
      {
        "text": "BE",
        "label": "CELLULAR_COMPONENT",
        "start_char": 2004,
        "end_char": 2006,
        "color": "blue"
      },
      {
        "text": "esophageal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 2140,
        "end_char": 2150,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 2163,
        "end_char": 2171,
        "color": "orange"
      },
      {
        "text": "BE",
        "label": "CANCER",
        "start_char": 2177,
        "end_char": 2179,
        "color": "blue"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 2446,
        "end_char": 2460,
        "color": "pink"
      },
      {
        "text": "Barrett's Esophagus",
        "label": "CANCER",
        "start_char": 2471,
        "end_char": 2490,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2793,
        "end_char": 2796,
        "color": "yellow"
      },
      {
        "text": "Barrett's Esophagus",
        "label": "CANCER",
        "start_char": 2835,
        "end_char": 2854,
        "color": "red"
      }
    ]
  },
  "Row_10_Col_Rifaximin Justification": {
    "original_text": "### Expert Analysis - Therapeutic Alignment and Repurposing Rationale for Rifaximin in Barrett\u2019s Esophagus\n\n#### 1. Mechanistic Convergence\n\n**Microbiome-Induced Immune Modulation**:\n- **Involved Mechanisms in Barrett\u2019s Esophagus**: Dysbiosis characterized by an increase in Gram-negative bacteria leads to chronic inflammation through Toll-like receptor (TLR) activation. Specifically, Gram-negative lipopolysaccharides (LPS) bind to **TLR4**, activating the **NF-\u03baB** pathway, resulting in the secretion of pro-inflammatory cytokines such as **TNF\u03b1** and **IL-1\u03b2**.\n  \n- **Rifaximin\u2019s Mechanism**: Rifaximin reduces the population of ammonia-producing and potentially pathogenic bacteria linked to inflammation, thus modulating immune responses. By directly inhibiting those bacteria and potentially reducing LPS-induced TLR4 activation, it can attenuate the inflammatory response.\n\n- **Mechanistic Alignment**: Both the disease pathophysiology related to Barrett's Esophagus and Rifaximin\u2019s action show overlap concerning the modulation of TLR signaling and reduction of TNF\u03b1 levels. The ability of Rifaximin to decrease **TNF\u03b1**, a central mediator in inflammatory pathways, underscores a significant connection between Rifaximin's pharmacologic effects and the disease's inflammatory drivers.\n\n**Metabolic Disruptions**:\n- **Involved Mechanisms in Barrett\u2019s Esophagus**: Transition to a Gram-negative microbiome may lead to metabolic alterations, notably the conversion of dietary nitrates to nitrites, fostering carcinogenic N-nitroso compound formation in acidic conditions.\n  \n- **Rifaximin\u2019s Mechanism**: By restoring a healthier gut microbiota profile\u2014enhancing levels of beneficial bacteria like **Lactobacillus** and **Ruminococcaceae**\u2014Rifaximin may mitigate conditions leading to the formation of harmful metabolites. \n\n- **Mechanistic Alignment**: Rifaximin's action in improving gut microbiota composition presents a direct therapeutic strategy to counteract the detrimental metabolic shifts that facilitate the progression of Barrett's Esophagus.\n\n**Cytokine Modulation**:\n- **Involved Mechanisms in Barrett\u2019s Esophagus**: The inflammatory environment in Barrett's Esophagus is marked by increased pro-inflammatory cytokines such as **TNF\u03b1**, **IL-1\u03b2**, and potential upregulation of **IL-17**.\n\n- **Rifaximin\u2019s Mechanism**: The drug promotes the production of the anti-inflammatory cytokine **IL-10** while reducing pro-inflammatory cytokines, contributing to a more balanced immune response in the gastrointestinal tract.\n\n- **Mechanistic Alignment**: Rifaximin's capacity to lower levels of pro-inflammatory cytokines such as **TNF\u03b1** and **IL-1\u03b2** supports its potential in managing the inflammatory aspects of Barrett's Esophagus.\n\n#### 2. Supporting Clinical or Preclinical Evidence\n\nThe provided observations align with Rifaximin's established therapeutic effects in related gastrointestinal disorders:\n- **Modulation of Microbiota**: Rifaximin alters the gut microbiota, increasing beneficial genera and reducing pathogenic strains, aligning with the microbial dysbiosis seen in Barrett's Esophagus.\n  \n- **Reduction of Inflammatory Markers**: The decrease in systemic ammonia levels and the associated cognitive improvement are indicative of Rifaximin's anti-inflammatory effects, which could positively impact the inflammatory milieu in Barrett's Esophagus.\n\nGiven the similar mechanisms of action where Rifaximin effectively reduces inflammatory cytokines and microbial imbalances, its potential repurposing appears justified based on these therapeutic effects.\n\n#### 3. Therapeutic Implications\n\nRifaximin may offer **partial therapeutic benefit** for Barrett\u2019s Esophagus through:\n- **Symptom Relief**: By addressing underlying dysbiosis and reducing inflammatory markers, Rifaximin might alleviate some gastrointestinal symptoms associated with Barrett's Esophagus.\n  \n- **Modulation of Gut-Brain Axis Dysfunction**: Improvements in cognitive function and reduction in systemic inflammation could translate to enhanced quality of life for patients. While Rifaximin may interact with pathways relevant to Barrett's Esophagus, it is clear that it is not a comprehensive treatment.\n\n**Limitations and Caveats**:\n- **Incomplete Pathway Targeting**: The multifactorial nature of Barrett\u2019s Esophagus may necessitate combination therapies due to Rifaximin's selective targeting of microbial imbalances.\n  \n- **Scope of Symptom Improvement**: Rifaximin primarily modulates gut health rather than directly addressing structural changes in the esophagus or the precancerous nature of Barrett's Esophagus.\n\nIn conclusion, while Rifaximin presents a compelling rationale for repurposing due to its mechanisms of modulating gut microbiota and inflammatory responses associated with Barrett\u2019s Esophagus, a comprehensive treatment strategy may require adjunct therapies to fully address the complexities of this condition.",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 74,
        "end_char": 83,
        "color": "red"
      },
      {
        "text": "Barrett\u2019s Esophagus",
        "label": "CANCER",
        "start_char": 87,
        "end_char": 106,
        "color": "green"
      },
      {
        "text": "Barrett\u2019s Esophagus",
        "label": "CANCER",
        "start_char": 210,
        "end_char": 229,
        "color": "green"
      },
      {
        "text": "Toll-like receptor",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 336,
        "end_char": 354,
        "color": "purple"
      },
      {
        "text": "LPS",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 422,
        "end_char": 425,
        "color": "yellow"
      },
      {
        "text": "TLR4",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 437,
        "end_char": 441,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 575,
        "end_char": 584,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 600,
        "end_char": 609,
        "color": "red"
      },
      {
        "text": "TLR4",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 823,
        "end_char": 827,
        "color": "blue"
      },
      {
        "text": "Barrett's Esophagus",
        "label": "CANCER",
        "start_char": 958,
        "end_char": 977,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 982,
        "end_char": 991,
        "color": "red"
      },
      {
        "text": "TLR",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1043,
        "end_char": 1046,
        "color": "green"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 1074,
        "end_char": 1078,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1102,
        "end_char": 1111,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1224,
        "end_char": 1233,
        "color": "red"
      },
      {
        "text": "Barrett\u2019s Esophagus",
        "label": "CANCER",
        "start_char": 1353,
        "end_char": 1372,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1589,
        "end_char": 1598,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1639,
        "end_char": 1642,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1863,
        "end_char": 1872,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1895,
        "end_char": 1898,
        "color": "teal"
      },
      {
        "text": "Barrett's Esophagus",
        "label": "CANCER",
        "start_char": 2043,
        "end_char": 2062,
        "color": "red"
      },
      {
        "text": "Barrett\u2019s Esophagus",
        "label": "CANCER",
        "start_char": 2117,
        "end_char": 2136,
        "color": "green"
      },
      {
        "text": "Barrett's Esophagus",
        "label": "CANCER",
        "start_char": 2172,
        "end_char": 2191,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2317,
        "end_char": 2326,
        "color": "red"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 2517,
        "end_char": 2539,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2571,
        "end_char": 2580,
        "color": "red"
      },
      {
        "text": "Barrett's Esophagus",
        "label": "CANCER",
        "start_char": 2732,
        "end_char": 2751,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2844,
        "end_char": 2853,
        "color": "red"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 2899,
        "end_char": 2915,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2959,
        "end_char": 2968,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2980,
        "end_char": 2983,
        "color": "teal"
      },
      {
        "text": "Barrett's Esophagus",
        "label": "CANCER",
        "start_char": 3104,
        "end_char": 3123,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3268,
        "end_char": 3277,
        "color": "red"
      },
      {
        "text": "Barrett's Esophagus",
        "label": "CANCER",
        "start_char": 3364,
        "end_char": 3383,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3431,
        "end_char": 3440,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3625,
        "end_char": 3634,
        "color": "red"
      },
      {
        "text": "Barrett\u2019s Esophagus",
        "label": "CANCER",
        "start_char": 3681,
        "end_char": 3700,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3802,
        "end_char": 3811,
        "color": "red"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3833,
        "end_char": 3849,
        "color": "orange"
      },
      {
        "text": "Barrett's Esophagus",
        "label": "CANCER",
        "start_char": 3875,
        "end_char": 3894,
        "color": "red"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 4069,
        "end_char": 4077,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4085,
        "end_char": 4094,
        "color": "red"
      },
      {
        "text": "Barrett's Esophagus",
        "label": "CANCER",
        "start_char": 4134,
        "end_char": 4153,
        "color": "red"
      },
      {
        "text": "Barrett\u2019s Esophagus",
        "label": "CANCER",
        "start_char": 4304,
        "end_char": 4323,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4369,
        "end_char": 4378,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4465,
        "end_char": 4474,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4495,
        "end_char": 4498,
        "color": "teal"
      },
      {
        "text": "esophagus",
        "label": "ORGAN",
        "start_char": 4564,
        "end_char": 4573,
        "color": "blue"
      },
      {
        "text": "Barrett's Esophagus",
        "label": "CANCER",
        "start_char": 4604,
        "end_char": 4623,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4647,
        "end_char": 4656,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4741,
        "end_char": 4744,
        "color": "teal"
      },
      {
        "text": "Barrett\u2019s Esophagus",
        "label": "CANCER",
        "start_char": 4799,
        "end_char": 4818,
        "color": "green"
      }
    ]
  },
  "Row_11_Col_Disease": {
    "original_text": "Sepsis",
    "annotated_entities": []
  },
  "Row_11_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_11_Col_Disease_Mechanism": {
    "original_text": "The research paper \"Methyl Diet Enhanced Sepsis-Induced Mortality Through Altering Gut Microbiota\" presents specific mechanisms linking alterations in gut microbiome to increased sepsis mortality. Here are the key insights:\n\n### Gut Microbiome-Induced Immune Modulation\n\n1. **Alteration in Microbiota Composition**: The high-methyl diet (HMD) resulted in a significant shift in gut microbiota composition, characterized by increased _Firmicutes_ and decreased _Verrucomicrobia_, as well as increased genera such as _Lachnoclostridium_ and _Blautia_, while reducing _Akkermansia_ and _Lachnospiraceae_NK4A136_group_. These specific changes in microbial fauna are highlighted as having implications for metabolic health and inflammatory response during sepsis.\n\n2. **Systemic Inflammation**: Mice fed the HMD showed heightened levels of pro-inflammatory cytokines IL-6 and TNF-\u03b1 both in serum and peritoneal lavage fluid. This observation suggests that the microbiome alterations may enhance systemic inflammatory pathways, contributing to higher mortality in the CLP-induced septic model.\n\n3. **Bacterial Burden**: The study demonstrated an increased bacterial burden in the blood and peritoneal cavity of HMD mice compared to those on the regular diet (RD). This aligns with evidence that the gut microbiota serves as a source of infection in the CLP model, implicating microbial changes as drivers of morbidity.\n\n### Key Bacteria and Metabolic Disruption\n\n1. **Role of _Akkermansia_**: The decrease in _Akkermansia_, a genus associated with beneficial metabolic effects, indicates a loss of protective microbiota that may play a role in modulating inflammation and immune responses during sepsis.\n\n2. **Fecal Microbiome Transplantation Experiment**: The transfer of feces from HMD mice to RD recipients led to increased inflammation and mortality, substantiating that altered microbiota composition directly affects inflammatory responses. Conversely, fecal microbiota from RD mice provided protective effects.\n\n### Inflammatory Pathways\n\n- The findings relate to inflammation being driven by changes in gut microbes, with increased cytokine levels (IL-6, TNF-\u03b1) and immune cell infiltration noted in lung tissues of HMD mice. Such immune responses reflect the interplay between gut dysbiosis and systemic inflammation.\n\n### Conclusion\n\nIn conclusion, the paper elucidates a mechanism where a high-methyl diet alters the gut microbiome, leading to an increased bacterial burden and heightened inflammatory responses during sepsis. This illustrates the importance of gut microbiota composition in modulating key inflammatory pathways and emphasizes the potential role of specific bacterial taxa in sepsis-related mortality.",
    "annotated_entities": [
      {
        "text": "Methyl",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 20,
        "end_char": 26,
        "color": "blue"
      },
      {
        "text": "Gut",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 83,
        "end_char": 86,
        "color": "purple"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 151,
        "end_char": 165,
        "color": "teal"
      },
      {
        "text": "Gut",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 229,
        "end_char": 232,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 378,
        "end_char": 381,
        "color": "purple"
      },
      {
        "text": "Firmicutes",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 434,
        "end_char": 444,
        "color": "blue"
      },
      {
        "text": "Mice",
        "label": "ORGANISM",
        "start_char": 790,
        "end_char": 794,
        "color": "orange"
      },
      {
        "text": "serum",
        "label": "ORGANISM_SUBSTANCE",
        "start_char": 885,
        "end_char": 890,
        "color": "yellow"
      },
      {
        "text": "peritoneal lavage fluid",
        "label": "IMMATERIAL_ANATOMICAL_ENTITY",
        "start_char": 895,
        "end_char": 918,
        "color": "teal"
      },
      {
        "text": "blood",
        "label": "ORGANISM_SUBSTANCE",
        "start_char": 1174,
        "end_char": 1179,
        "color": "red"
      },
      {
        "text": "peritoneal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1184,
        "end_char": 1194,
        "color": "purple"
      },
      {
        "text": "HMD mice",
        "label": "ORGANISM",
        "start_char": 1205,
        "end_char": 1213,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1293,
        "end_char": 1296,
        "color": "purple"
      },
      {
        "text": "feces",
        "label": "ORGANISM_SUBSTANCE",
        "start_char": 1767,
        "end_char": 1772,
        "color": "green"
      },
      {
        "text": "HMD mice",
        "label": "ORGANISM",
        "start_char": 1778,
        "end_char": 1786,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2105,
        "end_char": 2108,
        "color": "purple"
      },
      {
        "text": "IL-6",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2151,
        "end_char": 2155,
        "color": "pink"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2168,
        "end_char": 2179,
        "color": "red"
      },
      {
        "text": "lung tissues",
        "label": "TISSUE",
        "start_char": 2202,
        "end_char": 2214,
        "color": "green"
      },
      {
        "text": "HMD mice",
        "label": "ORGANISM",
        "start_char": 2218,
        "end_char": 2226,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2280,
        "end_char": 2283,
        "color": "purple"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 2422,
        "end_char": 2436,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2567,
        "end_char": 2570,
        "color": "purple"
      }
    ]
  },
  "Row_11_Col_Rifaximin Justification": {
    "original_text": "### Section 3: Expert Analysis - Therapeutic Alignment and Repurposing Rationale\n\n#### 1. Mechanistic Convergence\n\n**Sepsis Mechanisms:**\n- **Immune Modulation:** The study on the high-methyl diet (HMD) indicates that alterations in the gut microbiota lead to both systemic inflammation and an increased bacterial burden. Specific pro-inflammatory cytokines such as **IL-6** and **TNF-\u03b1** are elevated, indicating a robust immune response characterized by the infiltration of immune cells, such as macrophages and T-cells, into affected tissues (e.g., lung).\n- **Microbiota Composition Changes:** The decrease in beneficial bacteria like **Akkermansia** and the increase in pathogenic groups may disrupt metabolic health and inflammatory balance, driving catastrophic immune responses during sepsis.\n\n**Rifaximin's Mechanism:**\nRifaximin binds to the \u03b2-subunit of bacterial RNA polymerase, leading to:\n  - **Reduction in Bacterial Overgrowth:** Rifaximin specifically targets harmful, ammonia-producing bacteria in the gut, thereby potentially decreasing the overall bacterial load and, consequently, the likelihood of systemic bacterial translocation associated with sepsis.\n  - **Cytokine Modulation:** Rifaximin has been shown to reduce pro-inflammatory cytokines, including **TNF-\u03b1** and **IL-1\u03b2**, which are pivotal in driving sepsis-related inflammation.\n\n**Mechanistic Alignment:**\nThere is significant mechanistic overlap between Rifaximin's pharmacological effects and the pathophysiological drivers of sepsis. Rifaximin's actions align well with the highlighted features of sepsis:\n- It can **reduce TNF-\u03b1** levels directly, which correlates with the heightened levels observed in the HMD model of sepsis.\n- Its antimicrobial properties may mitigate the **increased bacterial burden** that is a hallmark of sepsis, thereby reducing the stimulus for systemic inflammation.\n- Furthermore, by modulating gut microbiota, Rifaximin addresses the dysbiosis noted in the sepsis model. \n\nThis alignment suggests that Rifaximin can act at multiple levels within the inflammatory cascades activated during sepsis.\n\n#### 2. Supporting Clinical or Preclinical Evidence\n\nThe clinical and preclinical data provided highlight Rifaximin's capability to:\n- **Modulate Gut Microbiota:** Rifaximin's effect on reducing pathogenic bacteria while enhancing beneficial strains aligns with the need to restore balance in dysbiotic states, which is critical in sepsis.\n- **Reduce Inflammatory Markers:** Its ability to lower levels of TNF-\u03b1 and other pro-inflammatory cytokines could translate into decreased systemic inflammation, potentially improving clinical outcomes during sepsis.\n- **Improve Cognitive Function:** While cognitive impairment has not been explicitly discussed in sepsis, the neurocognitive benefits observed in hepatic encephalopathy suggest a potential parallel in sepsis management where inflammation is similarly high and neuroinflammation is a concern.\n\nThese observations support the hypothesis that Rifaximin can yield therapeutic benefits in sepsis through microbiota modulation and inflammatory pathway intervention.\n\n#### 3. Therapeutic Implications\n\nBased on the evidence presented, Rifaximin may offer **partial therapeutic benefits** in sepsis by:\n- **Symptom Relief:** By reducing intestinal dysbiosis and inflammation, Rifaximin may alleviate some systemic symptoms associated with sepsis.\n- **Modulating Gut-Brain Axis Dysfunction:** Its neuroprotective effects observed in hepatic encephalopathy could extend to sepsis, where inflammatory responses might also affect cognitive function.\n- **Reducing Systemic Inflammation:** With its ability to lower pro-inflammatory cytokines and bacterial load, Rifaximin could represent an adjunctive therapy to mitigate the inflammatory component of sepsis.\n\n**Limitations and Caveats:**\n- **Incomplete Pathway Targeting:** While Rifaximin targets specific microbiota and cytokines, it may not address all aspects of sepsis pathophysiology, necessitating combination therapies.\n- **Scope of Symptom Improvement:** The extent of symptom relief might vary between individuals, particularly depending on unique gut microbiota compositions and other clinical factors.\n- **Need for Adjunct Therapies:** Rifaximin may not be a standalone solution, thus highlighting the importance of integrating it into a broader therapeutic regimen for effectively managing sepsis.\n\n### Conclusion\n\nIn summary, Rifaximin has promising repurposing potential for sepsis due to its mechanistic convergence with key pathogenic processes, including cytokine modulation and gut microbiota restoration. The therapeutic implications suggest it could serve as a valuable adjunct treatment, potentially improving patient outcomes in sepsis through its multifaceted effects on inflammation and gut health.",
    "annotated_entities": [
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 237,
        "end_char": 240,
        "color": "green"
      },
      {
        "text": "immune cells",
        "label": "CELL",
        "start_char": 476,
        "end_char": 488,
        "color": "orange"
      },
      {
        "text": "macrophages",
        "label": "CELL",
        "start_char": 498,
        "end_char": 509,
        "color": "yellow"
      },
      {
        "text": "T-cells",
        "label": "CELL",
        "start_char": 514,
        "end_char": 521,
        "color": "green"
      },
      {
        "text": "tissues",
        "label": "TISSUE",
        "start_char": 537,
        "end_char": 544,
        "color": "blue"
      },
      {
        "text": "lung",
        "label": "ORGAN",
        "start_char": 552,
        "end_char": 556,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 803,
        "end_char": 812,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 828,
        "end_char": 837,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 945,
        "end_char": 954,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1019,
        "end_char": 1022,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1205,
        "end_char": 1214,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1438,
        "end_char": 1447,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1520,
        "end_char": 1529,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1911,
        "end_char": 1914,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1927,
        "end_char": 1936,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2019,
        "end_char": 2028,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2221,
        "end_char": 2230,
        "color": "red"
      },
      {
        "text": "Gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2261,
        "end_char": 2264,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2279,
        "end_char": 2288,
        "color": "red"
      },
      {
        "text": "TNF-\u03b1",
        "label": "CELL",
        "start_char": 2521,
        "end_char": 2526,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 2819,
        "end_char": 2826,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3013,
        "end_char": 3022,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3201,
        "end_char": 3210,
        "color": "red"
      },
      {
        "text": "intestinal",
        "label": "ORGAN",
        "start_char": 3302,
        "end_char": 3312,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3341,
        "end_char": 3350,
        "color": "red"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3497,
        "end_char": 3504,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3722,
        "end_char": 3731,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3892,
        "end_char": 3901,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4170,
        "end_char": 4173,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4260,
        "end_char": 4269,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4452,
        "end_char": 4461,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4609,
        "end_char": 4612,
        "color": "green"
      },
      {
        "text": "patient",
        "label": "ORGANISM",
        "start_char": 4744,
        "end_char": 4751,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4824,
        "end_char": 4827,
        "color": "green"
      }
    ]
  },
  "Row_12_Col_Disease": {
    "original_text": "Cancer",
    "annotated_entities": [
      {
        "text": "Cancer",
        "label": "CANCER",
        "start_char": 0,
        "end_char": 6,
        "color": "red"
      }
    ]
  },
  "Row_12_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_12_Col_Disease_Mechanism": {
    "original_text": "The research paper presents a detailed exploration of the impact of gut microbiota on the metabolism of amygdalin, a compound used in alternative cancer therapies, and highlights how these interactions can lead to cyanide toxicity or therapeutic effects. This mechanistic insight specifically links gut microbiome alterations to cancer through various mechanisms:\n\n1. **Role of Gut Microbiota in Hydrolysis:**\n   - The **Bacteroidetes phylum**, which is prevalent in the gut microbiome, has high **\u03b2-glucosidase activity**. This enzyme is crucial for the breakdown of amygdalin into hydrogen cyanide (HCN). The paper indicates that the microbiota's enzymatic activity is responsible for the conversion of non-toxic compounds into toxic ones, showcasing a direct link between gut microbes and potential cancer toxicity.\n   - Anaerobic conditions in the intestines enhance the activity of \u03b2-glucosidase, facilitating the hydrolysis of amygdalin and increasing the availability of HCN, which can harm cellular structures, including cancerous cells.\n\n2. **Cyanide Toxicity Mechanism:**\n   - The released HCN can inhibit **cytochrome c oxidase** in the mitochondrial electron transport chain, leading to cell death. This mechanism suggests that in an environment rich with certain gut bacteria, the formation of HCN could be leveraged to target malignant cells.\n\n3. **Detoxification Pathways:**\n   - The enzyme **Rhodanese** plays a role in detoxification, converting cyanide to less toxic thiocyanate. However, the efficiency of this detoxification is contingent upon the microbial enzymatic landscape and the overall health of the gut flora. Thus, a gut microbiome dominated by beneficial bacteria can potentially facilitate safer metabolism of amygdalin and lower cyanide levels.\n\n4. **Influence of Diet and Probiotics:**\n   - The composition of the gut microbial community can be modified by dietary interventions or probiotic supplementation, indicating that manipulating these factors might either mitigate toxicity or enhance the therapeutic potential of amygdalin. For example, diets promoting a healthy balance of Bacteroidetes might foster a microbiome that sufficiently manages amygdalin without leading to harmful effects.\n  \n5. **Specificity Towards Malignant Cells:**\n   - Enhanced \u03b2-glucosidase activity in malignant cells suggests that cancerous environments could be more susceptible to the toxic effects of HCN derived from amygdalin. Thus, the paper hints at a potential therapeutic avenue where targeting the gut microbiome could affect cancer cell metabolism negatively.\n\n6. **Microbiome-Induced Immune Modulation:**\n   - Alterations in the gut microbiome could also affect systemic immune responses. By increasing or decreasing specific bacterial populations, there's potential for modulating immune pathways that may influence cancer progression or regression, although explicit signaling pathways and markers require further exploration.\n\nIn summary, the paper establishes that alterations in gut microbiota, particularly through \u03b2-glucosidase activity from Bacteroidetes, are central to the mechanism by which amygdalin can exert either toxic effects or potential therapeutic benefits in the context of cancer treatment.",
    "annotated_entities": [
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 68,
        "end_char": 71,
        "color": "blue"
      },
      {
        "text": "amygdalin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 104,
        "end_char": 113,
        "color": "red"
      },
      {
        "text": "cancer",
        "label": "CANCER",
        "start_char": 146,
        "end_char": 152,
        "color": "green"
      },
      {
        "text": "cyanide",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 214,
        "end_char": 221,
        "color": "red"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 299,
        "end_char": 313,
        "color": "purple"
      },
      {
        "text": "cancer",
        "label": "CANCER",
        "start_char": 329,
        "end_char": 335,
        "color": "green"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 378,
        "end_char": 392,
        "color": "teal"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 471,
        "end_char": 485,
        "color": "purple"
      },
      {
        "text": "amygdalin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 568,
        "end_char": 577,
        "color": "red"
      },
      {
        "text": "hydrogen cyanide",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 583,
        "end_char": 599,
        "color": "red"
      },
      {
        "text": "gut microbes",
        "label": "CANCER",
        "start_char": 775,
        "end_char": 787,
        "color": "orange"
      },
      {
        "text": "cancer",
        "label": "CANCER",
        "start_char": 802,
        "end_char": 808,
        "color": "green"
      },
      {
        "text": "intestines",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 852,
        "end_char": 862,
        "color": "green"
      },
      {
        "text": "amygdalin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 933,
        "end_char": 942,
        "color": "red"
      },
      {
        "text": "cellular",
        "label": "CELL",
        "start_char": 998,
        "end_char": 1006,
        "color": "yellow"
      },
      {
        "text": "cancerous cells",
        "label": "CELL",
        "start_char": 1029,
        "end_char": 1044,
        "color": "purple"
      },
      {
        "text": "Cyanide",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1052,
        "end_char": 1059,
        "color": "red"
      },
      {
        "text": "cytochrome c oxidase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1118,
        "end_char": 1138,
        "color": "green"
      },
      {
        "text": "mitochondrial",
        "label": "CELLULAR_COMPONENT",
        "start_char": 1148,
        "end_char": 1161,
        "color": "teal"
      },
      {
        "text": "cell",
        "label": "CELL",
        "start_char": 1199,
        "end_char": 1203,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1276,
        "end_char": 1279,
        "color": "blue"
      },
      {
        "text": "HCN",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1307,
        "end_char": 1310,
        "color": "yellow"
      },
      {
        "text": "malignant cells",
        "label": "CELL",
        "start_char": 1340,
        "end_char": 1355,
        "color": "purple"
      },
      {
        "text": "cyanide",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1463,
        "end_char": 1470,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1628,
        "end_char": 1631,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1647,
        "end_char": 1650,
        "color": "blue"
      },
      {
        "text": "amygdalin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1742,
        "end_char": 1751,
        "color": "red"
      },
      {
        "text": "lower",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1756,
        "end_char": 1761,
        "color": "blue"
      },
      {
        "text": "cyanide",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1762,
        "end_char": 1769,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1848,
        "end_char": 1851,
        "color": "blue"
      },
      {
        "text": "amygdalin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2057,
        "end_char": 2066,
        "color": "red"
      },
      {
        "text": "amygdalin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2184,
        "end_char": 2193,
        "color": "red"
      },
      {
        "text": "Malignant Cells",
        "label": "CELL",
        "start_char": 2258,
        "end_char": 2273,
        "color": "purple"
      },
      {
        "text": "malignant cells",
        "label": "CELL",
        "start_char": 2317,
        "end_char": 2332,
        "color": "purple"
      },
      {
        "text": "cancerous",
        "label": "CANCER",
        "start_char": 2347,
        "end_char": 2356,
        "color": "orange"
      },
      {
        "text": "HCN derived",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2420,
        "end_char": 2431,
        "color": "pink"
      },
      {
        "text": "amygdalin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2437,
        "end_char": 2446,
        "color": "red"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 2524,
        "end_char": 2538,
        "color": "purple"
      },
      {
        "text": "cancer cell",
        "label": "CELL",
        "start_char": 2552,
        "end_char": 2563,
        "color": "blue"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 2657,
        "end_char": 2671,
        "color": "purple"
      },
      {
        "text": "cancer",
        "label": "CANCER",
        "start_char": 2845,
        "end_char": 2851,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3012,
        "end_char": 3015,
        "color": "blue"
      },
      {
        "text": "amygdalin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3130,
        "end_char": 3139,
        "color": "red"
      },
      {
        "text": "cancer",
        "label": "CANCER",
        "start_char": 3223,
        "end_char": 3229,
        "color": "green"
      }
    ]
  },
  "Row_12_Col_Rifaximin Justification": {
    "original_text": "### Section 3: Expert Analysis - Therapeutic Alignment and Repurposing Rationale\n\n#### 1. Mechanistic Convergence\n\n**Mechanisms Identified in Cancer Pathophysiology:**\nThe provided information highlights **\u03b2-glucosidase activity** in the *Bacteroidetes* phylum as a key mechanism linking gut microbiota to cancer via the hydrolysis of amygdalin to hydrogen cyanide (HCN), which can target malignant cells by inhibiting cytochrome c oxidase, ultimately leading to cell death. Additionally, the paper discusses how the gut microbiome influences detoxification pathways, such as those involving Rhodanese, which converts cyanide to less harmful thiocyanate, and how dietary interventions can shape microbial populations and affect therapeutic outcomes.\n\n**Mechanisms of Action of Rifaximin:**\nRifaximin modulates gut microbiota by selectively reducing ammonia-producing bacteria like *Streptococcus salivarius* and the *Veillonellaceae* family, which have implications in hepatic encephalopathy and other conditions. Rifaximin\u2019s mechanism includes the downregulation of pro-inflammatory cytokines such as TNF-\u03b1, IL-1\u03b2, and IL-17, and promoting anti-inflammatory cytokines like IL-10. This modulation potentially influences systemic inflammation, which is a recognized factor in cancer progression.\n\n**Critical Assessment of Mechanistic Overlap:**\n- **Inflammatory Pathway Modulation:** Rifaximin\u2019s ability to lower TNF-\u03b1 and IL-1\u03b2 aligns with the inflammatory pathways implicated in cancer progression. Elevated TNF-\u03b1 is often associated with tumor growth and metastasis. By reducing TNF-\u03b1 levels, Rifaximin might help mitigate one of the pathways conducive to cancer development.\n- **Microbiota Interaction:** Just as specific gut microbiota drive the hydrolysis of amygdalin, Rifaximin alters gut microbiota composition, potentially leading to improved metabolic profiles and immune responses. The implication of gut microbiota in both scenarios presents an opportunity for Rifaximin to intervene at multiple levels in the cancer pathophysiology.\n\nIn light of these mechanistic alignments, Rifaximin may address some inflammatory and immune dysregulations present in cancer-related contexts, although it does not directly target the specific pathways involving \u03b2-glucosidase and HCN generation.\n\n#### 2. Supporting Clinical or Preclinical Evidence\n\nClinical applications of Rifaximin have demonstrated its effectiveness in modulating gut microbiota and reducing levels of pro-inflammatory markers. Specifically, it has been effective in managing conditions such as hepatic encephalopathy and irritable bowel syndrome, where inflammation plays a prominent role. The reduction of pro-inflammatory cytokines like TNF-\u03b1 and IL-1\u03b2 suggests a mechanism by which Rifaximin could yield benefits in cancer contexts, especially for inflammation-driven cancer types.\n\nMoreover, the modulation of the gut-brain axis and the potential to improve cognitive function and systemic symptoms could have implications for cancer patients, who often experience cognitive deficits and systemic inflammatory responses.\n\n#### 3. Therapeutic Implications\n\nBased on the available data, Rifaximin could offer partial therapeutic benefit in cancer scenarios through:\n- **Symptom Relief:** As seen in patients with IBS or hepatic encephalopathy, symptom improvement reflects Rifaximin's potential utility in alleviating discomfort related to gut dysbiosis that may accompany cancer.\n- **Modulation of Gut-Brain Axis Dysfunction:** By improving gut health and reducing systemic inflammation, Rifaximin may positively influence cognition and overall quality of life in cancer patients.\n- **Reduction in Systemic Inflammation:** Its action in lowering pro-inflammatory cytokines could benefit cancer patients by potentially reducing tumor-promoting inflammation.\n\n**Limitations or Caveats:**\n- While Rifaximin may address certain inflammatory pathways and improve gut health, it may not comprehensively target all mechanisms driving cancer progression, particularly those related to HCN production. \n- The potential need for adjunct therapies should be recognized, as Rifaximin alone may not provide a complete treatment strategy in the multifaceted landscape of cancer. \n\nIn conclusion, the mechanistic and clinical insights suggest that Rifaximin holds promise for repurposing in the cancer context, focusing on its role in immune modulation, gut microbiota improvement, and reduction in systemic inflammation, while acknowledging the need for further research to explore its full potential.",
    "annotated_entities": [
      {
        "text": "Cancer",
        "label": "CANCER",
        "start_char": 142,
        "end_char": 148,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 288,
        "end_char": 291,
        "color": "red"
      },
      {
        "text": "cancer",
        "label": "CANCER",
        "start_char": 306,
        "end_char": 312,
        "color": "orange"
      },
      {
        "text": "amygdalin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 335,
        "end_char": 344,
        "color": "red"
      },
      {
        "text": "hydrogen cyanide",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 348,
        "end_char": 364,
        "color": "purple"
      },
      {
        "text": "malignant cells",
        "label": "CELL",
        "start_char": 389,
        "end_char": 404,
        "color": "yellow"
      },
      {
        "text": "cytochrome c oxidase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 419,
        "end_char": 439,
        "color": "pink"
      },
      {
        "text": "cell",
        "label": "CELL",
        "start_char": 463,
        "end_char": 467,
        "color": "teal"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 517,
        "end_char": 531,
        "color": "green"
      },
      {
        "text": "cyanide",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 618,
        "end_char": 625,
        "color": "yellow"
      },
      {
        "text": "thiocyanate",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 642,
        "end_char": 653,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 777,
        "end_char": 786,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 790,
        "end_char": 799,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 810,
        "end_char": 813,
        "color": "red"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 969,
        "end_char": 976,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1014,
        "end_char": 1023,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1120,
        "end_char": 1125,
        "color": "teal"
      },
      {
        "text": "cancer",
        "label": "CANCER",
        "start_char": 1275,
        "end_char": 1281,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1383,
        "end_char": 1392,
        "color": "red"
      },
      {
        "text": "cancer",
        "label": "CANCER",
        "start_char": 1480,
        "end_char": 1486,
        "color": "orange"
      },
      {
        "text": "tumor",
        "label": "CANCER",
        "start_char": 1540,
        "end_char": 1545,
        "color": "orange"
      },
      {
        "text": "TNF-\u03b1",
        "label": "CELL",
        "start_char": 1581,
        "end_char": 1586,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1595,
        "end_char": 1604,
        "color": "red"
      },
      {
        "text": "cancer",
        "label": "CANCER",
        "start_char": 1658,
        "end_char": 1664,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1725,
        "end_char": 1728,
        "color": "red"
      },
      {
        "text": "amygdalin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1764,
        "end_char": 1773,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1775,
        "end_char": 1784,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1792,
        "end_char": 1795,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1912,
        "end_char": 1915,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1973,
        "end_char": 1982,
        "color": "red"
      },
      {
        "text": "cancer",
        "label": "CANCER",
        "start_char": 2022,
        "end_char": 2028,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2089,
        "end_char": 2098,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2373,
        "end_char": 2382,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2433,
        "end_char": 2436,
        "color": "red"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 2564,
        "end_char": 2571,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 2601,
        "end_char": 2606,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2755,
        "end_char": 2764,
        "color": "red"
      },
      {
        "text": "cancer",
        "label": "CANCER",
        "start_char": 2789,
        "end_char": 2795,
        "color": "orange"
      },
      {
        "text": "cancer",
        "label": "CANCER",
        "start_char": 2841,
        "end_char": 2847,
        "color": "orange"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2888,
        "end_char": 2897,
        "color": "blue"
      },
      {
        "text": "cancer patients",
        "label": "CANCER",
        "start_char": 3001,
        "end_char": 3016,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3159,
        "end_char": 3168,
        "color": "red"
      },
      {
        "text": "cancer",
        "label": "CANCER",
        "start_char": 3212,
        "end_char": 3218,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3271,
        "end_char": 3279,
        "color": "pink"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3292,
        "end_char": 3299,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3345,
        "end_char": 3354,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3412,
        "end_char": 3415,
        "color": "red"
      },
      {
        "text": "cancer",
        "label": "CANCER",
        "start_char": 3445,
        "end_char": 3451,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3514,
        "end_char": 3517,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3561,
        "end_char": 3570,
        "color": "red"
      },
      {
        "text": "cancer patients",
        "label": "CANCER",
        "start_char": 3637,
        "end_char": 3652,
        "color": "purple"
      },
      {
        "text": "cancer patients",
        "label": "CANCER",
        "start_char": 3760,
        "end_char": 3775,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3867,
        "end_char": 3876,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3931,
        "end_char": 3934,
        "color": "red"
      },
      {
        "text": "cancer",
        "label": "CANCER",
        "start_char": 4000,
        "end_char": 4006,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4135,
        "end_char": 4144,
        "color": "red"
      },
      {
        "text": "cancer",
        "label": "CANCER",
        "start_char": 4230,
        "end_char": 4236,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4306,
        "end_char": 4315,
        "color": "red"
      },
      {
        "text": "cancer",
        "label": "CANCER",
        "start_char": 4353,
        "end_char": 4359,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4412,
        "end_char": 4415,
        "color": "red"
      }
    ]
  },
  "Row_13_Col_Disease": {
    "original_text": "Influenza",
    "annotated_entities": []
  },
  "Row_13_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_13_Col_Disease_Mechanism": {
    "original_text": "The research paper outlines a clear mechanism linking gut microbiome alterations to influenza via the concept of the \"gut-lung axis.\" Here are the key points and mechanisms extracted from the paper:\n\n1. **Gut-Lung Axis**: The gut microbiota communicates with the respiratory system through secretion products, circulating immune cells, and metabolites. This crosstalk influences pulmonary immunity and can modulate immune responses to influenza virus infection.\n\n2. **Microbiota-Derived Metabolites**: Short-chain fatty acids (SCFAs) produced by gut microbiota play a vital role in this interplay. SCFAs can:\n   - Increase the pool of Ly6c\u207b monocytes in the bone marrow.\n   - Promote differentiation into alternatively activated macrophages in the lungs, which express lower levels of the neutrophil chemoattractant CXCL1, thereby reducing neutrophil influx and limiting lung immunopathology associated with influenza.\n   - Enhance the metabolism and antiviral activity of influenza-specific CD8\u207a T cells, balancing innate and adaptive immunity to facilitate the resolution of the infection.\n\n3. **Immune Activation**: Probiotics can stimulate the immune system through interactions with immune cells:\n   - Activation of antigen-presenting cells (APCs) and increased production of type I interferon (IFN) and interferon-stimulated genes (ISGs).\n   - Probiotics, such as those from the Lactobacillus and Bifidobacterium genera, can augment innate and adaptive immune responses, enhancing antiviral defenses against influenza.\n\n4. **Effect of Influenza on Gut Microbiota**: Conversely, influenza virus infection leads to significant alterations in gut microbiota:\n   - Infection induces dysbiosis characterized by a decrease in beneficial bacteria like **Lactobacillus** and an increase in potentially harmful bacteria.\n   - Lung-derived immune signals, such as CCR9\u207a CD4\u207a T cells and type I IFN, can alter intestinal microbiota composition, causing inflammation and affecting gut immunity.\n\n5. **Inflammatory Pathways**: The systemic effects of gut dysbiosis can lead to heightened immune responses:\n   - Probiotic administration can mitigate the \u201ccytokine storm\u201d associated with severe influenza infections by promoting regulated inflammatory responses and reducing excessive pro-inflammatory cytokines.\n\n6. **Restoration of Immune Function**: Antibiotics can induce dysbiosis, harming the generation of effective immune responses to influenza. The administration of TLR ligands (e.g., LPS) can restore these functions, demonstrating that maintaining gut microbiota integrity is essential for optimal immune performance against influenza.\n\nIn summary, alterations in the gut microbiome influence both local and systemic immune responses to influenza, fostering a complex interplay that can impact infection severity and resolution through metabolic signaling (e.g., SCFAs), immune modulation, and inflammatory pathway regulation. This understanding underscores the potential of probiotic interventions to prevent or alleviate influenza, particularly in vulnerable populations.",
    "annotated_entities": [
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 54,
        "end_char": 57,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 226,
        "end_char": 229,
        "color": "red"
      },
      {
        "text": "immune cells",
        "label": "CELL",
        "start_char": 322,
        "end_char": 334,
        "color": "blue"
      },
      {
        "text": "pulmonary",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 388,
        "color": "teal"
      },
      {
        "text": "Short-chain fatty acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 502,
        "end_char": 525,
        "color": "pink"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 527,
        "end_char": 532,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 546,
        "end_char": 549,
        "color": "red"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 598,
        "end_char": 603,
        "color": "yellow"
      },
      {
        "text": "Ly6c\u207b monocytes",
        "label": "CELL",
        "start_char": 635,
        "end_char": 650,
        "color": "blue"
      },
      {
        "text": "bone marrow",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 658,
        "end_char": 669,
        "color": "purple"
      },
      {
        "text": "macrophages",
        "label": "CELL",
        "start_char": 729,
        "end_char": 740,
        "color": "orange"
      },
      {
        "text": "lungs",
        "label": "ORGAN",
        "start_char": 748,
        "end_char": 753,
        "color": "green"
      },
      {
        "text": "neutrophil",
        "label": "CELL",
        "start_char": 789,
        "end_char": 799,
        "color": "purple"
      },
      {
        "text": "CXCL1",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 816,
        "end_char": 821,
        "color": "yellow"
      },
      {
        "text": "neutrophil",
        "label": "CELL",
        "start_char": 840,
        "end_char": 850,
        "color": "purple"
      },
      {
        "text": "lung",
        "label": "ORGAN",
        "start_char": 871,
        "end_char": 875,
        "color": "red"
      },
      {
        "text": "influenza-specific CD8\u207a T cells",
        "label": "ORGANISM",
        "start_char": 973,
        "end_char": 1004,
        "color": "orange"
      },
      {
        "text": "immune cells",
        "label": "CELL",
        "start_char": 1188,
        "end_char": 1200,
        "color": "blue"
      },
      {
        "text": "antigen-presenting cells",
        "label": "CELL",
        "start_char": 1221,
        "end_char": 1245,
        "color": "green"
      },
      {
        "text": "APCs",
        "label": "CELL",
        "start_char": 1247,
        "end_char": 1251,
        "color": "blue"
      },
      {
        "text": "type I interferon",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1281,
        "end_char": 1298,
        "color": "blue"
      },
      {
        "text": "ISGs",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1338,
        "end_char": 1342,
        "color": "teal"
      },
      {
        "text": "Lactobacillus",
        "label": "CELL",
        "start_char": 1385,
        "end_char": 1398,
        "color": "yellow"
      },
      {
        "text": "Bifidobacterium",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1403,
        "end_char": 1418,
        "color": "orange"
      },
      {
        "text": "Gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1554,
        "end_char": 1557,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1646,
        "end_char": 1649,
        "color": "red"
      },
      {
        "text": "CD4\u207a T cells",
        "label": "CELL",
        "start_char": 1866,
        "end_char": 1878,
        "color": "teal"
      },
      {
        "text": "type I IFN",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1883,
        "end_char": 1893,
        "color": "green"
      },
      {
        "text": "intestinal",
        "label": "ORGAN",
        "start_char": 1905,
        "end_char": 1915,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1975,
        "end_char": 1978,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2044,
        "end_char": 2047,
        "color": "red"
      },
      {
        "text": "Antibiotics",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2344,
        "end_char": 2355,
        "color": "red"
      },
      {
        "text": "TLR",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2467,
        "end_char": 2470,
        "color": "red"
      },
      {
        "text": "LPS",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2486,
        "end_char": 2489,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2551,
        "end_char": 2554,
        "color": "red"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 2671,
        "end_char": 2685,
        "color": "green"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2866,
        "end_char": 2871,
        "color": "yellow"
      }
    ]
  },
  "Row_13_Col_Rifaximin Justification": {
    "original_text": "## Expert Analysis - Therapeutic Alignment and Repurposing Rationale for Rifaximin in Influenza\n\n### 1. Mechanistic Convergence\n\nThe interplay between the gut microbiome and respiratory immunity, termed the **gut-lung axis**, highlights the potential of Rifaximin's mechanisms aligning with the immune challenges posed by influenza. Here\u2019s a breakdown of the mechanisms involved:\n\n#### Immune Cells and Cytokines:\n- **Influenza Infection Mechanisms**:\n  - **Ly6c\u207b Monocytes**: SCFAs produced by gut microbiota foster the differentiation of these monocytes, enhancing pulmonary immunity.\n  - **Type I Interferon (IFN)**: Essential for initiating antiviral responses, its production can be augmented by probiotics, which are reflective of Rifaximin's action in modulating the gut microbiota.\n\n- **Rifaximin Mechanisms**:\n  - **Cytokine Modulation**: Rifaximin reduces pro-inflammatory cytokines such as **TNF-\u03b1 and IL-1\u03b2**, which play crucial roles in maintaining inflammation during infections, including influenza. The ability to decrease these cytokines may mitigate excessive immune responses, such as the \"cytokine storm.\"\n  - **Gut Microbiota Modulation**: Rifaximin selectively reduces harmful bacteria and promotes the growth of beneficial gut flora (e.g., **Lactobacillus**), akin to the role probiotics play in supporting immune function against influenza.\n\n#### Mechanistic Overlap:\nRifaximin's modulation of systemic inflammatory pathways aligns directly with the immune dysregulation observed in influenza. By reducing TNF-\u03b1 and promoting beneficial changes in gut microbiota composition, Rifaximin potentially influences the immune modulation that prevents severe pathologies associated with influenza infection.\n\n### 2. Supporting Clinical or Preclinical Evidence\n\nWhile direct clinical evidence linking Rifaximin to influenza management specifically is limited, predominant observations lend support to its potential utility in this context:\n\n- **Modulation of Microbiota**: Rifaximin is known to alter gut microbial populations favorably, enhancing the presence of beneficial taxa that produce SCFAs, which have been implicated in improving immune responses.\n- **Reduction of Inflammatory Markers**: The ability of Rifaximin to decrease inflammatory cytokines (like TNF-\u03b1 and IL-1\u03b2) suggests it could mitigate the systemic inflammation seen in severe influenza cases, thus indirectly affecting overall clinical outcomes.\n\n### 3. Therapeutic Implications\n\nGiven the above mechanistic and observational evidence, Rifaximin warrants consideration as a therapeutic adjunct in influenza management:\n\n- **Partial Therapeutic Benefit**: Rifaximin could provide **symptom relief** and contribute to the **modulation of gut-brain axis dysfunction**. This may enhance cognitive function and potentially alleviate influenza-related immune dysregulation, leading to better overall recovery outcomes.\n- **Systemic Inflammation Reduction**: By targeting key inflammatory pathways associated with influenza, Rifaximin might help in reducing the severity of the immune response during infection, while improving gut health.\n\n#### Limitations:\nWhile there is promising alignment, Rifaximin's scope may primarily address inflammatory aspects rather than serving as a frontline antiviral agent. Additional therapies targeting viral replication could be necessary to achieve comprehensive management of influenza. \n\nIn conclusion, the mechanistic overlap between Rifaximin's pharmacologic profile and the pathophysiological drivers of influenza supports its repurposing potential, illustrating a viable approach to enhance immune modulation and gut health during influenza infections.",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 73,
        "end_char": 82,
        "color": "red"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 155,
        "end_char": 169,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 254,
        "end_char": 263,
        "color": "red"
      },
      {
        "text": "Immune Cells",
        "label": "CELL",
        "start_char": 386,
        "end_char": 398,
        "color": "purple"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 403,
        "end_char": 412,
        "color": "red"
      },
      {
        "text": "Ly6c\u207b Monocytes",
        "label": "CELL",
        "start_char": 458,
        "end_char": 473,
        "color": "teal"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 477,
        "end_char": 482,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 495,
        "end_char": 498,
        "color": "green"
      },
      {
        "text": "monocytes",
        "label": "CELL",
        "start_char": 546,
        "end_char": 555,
        "color": "yellow"
      },
      {
        "text": "pulmonary",
        "label": "ORGAN",
        "start_char": 567,
        "end_char": 576,
        "color": "pink"
      },
      {
        "text": "Type I Interferon",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 593,
        "end_char": 610,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 737,
        "end_char": 746,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 774,
        "end_char": 777,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 795,
        "end_char": 804,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 848,
        "end_char": 857,
        "color": "red"
      },
      {
        "text": "TNF-\u03b1",
        "label": "CELL",
        "start_char": 903,
        "end_char": 908,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1161,
        "end_char": 1170,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1246,
        "end_char": 1249,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1392,
        "end_char": 1401,
        "color": "red"
      },
      {
        "text": "TNF-\u03b1",
        "label": "CELL",
        "start_char": 1530,
        "end_char": 1535,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1572,
        "end_char": 1575,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1600,
        "end_char": 1609,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1817,
        "end_char": 1826,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1989,
        "end_char": 1998,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2017,
        "end_char": 2020,
        "color": "green"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2109,
        "end_char": 2114,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2230,
        "end_char": 2239,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2526,
        "end_char": 2535,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2645,
        "end_char": 2654,
        "color": "red"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2726,
        "end_char": 2735,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3008,
        "end_char": 3017,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3111,
        "end_char": 3114,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3178,
        "end_char": 3187,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3458,
        "end_char": 3467,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3640,
        "end_char": 3643,
        "color": "green"
      }
    ]
  },
  "Row_14_Col_Disease": {
    "original_text": "atopic dermatitis",
    "annotated_entities": []
  },
  "Row_14_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_14_Col_Disease_Mechanism": {
    "original_text": "The research paper elucidates significant mechanisms linking gut microbiome alterations, specifically focusing on the Clostridia strains, to immune modulation, which can be relevant in the context of atopic dermatitis. Here are the key mechanistic insights based on the provided content:\n\n1. **Microbiome-Induced Immune Modulation**:\n   - The strains of Clostridia induce **regulatory T cells (reg cells)** in the colon, specifically increasing the population of **CD4[+]Foxp3[+] cells**. This accumulation is critical for modulating immune response and maintaining immune homeostasis.\n   - The production of **short-chain fatty acids (SCFAs)**, particularly **butyrate**, plays a pivotal role in this process. SCFAs can suppress **dendritic cell activation** through the repression of the **NF\u03baB** component RelB and provoke a **GF-\u03b21 response** that aids in the de novo induction of peripheral regulatory T cells (preg).\n\n2. **Metabolic Disruptions and Disease Pathophysiology**:\n   - The Clostridia strains show a capacity for producing **acetate and butyrate**, which are critical in regulating inflammation. Butyrate is known to influence **GPR109a signaling** pathways in dendritic cells, enhancing anti-inflammatory gene expression and helping in the proliferation of Tregs and regulation of immune responses that are essential in atopic conditions.\n   - The study indicates that a dysbiotic microbiota with diminished levels of Clostridia is associated with increased risks of diseases like **atopic dermatitis** and **airway hypersensitivity**, linking microbial metabolism disruptions to altered inflammatory pathways.\n\n3. **Key Bacterial Species & Their Roles**:\n   - The identified **17 strains of Clostridia** isolated from healthy human gut microbiota are specifically functional in promoting reg cell accumulation and preventing conditions such as colitis. These strains, by producing SCFAs and other metabolites, contribute significantly to the immune-modulatory landscape, thus potentially alleviating inflammatory responses associated with atopic dermatitis.\n\n4. **Biological Mechanism & Molecular Pathways**:\n   - The interaction of SCFAs with host receptors such as **GPR43** not only bolsters butyrate's role in promoting Treg proliferation but also influences **histone acetylation**, which affects the transcriptional regulation of the Foxp3 gene, crucial for Treg differentiation and function.\n\nOverall, the alterations in the gut microbiome through the presence and activity of specific Clostridia strains facilitate the induction of regulatory immune responses via metabolic pathways involving SCFA production, thereby creating a mechanistic link to the modulation of inflammatory conditions such as atopic dermatitis.",
    "annotated_entities": [
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 61,
        "end_char": 64,
        "color": "green"
      },
      {
        "text": "T cells",
        "label": "CELL",
        "start_char": 385,
        "end_char": 392,
        "color": "purple"
      },
      {
        "text": "reg cells",
        "label": "CELL",
        "start_char": 394,
        "end_char": 403,
        "color": "pink"
      },
      {
        "text": "colon",
        "label": "CANCER",
        "start_char": 414,
        "end_char": 419,
        "color": "purple"
      },
      {
        "text": "short-chain fatty acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 611,
        "end_char": 634,
        "color": "orange"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 636,
        "end_char": 641,
        "color": "blue"
      },
      {
        "text": "butyrate",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 661,
        "end_char": 669,
        "color": "orange"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 711,
        "end_char": 716,
        "color": "blue"
      },
      {
        "text": "dendritic cell",
        "label": "CELL",
        "start_char": 732,
        "end_char": 746,
        "color": "teal"
      },
      {
        "text": "RelB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 809,
        "end_char": 813,
        "color": "red"
      },
      {
        "text": "peripheral",
        "label": "TISSUE",
        "start_char": 885,
        "end_char": 895,
        "color": "teal"
      },
      {
        "text": "T cells",
        "label": "CELL",
        "start_char": 907,
        "end_char": 914,
        "color": "purple"
      },
      {
        "text": "acetate",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1042,
        "end_char": 1049,
        "color": "red"
      },
      {
        "text": "butyrate",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1054,
        "end_char": 1062,
        "color": "orange"
      },
      {
        "text": "Butyrate",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1113,
        "end_char": 1121,
        "color": "orange"
      },
      {
        "text": "dendritic cells",
        "label": "CELL",
        "start_char": 1178,
        "end_char": 1193,
        "color": "yellow"
      },
      {
        "text": "Tregs",
        "label": "CELL",
        "start_char": 1275,
        "end_char": 1280,
        "color": "yellow"
      },
      {
        "text": "airway",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1527,
        "end_char": 1533,
        "color": "green"
      },
      {
        "text": "human gut",
        "label": "ORGANISM",
        "start_char": 1745,
        "end_char": 1754,
        "color": "purple"
      },
      {
        "text": "reg cell",
        "label": "CELL",
        "start_char": 1807,
        "end_char": 1815,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1900,
        "end_char": 1905,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2152,
        "end_char": 2157,
        "color": "blue"
      },
      {
        "text": "GPR43",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2188,
        "end_char": 2193,
        "color": "red"
      },
      {
        "text": "butyrate",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2214,
        "end_char": 2222,
        "color": "orange"
      },
      {
        "text": "Treg",
        "label": "CELL",
        "start_char": 2243,
        "end_char": 2247,
        "color": "teal"
      },
      {
        "text": "histone",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2284,
        "end_char": 2291,
        "color": "orange"
      },
      {
        "text": "Foxp3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2359,
        "end_char": 2364,
        "color": "pink"
      },
      {
        "text": "Treg",
        "label": "CELL",
        "start_char": 2383,
        "end_char": 2387,
        "color": "teal"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 2451,
        "end_char": 2465,
        "color": "blue"
      },
      {
        "text": "SCFA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2620,
        "end_char": 2624,
        "color": "green"
      }
    ]
  },
  "Row_14_Col_Rifaximin Justification": {
    "original_text": "### Expert Analysis - Therapeutic Alignment and Repurposing Rationale\n\n#### 1. Mechanistic Convergence\nAtopic dermatitis (AD) is characterized by a dysregulated immune response, notably involving deficits in regulatory T cells (Tregs), elevated pro-inflammatory cytokines, and specific alterations in the gut microbiome. Rifaximin's mechanism of action may align with these pathological features, presenting a potential repurposing opportunity:\n\n**Mechanisms in Atopic Dermatitis:**\n- **Regulatory T Cells and Immune Modulation:** In AD, there is typically a deficiency of CD4[+]Foxp3[+] Tregs, leading to uncontrolled inflammation. The Clostridia strains induce Tregs via short-chain fatty acids (SCFAs) like butyrate, which also suppresses dendritic cell activation and promotes regulatory pathways.\n- **Increased Pro-inflammatory Cytokines:** Elevated levels of TNF-\u03b1, IL-1\u03b2, and IL-6 are common in AD, contributing to inflammation and skin barrier dysfunction.\n- **Altered Gut Microbiota:** Diminished Clostridia strains are linked to both atopic dermatitis and increased airway hypersensitivity, suggesting that a healthier gut microbiome could mitigate immune dysregulation.\n\n**Rifaximin's Mechanisms:**\n- **Modulation of Gut Microbiota:** Rifaximin selectively reduces pathogenic bacteria while enhancing beneficial bacteria such as Lactobacillus and Ruminococcaceae, which may parallel the effects seen with Clostridia strains in promoting Treg function.\n- **Reduction of Pro-inflammatory Cytokines:** Rifaximin has been demonstrated to lower levels of TNF-\u03b1, IL-1\u03b2, and IL-17, directly targeting the inflammatory milieu characteristic of AD.\n- **Inhibition of Bacterial Overgrowth:** By reducing bacterial load, Rifaximin could help restore the microbial balance necessary for SCFA production, crucial for maintaining immune homeostasis.\n\n**Mechanistic Alignment:** \nThere is significant mechanistic alignment between Rifaximin's actions and the pathologies of atopic dermatitis. The ability of Rifaximin to increase Tregs and decrease pro-inflammatory cytokines directly addresses both the immune dysregulation and altered microbiota observed in AD. Rifaximin's role in modulating gut microbiota can potentially replicate the immune modulation seen with Clostridia strains, underscoring the possibility of repurposing Rifaximin as a therapeutic agent for AD.\n\n#### 2. Supporting Clinical or Preclinical Evidence\nWhile specific clinical trials evaluating Rifaximin's effects on atopic dermatitis are not detailed in the provided information, the drug\u2019s established impact on improving gut health and modulating cytokine profiles indicate a potential benefit in conditions associated with dysregulated immune responses. \n\n- **Modulation of Microbiota:** Rifaximin\u2019s antimicrobial action leads to a favorable shift in gut microbiota, which is critical for maintaining immune balance, akin to the beneficial effects of SCFAs produced by Clostridia. This shift could alleviate the immune dysregulation found in AD.\n- **Reduction of Inflammatory Markers:** The reduction of key inflammatory cytokines (e.g., TNF-\u03b1, IL-1\u03b2) aligns with the goal of mitigating symptoms and underlying inflammation seen in AD. Though direct evidence in AD may be limited, its effect on related conditions suggests a broader applicability.\n\n#### 3. Therapeutic Implications\nGiven the mechanistic and clinical considerations, Rifaximin could provide partial therapeutic benefits in the management of atopic dermatitis:\n\n- **Symptom Relief:** By reducing gut-derived pro-inflammatory cytokines and enhancing the regulatory immune response, Rifaximin might alleviate some inflammatory symptoms associated with AD.\n- **Modulation of Gut-Brain Axis Dysfunction:** The potential to improve gut health may consequently affect systemic inflammation and immune responses, suggesting benefits beyond localized skin symptoms.\n- **Need for Adjunct Therapies:** While Rifaximin may provide benefits, it may not address all dimensions of AD, such as skin barrier repair or allergen sensitivity. Therefore, it should be viewed as an adjunct therapy alongside traditional treatments for complete management.\n\n**Limitations and Caveats:** The effectiveness of Rifaximin could vary based on individual microbiota compositions, and ongoing research is needed to clarify its role and optimization in AD treatment strategies.\n\n### Conclusion\nRifaximin presents a promising repurposing opportunity for atopic dermatitis through its mechanisms of gut microbiota modulation and pro-inflammatory cytokine reduction. The alignment of its pharmacodynamics with the inflammatory and immunological deficits characteristic of AD supports potential therapeutic benefits, indicating the need for further clinical exploration in this disease context.",
    "annotated_entities": [
      {
        "text": "T cells",
        "label": "CELL",
        "start_char": 219,
        "end_char": 226,
        "color": "blue"
      },
      {
        "text": "Tregs",
        "label": "CELL",
        "start_char": 228,
        "end_char": 233,
        "color": "purple"
      },
      {
        "text": "gut microbiome",
        "label": "ORGAN",
        "start_char": 305,
        "end_char": 319,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 321,
        "end_char": 330,
        "color": "teal"
      },
      {
        "text": "Immune",
        "label": "CELL",
        "start_char": 510,
        "end_char": 516,
        "color": "orange"
      },
      {
        "text": "Tregs",
        "label": "CELL",
        "start_char": 663,
        "end_char": 668,
        "color": "purple"
      },
      {
        "text": "short-chain fatty acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 673,
        "end_char": 696,
        "color": "red"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 698,
        "end_char": 703,
        "color": "pink"
      },
      {
        "text": "dendritic cell",
        "label": "CELL",
        "start_char": 742,
        "end_char": 756,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 833,
        "end_char": 842,
        "color": "blue"
      },
      {
        "text": "IL-6",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 883,
        "end_char": 887,
        "color": "blue"
      },
      {
        "text": "skin",
        "label": "ORGAN",
        "start_char": 939,
        "end_char": 943,
        "color": "green"
      },
      {
        "text": "Gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 977,
        "end_char": 980,
        "color": "teal"
      },
      {
        "text": "airway",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1076,
        "end_char": 1082,
        "color": "green"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 1129,
        "end_char": 1143,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1184,
        "end_char": 1193,
        "color": "teal"
      },
      {
        "text": "Gut Microbiota:**",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1228,
        "end_char": 1245,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1246,
        "end_char": 1255,
        "color": "teal"
      },
      {
        "text": "Lactobacillus",
        "label": "CELLULAR_COMPONENT",
        "start_char": 1340,
        "end_char": 1353,
        "color": "purple"
      },
      {
        "text": "Treg",
        "label": "CELL",
        "start_char": 1448,
        "end_char": 1452,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1497,
        "end_char": 1506,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1510,
        "end_char": 1519,
        "color": "teal"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1579,
        "end_char": 1584,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1721,
        "end_char": 1730,
        "color": "teal"
      },
      {
        "text": "SCFA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1786,
        "end_char": 1790,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1927,
        "end_char": 1936,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "teal"
      },
      {
        "text": "Tregs",
        "label": "CELL",
        "start_char": 2026,
        "end_char": 2031,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2160,
        "end_char": 2169,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2191,
        "end_char": 2194,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2328,
        "end_char": 2337,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2464,
        "end_char": 2473,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2594,
        "end_char": 2597,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2762,
        "end_char": 2771,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2825,
        "end_char": 2828,
        "color": "teal"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2925,
        "end_char": 2930,
        "color": "pink"
      },
      {
        "text": "AD",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3236,
        "end_char": 3238,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3407,
        "end_char": 3416,
        "color": "teal"
      },
      {
        "text": "gut-derived pro-inflammatory cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3535,
        "end_char": 3573,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3620,
        "end_char": 3629,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3766,
        "end_char": 3769,
        "color": "teal"
      },
      {
        "text": "skin",
        "label": "ORGAN",
        "start_char": 3882,
        "end_char": 3886,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3937,
        "end_char": 3946,
        "color": "teal"
      },
      {
        "text": "skin",
        "label": "ORGAN",
        "start_char": 4018,
        "end_char": 4022,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4225,
        "end_char": 4234,
        "color": "teal"
      },
      {
        "text": "AD",
        "label": "CANCER",
        "start_char": 4362,
        "end_char": 4364,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4403,
        "end_char": 4412,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4506,
        "end_char": 4509,
        "color": "teal"
      }
    ]
  },
  "Row_15_Col_Disease": {
    "original_text": "COVID-19",
    "annotated_entities": [
      {
        "text": "COVID-19",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 0,
        "end_char": 8,
        "color": "red"
      }
    ]
  },
  "Row_15_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_15_Col_Disease_Mechanism": {
    "original_text": "The research paper outlines several mechanisms linking gut microbiome alterations to COVID-19, highlighting specific pathways, inflammatory mediators, and bacterial taxa involved in the process. Here are the key points extracted from the text:\n\n1. **Microbiome-Induced Immune Modulation**:\n   - The gut microbiota plays a crucial role in modulating the immune response. For instance, beneficial bacteria such as *Faecalibacterium prausnitzii*, *Bifidobacterium adolescentis*, and *Bifidobacterium longum* are reduced in COVID-19 patients, correlating with elevated levels of inflammatory cytokines such as IL-6 and TNF-\u03b1. This indicates that these bacteria may help to suppress excessive inflammation.\n   - The pathway involving the **NF-\u03baB, IRF3, and JAK/STAT** signaling pathways is activated upon SARS-CoV-2 infection, leading to the expression of various pro-inflammatory factors, contributing to the so-called \"cytokine storm.\" Gut dysbiosis exacerbates this inflammatory response by damaging intestinal barriers.\n\n2. **Metabolic Disruptions and Disease Pathophysiology**:\n   - Dysbiosis results in the depletion of beneficial metabolites, such as short-chain fatty acids (SCFAs) like butyrate, propionate, and acetate. These metabolites are known to play vital roles in anti-inflammatory responses, systemic immunity, and microbial homeostasis.\n   - SCFAs, particularly butyrate, influence the differentiation of T regulatory (Treg) cells and enhance epithelial barrier functions, thus reducing the susceptibility to inflammation and infection.\n\n3. **Gut Microbial Composition & Biomarkers**:\n   - COVID-19 is associated with a dysbiotic microbiota characterized by an **increase in opportunistic pathogens** (e.g., *Clostridium*, *Streptococcus*, and *Escherichia*) and a **decrease in beneficial commensals** (e.g., members of the *Bacteroidetes* and *Actinobacteria* phyla). This shift contributes to disease severity and correlates with inflammatory markers and clinical outcomes.\n   - The presence of specific microbial taxa such as *Bacteroides dorei* and *Bacteroides thetaiotaomicron* are negatively associated with viral load, suggesting a protective role against severe COVID-19.\n\n4. **Gut-Organ Crosstalk**:\n   - The study explores how gut dysbiosis can influence systemic inflammation through the circulation. Viral components or inflammatory markers released from the gut can promote systemic inflammation, leading to exacerbation of respiratory symptoms.\n   - The gut microbiota also interacts with lung immunity through the \"gut-lung axis,\" where gut-derived metabolites can reach the lungs, affecting immune responses to SARS-CoV-2.\n\n5. **Key Bacterial Species & Their Roles**:\n   - Specific bacteria have been identified that either contribute to or mitigate COVID-19 severity. For example, *Clostridium* species are mentioned to have potential opposing effects on ACE2 expression, which is critical as ACE2 is a primary receptor for SARS-CoV-2.\n\n6. **Biological Mechanism & Molecular Pathways**:\n   - The internalization of SARS-CoV-2 leads to the downregulation of ACE2, affecting the intestinal epithelium and promoting dysbiosis. This downregulation of ACE2 can disrupt amino acid transport and gut barrier integrity, contributing to infections and inflammation proliferation.\n   - Furthermore, dysbiosis enhances gut inflammation and the cycle of immune dysregulation, with elevated pro-inflammatory cytokines causing extensive systemic consequences.\n\nIn summary, the interplay between gut microbiota alterations and COVID-19 severity involves immune modulation through specific bacterial taxa, the impact of microbial metabolites on inflammation, and significant bidirectional communication between gut and lung systems. Interventions that target the gut microbiome, such as probiotics, prebiotics, and fecal microbiota transplantation, are proposed as promising therapeutic strategies to manage COVID-19-associated gastrointestinal symptoms and reduce overall disease severity.",
    "annotated_entities": [
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 55,
        "end_char": 58,
        "color": "orange"
      },
      {
        "text": "COVID-19",
        "label": "CELLULAR_COMPONENT",
        "start_char": 85,
        "end_char": 93,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 299,
        "end_char": 302,
        "color": "orange"
      },
      {
        "text": "Bifidobacterium adolescentis",
        "label": "CELLULAR_COMPONENT",
        "start_char": 445,
        "end_char": 473,
        "color": "purple"
      },
      {
        "text": "Bifidobacterium longum",
        "label": "CELLULAR_COMPONENT",
        "start_char": 481,
        "end_char": 503,
        "color": "teal"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 529,
        "end_char": 537,
        "color": "purple"
      },
      {
        "text": "IL-6",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 606,
        "end_char": 610,
        "color": "yellow"
      },
      {
        "text": "IRF3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 742,
        "end_char": 746,
        "color": "green"
      },
      {
        "text": "Gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 933,
        "end_char": 936,
        "color": "orange"
      },
      {
        "text": "intestinal",
        "label": "ORGAN",
        "start_char": 998,
        "end_char": 1008,
        "color": "pink"
      },
      {
        "text": "short-chain fatty acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1153,
        "end_char": 1176,
        "color": "pink"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1178,
        "end_char": 1183,
        "color": "yellow"
      },
      {
        "text": "propionate",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1200,
        "end_char": 1210,
        "color": "teal"
      },
      {
        "text": "acetate",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1216,
        "end_char": 1223,
        "color": "green"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1356,
        "end_char": 1361,
        "color": "yellow"
      },
      {
        "text": "butyrate",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1376,
        "end_char": 1384,
        "color": "yellow"
      },
      {
        "text": "epithelial",
        "label": "TISSUE",
        "start_char": 1457,
        "end_char": 1467,
        "color": "red"
      },
      {
        "text": "Bacteroides thetaiotaomicron",
        "label": "ORGANISM",
        "start_char": 2069,
        "end_char": 2097,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2253,
        "end_char": 2256,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2387,
        "end_char": 2390,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2484,
        "end_char": 2487,
        "color": "orange"
      },
      {
        "text": "lung",
        "label": "ORGAN",
        "start_char": 2519,
        "end_char": 2523,
        "color": "blue"
      },
      {
        "text": "gut-derived metabolites",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2568,
        "end_char": 2591,
        "color": "teal"
      },
      {
        "text": "lungs",
        "label": "ORGAN",
        "start_char": 2606,
        "end_char": 2611,
        "color": "orange"
      },
      {
        "text": "ACE2",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2888,
        "end_char": 2892,
        "color": "red"
      },
      {
        "text": "ACE2",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2926,
        "end_char": 2930,
        "color": "red"
      },
      {
        "text": "ACE2",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3090,
        "end_char": 3094,
        "color": "red"
      },
      {
        "text": "intestinal epithelium",
        "label": "TISSUE",
        "start_char": 3110,
        "end_char": 3131,
        "color": "red"
      },
      {
        "text": "ACE2",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3180,
        "end_char": 3184,
        "color": "red"
      },
      {
        "text": "amino acid",
        "label": "AMINO_ACID",
        "start_char": 3197,
        "end_char": 3207,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3222,
        "end_char": 3225,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3341,
        "end_char": 3344,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3514,
        "end_char": 3517,
        "color": "orange"
      },
      {
        "text": "COVID-19",
        "label": "CELLULAR_COMPONENT",
        "start_char": 3545,
        "end_char": 3553,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3728,
        "end_char": 3731,
        "color": "orange"
      },
      {
        "text": "lung",
        "label": "ORGAN",
        "start_char": 3736,
        "end_char": 3740,
        "color": "blue"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 3780,
        "end_char": 3794,
        "color": "purple"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3945,
        "end_char": 3961,
        "color": "green"
      }
    ]
  },
  "Row_15_Col_Rifaximin Justification": {
    "original_text": "### Section 3: Expert Analysis - Therapeutic Alignment and Repurposing Rationale\n\n1. **Mechanistic Convergence**\n\n   The interplay between gut microbiota and COVID-19 involves multiple mechanisms that provide a potential pathway for Rifaximin's therapeutic role:\n\n   - **Microbiome-Induced Immune Modulation:** COVID-19 is characterized by increased levels of inflammatory cytokines, notably IL-6 and TNF-\u03b1, following the reduction of beneficial gut bacteria such as *Faecalibacterium prausnitzii* and *Bifidobacterium* species. Rifaximin, through its mechanism of action in modulating gut microbiota, specifically targets pathogenic bacteria while enhancing the abundance of beneficial genera like *Lactobacillus* and *Ruminococcaceae*. This modulation can reduce TNF-\u03b1 and other pro-inflammatory cytokines that are elevated in COVID-19, thus aligning with the observed immune dysregulation.\n\n   - **Inflammatory Pathway Activation:** The activation of NF-\u03baB, IRF3, and JAK/STAT signaling pathways contributes to cytokine storms in COVID-19. Rifaximin's ability to reduce TNF-\u03b1 levels and suppress NF-\u03baB activation could directly counter the inflammation exacerbated by SARS-CoV-2. Moreover, Rifaximin\u2019s influence on T regulatory (Treg) cell differentiation and its ability to promote anti-inflammatory cytokines like IL-10 further align with the need to restore balance in hyper-inflammatory states.\n\n   - **Metabolic Disruptions:** The depletion of beneficial short-chain fatty acids (SCFAs) in COVID-19 patients exacerbates inflammation and diminishes gut barrier integrity. Rifaximin has been shown to restore microbial balance and increase SCFA-producing bacteria, potentially mitigating gut dysbiosis and its systemic effects.\n\n   - **Gut-Organ Crosstalk:** The \"gut-lung axis\" suggests that gut-derived metabolites can influence lung immunity. By restoring healthy gut microbiota and enhancing metabolite production, Rifaximin may help modulate systemic inflammation and respiratory symptoms associated with COVID-19.\n\n   Considering these overlapping mechanisms, Rifaximin presents a **direct mechanistic alignment** with the inflammatory and immune response alterations seen in COVID-19. Its potential to modulate dysregulated immune responses, reduce pro-inflammatory cytokines, and reestablish beneficial gut microbial ecology underscores its repurposing viability in this context.\n\n2. **Supporting Clinical or Preclinical Evidence**\n\n   Clinical observations related to Rifaximin's efficacy in gastrointestinal and hepatic conditions provide supportive evidence for its potential use in COVID-19. Specifically:\n\n   - **Reduction of Inflammatory Markers:** Rifaximin effectively decreases TNF-\u03b1, IL-1\u03b2, and IL-17 levels in conditions associated with gut dysbiosis, suggesting it could similarly reduce these markers in COVID-19 patients. \n   - **Improvement of Gut Health:** Rifaximin's ability to change gut microbiota composition, restoring beneficial taxa while inhibiting pathogenic species, aligns with findings that suggest the importance of microbiota stability in COVID-19 disease outcomes.\n   - **Cognitive and Systemic Improvements:** While Rifaximin is primarily noted for its effects on hepatic encephalopathy, its neuroprotective properties and impact on systemic inflammation could translate into symptomatic benefits for cognitive disruptions noted in severe COVID-19 cases.\n\n3. **Therapeutic Implications**\n\n   Based on the available data, Rifaximin may offer **partial therapeutic benefits** in the management of COVID-19, particularly through:\n\n   - **Symptom Relief:** By restoring gut microbiota, Rifaximin may alleviate gastrointestinal symptoms commonly reported in COVID-19 patients, such as diarrhea and abdominal discomfort.\n   - **Modulation of Gut-Brain Axis Dysfunction:** Its effects on reducing neuroinflammation could improve cognitive symptoms often seen in post-COVID conditions, supporting overall mental well-being in affected patients.\n   - **Reduction in Systemic Inflammation:** By targeting both microbial imbalances and modulating key pro-inflammatory cytokines, Rifaximin could lower the inflammatory burden associated with viral infections.\n\n**Limitations/Caveats:**\n- **Incomplete Pathway Targeting:** While Rifaximin offers a promising approach, it may not comprehensively address all pathways involved in COVID-19 pathophysiology, particularly the viral components and their direct effects.\n- **Need for Adjunct Therapies:** Rifaximin's efficacy may be enhanced when used alongside other therapies targeting the viral replication process or additional immune-modulating agents.\n\nIn summary, Rifaximin's potential repurposing for COVID-19 is supported by **mechanistic overlap** with key inflammatory pathways, positive impacts on microbiota composition, and the modulation of immune responses. Given these factors, its integration into COVID-19 management protocols warrants further investigation.",
    "annotated_entities": [
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 139,
        "end_char": 142,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 233,
        "end_char": 242,
        "color": "yellow"
      },
      {
        "text": "IL-6",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 392,
        "end_char": 396,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 446,
        "end_char": 449,
        "color": "teal"
      },
      {
        "text": "Bifidobacterium",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 503,
        "end_char": 518,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 529,
        "end_char": 538,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 586,
        "end_char": 589,
        "color": "teal"
      },
      {
        "text": "TNF-\u03b1",
        "label": "CELL",
        "start_char": 765,
        "end_char": 770,
        "color": "green"
      },
      {
        "text": "COVID-19",
        "label": "CELLULAR_COMPONENT",
        "start_char": 829,
        "end_char": 837,
        "color": "blue"
      },
      {
        "text": "IRF3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 961,
        "end_char": 965,
        "color": "blue"
      },
      {
        "text": "JAK/STAT",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 971,
        "end_char": 979,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1043,
        "end_char": 1052,
        "color": "yellow"
      },
      {
        "text": "TNF-\u03b1",
        "label": "CELL",
        "start_char": 1073,
        "end_char": 1078,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1193,
        "end_char": 1202,
        "color": "yellow"
      },
      {
        "text": "Treg",
        "label": "CELL",
        "start_char": 1232,
        "end_char": 1236,
        "color": "blue"
      },
      {
        "text": "short-chain fatty acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1463,
        "end_char": 1486,
        "color": "red"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1488,
        "end_char": 1493,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 1507,
        "end_char": 1515,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1556,
        "end_char": 1559,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1579,
        "end_char": 1588,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1694,
        "end_char": 1697,
        "color": "teal"
      },
      {
        "text": "gut-derived metabolites",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1799,
        "end_char": 1822,
        "color": "yellow"
      },
      {
        "text": "lung",
        "label": "ORGAN",
        "start_char": 1837,
        "end_char": 1841,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1873,
        "end_char": 1876,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1925,
        "end_char": 1934,
        "color": "yellow"
      },
      {
        "text": "COVID-19",
        "label": "CELLULAR_COMPONENT",
        "start_char": 2016,
        "end_char": 2024,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2072,
        "end_char": 2081,
        "color": "yellow"
      },
      {
        "text": "COVID-19",
        "label": "CELLULAR_COMPONENT",
        "start_char": 2188,
        "end_char": 2196,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2317,
        "end_char": 2320,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2483,
        "end_char": 2492,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 2507,
        "end_char": 2523,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 2528,
        "end_char": 2535,
        "color": "pink"
      },
      {
        "text": "COVID-19",
        "label": "CELLULAR_COMPONENT",
        "start_char": 2600,
        "end_char": 2608,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2669,
        "end_char": 2678,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2719,
        "end_char": 2724,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2762,
        "end_char": 2765,
        "color": "teal"
      },
      {
        "text": "Gut",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 2873,
        "end_char": 2876,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2887,
        "end_char": 2896,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2917,
        "end_char": 2920,
        "color": "teal"
      },
      {
        "text": "COVID-19",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 3084,
        "end_char": 3092,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3163,
        "end_char": 3172,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3211,
        "end_char": 3218,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3468,
        "end_char": 3477,
        "color": "yellow"
      },
      {
        "text": "COVID-19",
        "label": "CELLULAR_COMPONENT",
        "start_char": 3542,
        "end_char": 3550,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3613,
        "end_char": 3616,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3629,
        "end_char": 3638,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3653,
        "end_char": 3669,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3709,
        "end_char": 3717,
        "color": "teal"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3740,
        "end_char": 3749,
        "color": "red"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3974,
        "end_char": 3982,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4115,
        "end_char": 4124,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4263,
        "end_char": 4272,
        "color": "yellow"
      },
      {
        "text": "COVID-19",
        "label": "CELLULAR_COMPONENT",
        "start_char": 4362,
        "end_char": 4370,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4482,
        "end_char": 4491,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4648,
        "end_char": 4657,
        "color": "yellow"
      },
      {
        "text": "COVID-19",
        "label": "CELLULAR_COMPONENT",
        "start_char": 4893,
        "end_char": 4901,
        "color": "blue"
      }
    ]
  },
  "Row_16_Col_Disease": {
    "original_text": "Dementia",
    "annotated_entities": []
  },
  "Row_16_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_16_Col_Disease_Mechanism": {
    "original_text": "The research paper \"The effects of the interplay between vitamins, antibiotics, and gut microbiota on the pathogenesis and progression of dementia: A systematic review and meta\u2010analysis\" provides insights into the mechanism linking gut microbiome alterations to dementia through multiple key points:\n\n1. **Gut Dysbiosis and Inflammation**: The paper highlights that gut dysbiosis, or microbial imbalance, can lead to low-grade systemic inflammation, which is a critical factor in the development and progression of dementia. It mentions that alterations in gut microbiota contribute to inflammatory pathways that negatively affect brain health, potentially resulting in cognitive decline and neurodegenerative diseases.\n\n2. **Impact on the Blood-Brain Barrier**: The gut microbiota is noted to play a role in maintaining the integrity of the blood-brain barrier (BBB). Disruptions in gut microbiota can increase gut permeability and promote inflammation, leading to the failure of the BBB, which allows harmful substances to enter the brain and exacerbate neuroinflammation linked to dementia.\n\n3. **Neurotransmitter Alterations**: The paper discusses how specific bacteria in the gut are responsible for the production of neurotransmitters such as serotonin and dopamine, which are crucial for cognitive function. Dysbiosis can disrupt the synthesis of these neurotransmitters, potentially impairing cognitive abilities and accelerating dementia progression.\n\n4. **Metabolite Production**: Key microbial products like short-chain fatty acids (SCFAs), which are produced by beneficial gut bacteria, influence brain health. The balance of these metabolites is disturbed during dysbiosis, which can have downstream effects on mental and cognitive health, as these metabolites are involved in signaling pathways relevant to neuroinflammation.\n\n5. **Microglial Activation**: The paper indicates that inflammatory cytokines produced during gut dysbiosis can activate microglia in the brain, leading to neuroinflammation. This process is integral to the pathogenesis of dementia, as chronic activation of microglia is associated with neurodegenerative processes.\n\n6. **Specific Bacterial Taxa**: While the paper does not specify individual bacterial taxa that are linked to dementia, it states that gut dysbiosis is associated with a decrease in beneficial bacteria and an increase in harmful bacteria. This alteration in microbial composition is linked to cognitive impairment and dementia progression.\n\n7. **Vitamin Interactions and Cognitive Function**: The review emphasizes the role of vitamins, particularly B vitamins, in supporting gut health and, by extension, cognitive function. The synthesis of these vitamins by gut bacteria is disrupted by antibiotic-induced dysbiosis, leading to deficiencies that may adversely impact cognitive performance.\n\nIn summary, the paper establishes that **gut dysbiosis leads to systemic inflammation, disrupts neurotransmitter and metabolite production, impairs the blood-brain barrier**, and **activates microglia**, all of which contribute to the pathogenesis and progression of dementia. Addressing these alterations in gut microbiota through dietary changes or supplementation may provide therapeutic avenues for preventing or managing dementia.",
    "annotated_entities": [
      {
        "text": "vitamins",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 57,
        "end_char": 65,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 84,
        "end_char": 87,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 232,
        "end_char": 235,
        "color": "pink"
      },
      {
        "text": "Gut",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 306,
        "end_char": 309,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 366,
        "end_char": 369,
        "color": "pink"
      },
      {
        "text": "low-grade",
        "label": "CANCER",
        "start_char": 417,
        "end_char": 426,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 557,
        "end_char": 560,
        "color": "pink"
      },
      {
        "text": "brain",
        "label": "ORGAN",
        "start_char": 631,
        "end_char": 636,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 767,
        "end_char": 770,
        "color": "pink"
      },
      {
        "text": "blood-brain barrier",
        "label": "IMMATERIAL_ANATOMICAL_ENTITY",
        "start_char": 842,
        "end_char": 861,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 884,
        "end_char": 887,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 912,
        "end_char": 915,
        "color": "pink"
      },
      {
        "text": "brain",
        "label": "ORGAN",
        "start_char": 1035,
        "end_char": 1040,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1181,
        "end_char": 1184,
        "color": "pink"
      },
      {
        "text": "serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1249,
        "end_char": 1258,
        "color": "purple"
      },
      {
        "text": "dopamine",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1263,
        "end_char": 1271,
        "color": "teal"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1544,
        "end_char": 1549,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1585,
        "end_char": 1588,
        "color": "pink"
      },
      {
        "text": "brain",
        "label": "ORGAN",
        "start_char": 1609,
        "end_char": 1614,
        "color": "purple"
      },
      {
        "text": "Microglial",
        "label": "CELL",
        "start_char": 1846,
        "end_char": 1856,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "pink"
      },
      {
        "text": "microglia",
        "label": "CELL",
        "start_char": 1962,
        "end_char": 1971,
        "color": "green"
      },
      {
        "text": "brain",
        "label": "ORGAN",
        "start_char": 1979,
        "end_char": 1984,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2293,
        "end_char": 2296,
        "color": "pink"
      },
      {
        "text": "Vitamin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2504,
        "end_char": 2511,
        "color": "teal"
      },
      {
        "text": "vitamins",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2585,
        "end_char": 2593,
        "color": "yellow"
      },
      {
        "text": "B vitamins",
        "label": "CELL",
        "start_char": 2608,
        "end_char": 2618,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2634,
        "end_char": 2637,
        "color": "pink"
      },
      {
        "text": "vitamins",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2707,
        "end_char": 2715,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2719,
        "end_char": 2722,
        "color": "pink"
      },
      {
        "text": "antibiotic-induced",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2748,
        "end_char": 2766,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2893,
        "end_char": 2896,
        "color": "pink"
      },
      {
        "text": "blood-brain",
        "label": "ORGANISM",
        "start_char": 3004,
        "end_char": 3015,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3161,
        "end_char": 3164,
        "color": "pink"
      }
    ]
  },
  "Row_16_Col_Rifaximin Justification": {
    "original_text": "### Section 3: Expert Analysis - Therapeutic Alignment and Repurposing Rationale\n\n#### 1. Mechanistic Convergence\n\n**Mechanisms of Dementia:**\n- **Gut Dysbiosis and Inflammation:** The literature indicates that gut dysbiosis contributes to **low-grade systemic inflammation**, impacting cognitive health. This is characterized by an imbalance of microbial taxa, leading to an increase in pro-inflammatory cytokines such as **TNF\u03b1** and **IL-1\u03b2**.\n  \n- **Blood-Brain Barrier Integrity:** Disruption of gut microbiota integrity contributes to the permeability of the **blood-brain barrier (BBB)**, allowing inflammatory cytokines and harmful substances to enter the brain, which exacerbates neuroinflammation and cognitive decline.\n\n- **Neurotransmitter Alteration:** Certain gut bacteria are crucial for synthesizing neurotransmitters like **serotonin** and **dopamine**. Disruptions can impair cognitive function and accelerate dementia progression.\n\n- **Metabolite Production:** Beneficial gut bacteria produce **short-chain fatty acids (SCFAs)**, which support brain health. Their production decreases during dysbiosis, impairing signaling pathways relevant to neuroinflammation.\n\n- **Microglial Activation:** Inflammatory cytokines from gut dysbiosis activate **microglia** in the brain, triggering neuroinflammation, which is implicated in dementia pathogenesis.\n\n**Rifaximin's Mechanistic Action:**\n- **Cytokine Modulation:** Rifaximin reduces levels of pro-inflammatory cytokines such as **TNF\u03b1** and **IL-1\u03b2**, aligning with the inflammatory pathways implicated in dementia.\n\n- **Microbial Targeting:** By targeting ammonia-producing bacteria and promoting beneficial gut bacteria (like **Lactobacillus**), Rifaximin supports gut microbiota balance. This modulation may reduce systemic inflammation and its effects on the brain.\n\n- **Immune Response Modulation:** Rifaximin enhances **IL-10**, an anti-inflammatory cytokine, thereby contributing to modulating gut and brain inflammation.\n\n- **Impact on Gut-Brain Axis:** By decreasing systemic ammonia levels and neuroinflammation, Rifaximin may improve cognitive function, particularly in conditions where gut health is compromised.\n\n**Critical Assessment:**\nThere is a direct mechanistic overlap between the pathways involved in dementia and those modulated by Rifaximin. The drug's ability to reduce **TNF\u03b1 and IL-1\u03b2**, inhibit **pro-inflammatory pathways**, and improve gut microbiota supports its potential efficacy in addressing the inflammatory milieu and microbial patterns associated with dementia. This convergence suggests a viable repurposing pathway for Rifaximin in dementia treatment.\n\n---\n\n#### 2. Supporting Clinical or Preclinical Evidence\n\nThe provided information indicates that Rifaximin has therapeutic effects that could extend into dementia management:\n- By showing efficacy in reducing **ammonia** levels in hepatic encephalopathy, Rifaximin demonstrates its potential to alleviate neurotoxic compounds linked to cognitive dysfunction.\n- Rifaximin's modulation of the gut microbiota, leading to reduced **pro-inflammatory cytokine** levels, could reflect positively on cognitive outcomes by addressing the underlying inflammation associated with dementia.\n\nWhile the evidence does not explicitly categorize Rifaximin's effect on dementia, the analogous mechanisms in gut inflammation and neuroprotection strongly support the plausibility of its therapeutic role in this area.\n\n---\n\n#### 3. Therapeutic Implications\n\nGiven the mechanistic convergence identified:\n- **Partial Therapeutic Benefit:** Rifaximin could offer **symptom relief** by modulating the gut-brain axis dysfunction and reducing **systemic inflammation** linked to dementia. Improved gut health and decreased inflammatory marker levels might alleviate certain cognitive symptoms associated with dementia.\n\n- **Limitations and Caveats:** Potential limitations include:\n  - Incomplete targeting of all relevant pathways associated with dementia, suggesting Rifaximin should be considered as an adjunct therapy rather than a standalone treatment.\n  - Variability in patient response based on individual gut microbiota composition, which may affect the overall efficacy.\n\nIn summary, Rifaximin presents a compelling case for repurposing in dementia management due to its actions on inflammation, microbiota composition, and potential neuroprotective effects. The mechanism of action aligns closely with the pathophysiological features of dementia, providing a strategic opportunity for therapeutic intervention.",
    "annotated_entities": [
      {
        "text": "Gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 147,
        "end_char": 150,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 211,
        "end_char": 214,
        "color": "blue"
      },
      {
        "text": "low-grade",
        "label": "CANCER",
        "start_char": 242,
        "end_char": 251,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 501,
        "end_char": 504,
        "color": "blue"
      },
      {
        "text": "brain",
        "label": "ORGAN",
        "start_char": 664,
        "end_char": 669,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 774,
        "end_char": 777,
        "color": "blue"
      },
      {
        "text": "serotonin",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 841,
        "end_char": 850,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 991,
        "end_char": 994,
        "color": "blue"
      },
      {
        "text": "short-chain fatty acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1014,
        "end_char": 1037,
        "color": "purple"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1039,
        "end_char": 1044,
        "color": "blue"
      },
      {
        "text": "brain",
        "label": "ORGAN",
        "start_char": 1063,
        "end_char": 1068,
        "color": "red"
      },
      {
        "text": "Microglial",
        "label": "CELL",
        "start_char": 1187,
        "end_char": 1197,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1240,
        "end_char": 1243,
        "color": "blue"
      },
      {
        "text": "brain",
        "label": "ORGAN",
        "start_char": 1284,
        "end_char": 1289,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1370,
        "end_char": 1379,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1431,
        "end_char": 1440,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1675,
        "end_char": 1678,
        "color": "blue"
      },
      {
        "text": "Lactobacillus",
        "label": "AMINO_ACID",
        "start_char": 1696,
        "end_char": 1709,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1714,
        "end_char": 1723,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1733,
        "end_char": 1736,
        "color": "blue"
      },
      {
        "text": "brain",
        "label": "ORGAN",
        "start_char": 1829,
        "end_char": 1834,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1871,
        "end_char": 1880,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1967,
        "end_char": 1970,
        "color": "blue"
      },
      {
        "text": "brain",
        "label": "ORGAN",
        "start_char": 1975,
        "end_char": 1980,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2089,
        "end_char": 2098,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2164,
        "end_char": 2167,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2320,
        "end_char": 2329,
        "color": "green"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2362,
        "end_char": 2366,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2431,
        "end_char": 2434,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2624,
        "end_char": 2633,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2756,
        "end_char": 2765,
        "color": "green"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 2890,
        "end_char": 2897,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2914,
        "end_char": 2923,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3050,
        "end_char": 3053,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3289,
        "end_char": 3298,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3349,
        "end_char": 3352,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3579,
        "end_char": 3588,
        "color": "green"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3638,
        "end_char": 3647,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3733,
        "end_char": 3736,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4004,
        "end_char": 4013,
        "color": "green"
      },
      {
        "text": "patient",
        "label": "ORGANISM",
        "start_char": 4112,
        "end_char": 4119,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4149,
        "end_char": 4152,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4229,
        "end_char": 4238,
        "color": "green"
      }
    ]
  },
  "Row_17_Col_Disease": {
    "original_text": "Diabesity",
    "annotated_entities": []
  },
  "Row_17_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\n[red[Rifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB)]], preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin [red[selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO]]. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022[orange[Ruminococcaceae and Lachnospiraceae: These beneficial bacteria increase]] in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin [blue[reduces TNF\u03b1 levels]], which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to ][blue[reduce IL-1\u03b2 levels]] in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s [blue[ability to reduce IL-17 is critical in preventing tissue damage]] and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin [blue[promotes the production of IL-10]], an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can [orange[increase the levels of SCFAs]]. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially [green[improving mood and cognitive function]] in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "blue"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 627,
        "end_char": 641,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 836,
        "end_char": 839,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 916,
        "end_char": 930,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 942,
        "end_char": 951,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 995,
        "end_char": 1002,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1044,
        "end_char": 1046,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1124,
        "end_char": 1139,
        "color": "green"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1161,
        "end_char": 1172,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1286,
        "end_char": 1295,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1316,
        "end_char": 1331,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1382,
        "end_char": 1391,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1420,
        "end_char": 1424,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1538,
        "end_char": 1547,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1710,
        "end_char": 1719,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1802,
        "end_char": 1811,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1958,
        "end_char": 1961,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2027,
        "end_char": 2036,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2157,
        "end_char": 2160,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2206,
        "end_char": 2215,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2219,
        "end_char": 2223,
        "color": "pink"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2225,
        "end_char": 2252,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2255,
        "end_char": 2264,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2355,
        "end_char": 2360,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2396,
        "end_char": 2400,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2426,
        "end_char": 2429,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2447,
        "end_char": 2452,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2475,
        "end_char": 2493,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2545,
        "end_char": 2556,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2587,
        "end_char": 2596,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2700,
        "end_char": 2703,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2708,
        "end_char": 2713,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2717,
        "end_char": 2722,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2741,
        "end_char": 2746,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2815,
        "end_char": 2824,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2851,
        "end_char": 2856,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2883,
        "end_char": 2889,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2948,
        "end_char": 2953,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2967,
        "end_char": 2971,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2973,
        "end_char": 2991,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 3035,
        "end_char": 3041,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3059,
        "end_char": 3068,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3096,
        "end_char": 3100,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3165,
        "end_char": 3168,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3173,
        "end_char": 3178,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3196,
        "end_char": 3204,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3218,
        "end_char": 3223,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3251,
        "end_char": 3260,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3271,
        "end_char": 3280,
        "color": "pink"
      },
      {
        "text": "IL-10]]",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3314,
        "end_char": 3321,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3451,
        "end_char": 3454,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3481,
        "end_char": 3490,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3534,
        "end_char": 3537,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3583,
        "end_char": 3588,
        "color": "green"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3598,
        "end_char": 3603,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3780,
        "end_char": 3789,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3818,
        "end_char": 3821,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3855,
        "end_char": 3862,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4010,
        "end_char": 4013,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4015,
        "end_char": 4024,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4124,
        "end_char": 4142,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4165,
        "end_char": 4174,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4230,
        "end_char": 4234,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4394,
        "end_char": 4397,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4458,
        "end_char": 4468,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4470,
        "end_char": 4518,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4520,
        "end_char": 4524,
        "color": "teal"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4534,
        "end_char": 4543,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4706,
        "end_char": 4715,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4762,
        "end_char": 4765,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4862,
        "end_char": 4869,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5042,
        "end_char": 5051,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5133,
        "end_char": 5149,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5154,
        "end_char": 5161,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5205,
        "end_char": 5214,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5318,
        "end_char": 5326,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5355,
        "end_char": 5360,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5377,
        "end_char": 5386,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5398,
        "end_char": 5401,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5510,
        "end_char": 5522,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5548,
        "end_char": 5556,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5561,
        "end_char": 5570,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5640,
        "end_char": 5649,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5691,
        "end_char": 5706,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5747,
        "end_char": 5750,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5827,
        "end_char": 5836,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5846,
        "end_char": 5853,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5868,
        "end_char": 5876,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5976,
        "end_char": 5979,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6003,
        "end_char": 6012,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6201,
        "end_char": 6205,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6214,
        "end_char": 6219,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6225,
        "end_char": 6229,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6253,
        "end_char": 6260,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6278,
        "end_char": 6281,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6383,
        "end_char": 6390,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6437,
        "end_char": 6440,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6496,
        "end_char": 6499,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6568,
        "end_char": 6577,
        "color": "red"
      }
    ]
  },
  "Row_17_Col_Disease_Mechanism": {
    "original_text": "The research paper discusses the contributions of the gut microbiome in the context of diabesity, focusing on the effects of High-Intensity Interval Training (HIIT) and its cessation and retraining on microbial diversity and composition.\n\n### Mechanisms Linking Gut Microbiome Alterations to Diabesity\n\n1. **Microbial Composition Changes**:\n   - The paper indicates that both HIIT and subsequent retraining lead to modifications in the gut microbiome's alpha- and beta-diversity, particularly in genera associated with beneficial metabolic outcomes. For instance, butyrate-producing genera such as [orange[*Eubacterium xylanophilum* and *Desulfovibrio* were increased post-HIIT ]]retraining. These genera are noted for their positive correlation with glycemic control, which might explain the reduction in blood glucose levels observed following this training.\n\n2. **Gut-Organ Crosstalk**:\n   - The alterations in gut microbiota during HIIT and its retraining appear to influence systemic metabolic health. Although retraining did not effectively induce significant improvements in fat reduction or glucose regulation compared to initial HIIT, changes in intestinal health, such as [green[increased goblet cell number and deeper crypts]], were highlighted. These modifications in gut morphology suggest a reinforced barrier function and potential impacts on nutrient absorption and immune responses.\n\n3. **Metabolic Disruptions and Disease Pathophysiology**:\n   - The [blue[detrimental effects seen during the period of detraining (increased adiposity index, caloric intake, and glycemic kinetics) point towards the role of gut dysbiosis in metabolic dysfunction associated with diabesity]]. The study shows that the Western diet significantly impacted gut microbiota even in the presence of physical training, suggesting dietary influences may outweigh exercise impacts on gut health.\n\n4. **Key Bacterial Species**:\n   - Specific bacterial taxa such as[orange[ *Turicibacter* and *Lachnospiraceae UCG 006* were enriched through HIIT]], reflecting a shift towards a more diverse and potentially beneficial microbiome in trained subjects.\n\n### Conclusion\n\nThe gut microbiota is intricately linked to diabesity through mechanisms that involve beneficial microbial species alterations and their metabolites' influence on systemic health indicators such as blood glucose levels and inflammatory responses. These insights highlight the potential for targeted microbiome repurposing strategies in managing diabesity through dietary modifications and exercise interventions like HIIT.",
    "annotated_entities": [
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 54,
        "end_char": 68,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiome Alterations",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 262,
        "end_char": 288,
        "color": "pink"
      },
      {
        "text": "gut microbiome",
        "label": "ORGAN",
        "start_char": 436,
        "end_char": 450,
        "color": "yellow"
      },
      {
        "text": "blood glucose",
        "label": "ORGANISM_SUBSTANCE",
        "start_char": 806,
        "end_char": 819,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 914,
        "end_char": 917,
        "color": "teal"
      },
      {
        "text": "fat",
        "label": "TISSUE",
        "start_char": 1082,
        "end_char": 1085,
        "color": "blue"
      },
      {
        "text": "glucose",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1099,
        "end_char": 1106,
        "color": "orange"
      },
      {
        "text": "intestinal",
        "label": "ORGAN",
        "start_char": 1155,
        "end_char": 1165,
        "color": "green"
      },
      {
        "text": "[green[increased",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1182,
        "end_char": 1198,
        "color": "red"
      },
      {
        "text": "goblet cell",
        "label": "CELL",
        "start_char": 1199,
        "end_char": 1210,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1280,
        "end_char": 1283,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1624,
        "end_char": 1627,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1753,
        "end_char": 1756,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1874,
        "end_char": 1877,
        "color": "teal"
      },
      {
        "text": "HIIT]]",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2029,
        "end_char": 2035,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2159,
        "end_char": 2162,
        "color": "teal"
      },
      {
        "text": "blood glucose",
        "label": "ORGANISM_SUBSTANCE",
        "start_char": 2353,
        "end_char": 2366,
        "color": "green"
      }
    ]
  },
  "Row_17_Col_Rifaximin Justification": {
    "original_text": "## Expert Analysis - Therapeutic Alignment and Repurposing Rationale\n\n### 1. Mechanistic Convergence\n\nThe mechanisms contributing to diabesity, particularly through the role of the gut microbiome, align closely with Rifaximin's effects:\n\n- **Microbial Composition Changes**: The hosting of specific beneficial genera (e.g., butyrate-producing genera like *Eubacterium xylanophilum* and *Desulfovibrio*) is essential for glycemic control and systemic metabolic health. Rifaximin\u2019s modulation of the gut microbiota leads to a reduction in pathogenic bacteria and enhancement of beneficial species, such as Lactobacillus and Ruminococcaceae. This parallel amplifies the potential for Rifaximin to reinstate microbial diversity beneficial for metabolic outcomes.\n\n- **Gut-Organ Crosstalk**: Rifaximin's systemic effects arise from localized antibacterial action, substantially altering cytokine profiles that may affect gut-organ axis communication. Rifaximin's ability to [blue[lower pro-inflammatory cytokines (e.g., TNF-\u03b1 and IL-1\u03b2) corresponds with improved metabolic health, likely influencing conditions associated with diabesity]], such as adiposity and glucose regulation. By enhancing [green[gut barrier function and possibly modifying nutrient absorption pathways]], Rifaximin aligns mechanistically with observed improvements in gut morphology post-HIIT.\n\n- **Metabolic Disruptions and Disease Pathophysiology**: The increased adiposity index and impaired glycemic control seen with gut dysbiosis during detraining signify a breakdown in metabolic function that Rifaximin is uniquely positioned to address. Its modulation of key inflammatory pathways and gut microbiota presents a mechanism whereby Rifaximin may reverse or attenuate the adverse effects of gut dysbiosis.\n\n- **Key Bacterial Species**: The enrichment of specific taxa like *Turicibacter* through HIIT suggests a shift towards a healthier microbiome. Rifaximin's selective antibacterial action could further support this shift, thereby not only addressing immediate dysbiotic states but also augmenting positive microbiome restructuring.\n\nIn summary, there is **significant mechanistic overlap** between Rifaximin\u2019s modulation of inflammatory markers and the pathways implicated in the pathophysiology of diabesity. By targeting the gut microbiota and influencing cytokine profiles, Rifaximin may provide therapeutic benefits relevant to the dysregulation seen in diabesity.\n\n### 2. Supporting Clinical or Preclinical Evidence\n\nRifaximin has demonstrated therapeutic effects that could extend to the context of diabesity:\n- **Gut Microbiota Modulation**: Rifaximin promotes the expansion of beneficial microbial populations while suppressing harmful ones, contributing to improved gut health\u2014an essential factor in managing diabesity.\n- **Reduction of Inflammatory Markers**: By [bluelowering levels of pro-inflammatory cytokines such as TNF-\u03b1 and IL-1\u03b2]], Rifaximin may reduce systemic inflammation associated with metabolic syndromes, suggesting potential symbiotic effects in treating aspects of diabesity.\n- **Improvements in Cognitive and Systemic Symptoms**: Evidence indicates that Rifaximin's neuroprotective effects in conditions like hepatic encephalopathy may also apply indirectly to aspects of diabesity, where cognitive dysfunction and systemic metabolic disruption often co-occur.\n\n### 3. Therapeutic Implications\n\nRifaximin presents a promising **partial therapeutic benefit** in managing diabesity due to its:\n- **Symptom Relief**: By targeting gut dysbiosis and lowering systemic inflammation, Rifaximin may provide significant symptomatic improvements in related gastrointestinal disturbances often present in obese individuals.\n- **Modulation of Gut-Brain Axis Dysfunction**: The drug\u2019s influence on microbial composition and cytokine modulation may support improvements in the gut-brain axis, potentially [green[enhancing cognitive and emotional outcomes]] in patients suffering from both obesity and its metabolic consequences.\n- **Reduction in Systemic Inflammation**: A direct correlation can be established between Rifaximin\u2019s anti-inflammatory effects and improvements in the systemic inflammatory state often seen in diabesity.\n\nHowever, several **limitations or caveats** must be considered:\n- **Incomplete Pathway Targeting**: Rifaximin may not comprehensively address all the pathophysiological aspects of diabesity, particularly those stemming from dietary influences that affect gut microbiota more significantly than exercise alone.\n- **Scope of Symptom Improvement**: While Rifaximin could alleviate certain symptoms related to gut health, it may not fully resolve overarching issues of glucose homeostasis or adiposity without additional behavioral or lifestyle interventions.\n- **Need for Adjunct Therapies**: The drug may need to be integrated into broader therapeutic strategies to maximize its effectiveness in managing diabesity comprehensively.\n\nIn conclusion, the repurposing of Rifaximin for diabesity is supported through a nuanced understanding of its microbial and inflammatory modulation capacities, highlighting its potential as part of a multifaceted treatment strategy aimed at this complex disease.",
    "annotated_entities": [
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 181,
        "end_char": 195,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 216,
        "end_char": 225,
        "color": "blue"
      },
      {
        "text": "butyrate-producing genera like *Eubacterium",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 324,
        "end_char": 367,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 468,
        "end_char": 477,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 498,
        "end_char": 501,
        "color": "purple"
      },
      {
        "text": "Lactobacillus",
        "label": "CELLULAR_COMPONENT",
        "start_char": 604,
        "end_char": 617,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 681,
        "end_char": 690,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 787,
        "end_char": 796,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 946,
        "end_char": 955,
        "color": "blue"
      },
      {
        "text": "blue[lower",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 970,
        "end_char": 980,
        "color": "red"
      },
      {
        "text": "TNF-\u03b1",
        "label": "CELL",
        "start_char": 1015,
        "end_char": 1020,
        "color": "orange"
      },
      {
        "text": "glucose",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1157,
        "end_char": 1164,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1273,
        "end_char": 1282,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1336,
        "end_char": 1339,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1490,
        "end_char": 1493,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1569,
        "end_char": 1578,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1662,
        "end_char": 1665,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1706,
        "end_char": 1715,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1764,
        "end_char": 1767,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1923,
        "end_char": 1932,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2176,
        "end_char": 2185,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2305,
        "end_char": 2308,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2355,
        "end_char": 2364,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2500,
        "end_char": 2509,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2627,
        "end_char": 2636,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2753,
        "end_char": 2756,
        "color": "purple"
      },
      {
        "text": "TNF-\u03b1",
        "label": "CELL",
        "start_char": 2910,
        "end_char": 2915,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2929,
        "end_char": 2938,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3161,
        "end_char": 3170,
        "color": "blue"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3216,
        "end_char": 3223,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3402,
        "end_char": 3411,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3534,
        "end_char": 3537,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3584,
        "end_char": 3593,
        "color": "blue"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 3654,
        "end_char": 3670,
        "color": "blue"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3870,
        "end_char": 3879,
        "color": "yellow"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3953,
        "end_char": 3961,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4112,
        "end_char": 4121,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4328,
        "end_char": 4337,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4483,
        "end_char": 4486,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4580,
        "end_char": 4589,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4634,
        "end_char": 4637,
        "color": "purple"
      },
      {
        "text": "glucose",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4693,
        "end_char": 4700,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4993,
        "end_char": 5002,
        "color": "blue"
      }
    ]
  },
  "Row_18_Col_Disease": {
    "original_text": "Woody Breast Myopathy",
    "annotated_entities": []
  },
  "Row_18_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by [red[binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis]]. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin [gtreen[increases beneficial genera like Lactobacillus and Ruminococcaceae]], while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin [blue[reduces TNF\u03b1 levels, which is a central mediator]] of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been [blue[shown to reduce IL-1\u03b2 levels]] in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By [green[reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels]], which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids:[orange[Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity]] of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "pink"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 627,
        "end_char": 641,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 643,
        "end_char": 647,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 836,
        "end_char": 839,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 916,
        "end_char": 930,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 942,
        "end_char": 951,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 990,
        "end_char": 997,
        "color": "green"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1039,
        "end_char": 1041,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1117,
        "end_char": 1132,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1154,
        "end_char": 1165,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1279,
        "end_char": 1288,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1309,
        "end_char": 1324,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1375,
        "end_char": 1384,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1413,
        "end_char": 1417,
        "color": "orange"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1522,
        "end_char": 1531,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1694,
        "end_char": 1703,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1786,
        "end_char": 1795,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1952,
        "end_char": 1955,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2021,
        "end_char": 2030,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2151,
        "end_char": 2154,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2200,
        "end_char": 2209,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2213,
        "end_char": 2217,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2219,
        "end_char": 2246,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2249,
        "end_char": 2258,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2349,
        "end_char": 2354,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2390,
        "end_char": 2394,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2420,
        "end_char": 2423,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2441,
        "end_char": 2446,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2469,
        "end_char": 2487,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2539,
        "end_char": 2550,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2581,
        "end_char": 2590,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2693,
        "end_char": 2696,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2701,
        "end_char": 2706,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2710,
        "end_char": 2715,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2734,
        "end_char": 2739,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2808,
        "end_char": 2817,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2838,
        "end_char": 2843,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2870,
        "end_char": 2876,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2933,
        "end_char": 2938,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2952,
        "end_char": 2956,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2958,
        "end_char": 2976,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 3020,
        "end_char": 3026,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3044,
        "end_char": 3053,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3081,
        "end_char": 3085,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3150,
        "end_char": 3153,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3158,
        "end_char": 3163,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3181,
        "end_char": 3189,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3203,
        "end_char": 3208,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3236,
        "end_char": 3245,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3256,
        "end_char": 3265,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3293,
        "end_char": 3298,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3428,
        "end_char": 3431,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3458,
        "end_char": 3467,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3511,
        "end_char": 3514,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3552,
        "end_char": 3557,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3565,
        "end_char": 3570,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3747,
        "end_char": 3756,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3785,
        "end_char": 3788,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3822,
        "end_char": 3829,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3984,
        "end_char": 3987,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3989,
        "end_char": 3998,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4100,
        "end_char": 4118,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4141,
        "end_char": 4150,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4206,
        "end_char": 4210,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4361,
        "end_char": 4364,
        "color": "yellow"
      },
      {
        "text": "Bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4425,
        "end_char": 4429,
        "color": "orange"
      },
      {
        "text": "bile acids like taurodeoxycholic acid",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4455,
        "end_char": 4492,
        "color": "purple"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4494,
        "end_char": 4498,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4508,
        "end_char": 4517,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4682,
        "end_char": 4691,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4738,
        "end_char": 4741,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4838,
        "end_char": 4845,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5018,
        "end_char": 5027,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5109,
        "end_char": 5125,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5130,
        "end_char": 5137,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5181,
        "end_char": 5190,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5294,
        "end_char": 5302,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5331,
        "end_char": 5336,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5353,
        "end_char": 5362,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5374,
        "end_char": 5377,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5486,
        "end_char": 5498,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5524,
        "end_char": 5532,
        "color": "teal"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5537,
        "end_char": 5546,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5616,
        "end_char": 5625,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5667,
        "end_char": 5682,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5723,
        "end_char": 5726,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5803,
        "end_char": 5812,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5822,
        "end_char": 5829,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5844,
        "end_char": 5852,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5952,
        "end_char": 5955,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5979,
        "end_char": 5988,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6177,
        "end_char": 6181,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6190,
        "end_char": 6195,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6201,
        "end_char": 6205,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6229,
        "end_char": 6236,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6254,
        "end_char": 6257,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6359,
        "end_char": 6366,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6413,
        "end_char": 6416,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6472,
        "end_char": 6475,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6544,
        "end_char": 6553,
        "color": "red"
      }
    ]
  },
  "Row_18_Col_Disease_Mechanism": {
    "original_text": "The research paper \"Cecal microbiota contribute to the development of woody breast myopathy\" provides insights into the mechanisms linking gut microbiome alterations to Woody Breast Myopathy (WB). Here are the specific mechanistic insights from the paper:\n\n1. **Microbiome Composition and Disease Correlation**: The study identifies specific bacteria that are enriched in birds with Woody Breast (WB) myopathy. [red[Predominant bacteria in the WB group included **Selenomonas bovis** and **Bacteroides plebeius**]], which had significantly higher relative abundances compared to normal birds. In contrast, beneficial bacteria such as **Alistipes putredinis** and **Butyricicoccus pullicaecorum** were more abundant in normal birds.\n\n2. **Altered Metabolic Pathways**: The functional profiling of the gut microbiota revealed that various microbial metabolic activities differ between normal and WB birds. Key metabolic pathways that were found to be altered include:\n   - **[orange[Downregulated pathways** in WB birds]] encompassed amino acid pathways like L-lysine and L-threonine.\n   - **[orange[Upregulated pathways** included those related to nucleotide metabolism]] (specifically purine and pyrimidine pathways), and sugar degradation pathways (mannan, fucose, and rhamnose degradation), indicating a shift in energy and metabolic processing.\n\n3. **Immune Modulation**: The changes in gut microbiota composition among WB myopathy affected the metabolic potential of the bacteria, influencing energy metabolism and potentially leading to inflammatory responses. Specific [blue[pathways related to nucleotide metabolism were upregulated]], which may have implications on signaling mechanisms that are relevant to inflammation.\n\n4. **Overall Gut Dysbiosis**: The study suggests that the microbial dysbiosis characterized by the relative abundance shifts [red[contributes to metabolic disruptions and possibly to the inflammatory processes involved in the pathophysiology of WB myopathy. The upregulation of pathways associated with inflammation and metabolic dysfunction points towards a link between gut microbiota and muscle tissue condition.\n\nThese findings support the hypothesis that specific microbial community alterations contribute to the development of Woody Breast Myopathy via immune and metabolic pathways, influencing both local and systemic physiological processes.",
    "annotated_entities": [
      {
        "text": "Cecal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 20,
        "end_char": 25,
        "color": "blue"
      },
      {
        "text": "woody breast",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 70,
        "end_char": 82,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 139,
        "end_char": 142,
        "color": "teal"
      },
      {
        "text": "Bacteroides plebeius",
        "label": "ORGANISM",
        "start_char": 490,
        "end_char": 510,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 800,
        "end_char": 803,
        "color": "teal"
      },
      {
        "text": "amino acid",
        "label": "AMINO_ACID",
        "start_char": 1032,
        "end_char": 1042,
        "color": "red"
      },
      {
        "text": "L-lysine",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1057,
        "end_char": 1065,
        "color": "yellow"
      },
      {
        "text": "L-threonine",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1070,
        "end_char": 1081,
        "color": "pink"
      },
      {
        "text": "nucleotide",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1147,
        "end_char": 1157,
        "color": "green"
      },
      {
        "text": "purine",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1185,
        "end_char": 1191,
        "color": "blue"
      },
      {
        "text": "pyrimidine",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1196,
        "end_char": 1206,
        "color": "orange"
      },
      {
        "text": "sugar",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1222,
        "end_char": 1227,
        "color": "teal"
      },
      {
        "text": "fucose",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1258,
        "end_char": 1264,
        "color": "orange"
      },
      {
        "text": "rhamnose",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1270,
        "end_char": 1278,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1390,
        "end_char": 1393,
        "color": "teal"
      },
      {
        "text": "nucleotide",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1601,
        "end_char": 1611,
        "color": "green"
      },
      {
        "text": "Gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1744,
        "end_char": 1747,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2103,
        "end_char": 2106,
        "color": "teal"
      },
      {
        "text": "muscle tissue",
        "label": "TISSUE",
        "start_char": 2122,
        "end_char": 2135,
        "color": "red"
      }
    ]
  },
  "Row_18_Col_Rifaximin Justification": {
    "original_text": "### Expert Analysis - Therapeutic Alignment and Repurposing Rationale for Rifaximin in Woody Breast Myopathy\n\n#### 1. Mechanistic Convergence\n\n**Altered Gut Microbiota and Dysbiosis**: Woody Breast Myopathy (WB) is characterized by dysbiosis in the gut microbiota, particularly with the enrichment of pathogenic bacteria such as **Selenomonas bovis** and **Bacteroides plebeius**, and a decrease in beneficial bacteria like **Alistipes putredinis** and **Butyricicoccus pullicaecorum**. Rifaximin, through its bactericidal action, specifically targets pathogenic bacteria while promoting the growth of beneficial microbes. By modulating gut microbiota, Rifaximin helps restore microbial balance, which is directly linked to the inflammatory processes observed in WB.\n\n**Immune Modulation**: The study notes that WB myopathy leads to altered immune responses due to changes in gut microbiota, influencing energy metabolism and potentially eliciting inflammatory responses. Rifaximin reduces pro-inflammatory cytokines such as **TNF-\u03b1**, **IL-1\u03b2**, and **IL-17**, which may be elevated in WB due to dysbiosis-related immune activation. The **reduction in TNF-\u03b1** levels, crucial for inflammation in muscle pathology, provides a direct mechanistic match where Rifaximin could mitigate systemic inflammation associated with WB.\n\n**Metabolic Pathway Alterations**: WB myopathy shows dysregulation in metabolic pathways, with nucleotide metabolism being upregulated and amino acid pathways downregulated. Rifaximin\u2019s impact on gut microbial metabolism may help normalize these pathways by restoring beneficial metabolites and reducing the inflammatory load linked to changes in microbial function. The modulation of bacterial metabolic pathways aligns with Rifaximin's therapeutic aim of restoring gut health and, consequently, muscle health.\n\n**Inflammatory Pathways**: There is a potential overlap between the cytokine profiles altered in WB myopathy and those modulated by Rifaximin. The decreased production of **pro-inflammatory cytokines** and the promotion of **anti-inflammatory cytokines** (like IL-10) could attenuate the immune reactions contributing to the muscle dysfunction seen in WB.\n\n#### 2. Supporting Clinical or Preclinical Evidence\n\nRifaximin has documented effects in modulating **gut microbiota** and reducing inflammatory markers in various conditions, which could extend to the context of WB myopathy. The antibiotic not only lowers levels of ammonia-producing bacteria (pertinent to HE and systemic inflammation) but also enhances the presence of beneficial strains. Evidence suggests that these changes can translate to systemic improvements, such as **reduced neuroinflammation** and cognitive benefits in patients with liver conditions. The relevance of these effects could imply similar benefits for muscle integrity and overall health in birds experiencing WB myopathy.\n\n#### 3. Therapeutic Implications\n\nBased on the provided data, Rifaximin may offer a **partial therapeutic benefit** in Woody Breast Myopathy through several mechanisms:\n- **Symptom Relief**: By addressing dysbiosis and modulating inflammation, Rifaximin might alleviate the underlying conditions contributing to muscle dysfunction.\n- **Gut-Brain Axis Modulation**: Its neuroprotective effects and impact on immune signaling pathways could improve overall well-being and stress resilience, which may be linked to muscle health in the context of WB.\n- **Reduction in Systemic Inflammation**: The ability to lower pro-inflammatory cytokines (e.g., TNF-\u03b1 and IL-1\u03b2) presents a clear opportunity to counteract the inflammatory milieu impacting muscle pathology.\n\n**Limitations and Caveats**: Potential limitations include the need for comprehensive targeting of all pathway drivers associated with WB. Rifaximin acts primarily on gut bacteria and inflammation; however, if other factors (such as genetic or metabolic dysfunctions) significantly contribute to WB myopathy, additional therapies could be necessary. The therapeutic scope may also be limited if the specific microbe alterations in WB do not overlap sufficiently with Rifaximin's primary targets.\n\nIn summary, Rifaximin's mechanism aligns compellingly with the pathophysiological drivers of Woody Breast Myopathy, indicating a **valid rationale for its repurposing** in this context, with strong implications for improving muscle health and gut microbiota balance.",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 74,
        "end_char": 83,
        "color": "blue"
      },
      {
        "text": "Gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 153,
        "end_char": 156,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 249,
        "end_char": 252,
        "color": "orange"
      },
      {
        "text": "Bacteroides plebeius",
        "label": "ORGANISM",
        "start_char": 357,
        "end_char": 377,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 487,
        "end_char": 496,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 637,
        "end_char": 640,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 653,
        "end_char": 662,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 876,
        "end_char": 879,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 972,
        "end_char": 981,
        "color": "blue"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1053,
        "end_char": 1058,
        "color": "teal"
      },
      {
        "text": "muscle",
        "label": "ORGAN",
        "start_char": 1197,
        "end_char": 1203,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1257,
        "end_char": 1266,
        "color": "blue"
      },
      {
        "text": "nucleotide",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1420,
        "end_char": 1430,
        "color": "red"
      },
      {
        "text": "amino acid",
        "label": "AMINO_ACID",
        "start_char": 1464,
        "end_char": 1474,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1499,
        "end_char": 1508,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1521,
        "end_char": 1524,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1751,
        "end_char": 1760,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1792,
        "end_char": 1795,
        "color": "orange"
      },
      {
        "text": "muscle",
        "label": "ORGAN",
        "start_char": 1822,
        "end_char": 1828,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1970,
        "end_char": 1979,
        "color": "blue"
      },
      {
        "text": "muscle",
        "label": "TISSUE",
        "start_char": 2163,
        "end_char": 2169,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2248,
        "end_char": 2257,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2297,
        "end_char": 2300,
        "color": "orange"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2503,
        "end_char": 2505,
        "color": "purple"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 2728,
        "end_char": 2736,
        "color": "green"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2742,
        "end_char": 2747,
        "color": "yellow"
      },
      {
        "text": "muscle",
        "label": "ORGAN",
        "start_char": 2824,
        "end_char": 2830,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2958,
        "end_char": 2967,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3140,
        "end_char": 3149,
        "color": "blue"
      },
      {
        "text": "muscle",
        "label": "TISSUE",
        "start_char": 3208,
        "end_char": 3214,
        "color": "pink"
      },
      {
        "text": "muscle",
        "label": "ORGAN",
        "start_char": 3408,
        "end_char": 3414,
        "color": "pink"
      },
      {
        "text": "TNF-\u03b1",
        "label": "CELL",
        "start_char": 3541,
        "end_char": 3546,
        "color": "orange"
      },
      {
        "text": "muscle",
        "label": "ORGAN",
        "start_char": 3635,
        "end_char": 3641,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3793,
        "end_char": 3802,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3821,
        "end_char": 3824,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4121,
        "end_char": 4130,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4163,
        "end_char": 4172,
        "color": "blue"
      },
      {
        "text": "muscle",
        "label": "ORGAN",
        "start_char": 4376,
        "end_char": 4382,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4394,
        "end_char": 4397,
        "color": "orange"
      }
    ]
  },
  "Row_19_Col_Disease": {
    "original_text": "Rheumatoid Arthritis",
    "annotated_entities": []
  },
  "Row_19_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_19_Col_Disease_Mechanism": {
    "original_text": "Based on the provided research paper, the mechanism linking gut microbiome alterations to Rheumatoid Arthritis (RA) can be summarized as follows:\n\n### Microbiome-Induced Immune Modulation\n- **Influence on Immune System Development**: The gut microbiome plays a crucial role in the maturation of the host's immune system, specifically impacting gut-associated lymphoid tissue (GALT). For example, germ-free mice exhibit hypoplastic Peyer's patches with a low quantity of immune cells, suggesting that gut bacteria are necessary for proper immune system development.\n  \n- **T Regulatory (Treg) Cells and Th17 Balance**: The presence of certain bacteria such as _Bacteroides fragilis_ can restore the balance between Th1 and Th2 lymphocytes. Dysregulation in this balance, with increased Th17 lymphocytes and diminished Treg lymphocytes, has been observed in RA patients, leading to more aggressive inflammatory responses. Butyrate, a short-chain fatty acid (SCFA) produced by intestinal bacteria, can induce Treg differentiation, contributing to anti-inflammatory responses. \n\n- **Signaling Pathways**: The paper highlights that pathways involving Toll-like receptors (TLRs), specifically TLR-2, are engaged by microbial components (e.g., polysaccharide A from _Bacteroides fragilis_), which can modulate immune responses by promoting Treg cell differentiation and IL-10 production. This indicates an interplay between gut-derived microbial signals and the host's immune regulatory mechanisms.\n\n### Key Bacterial Species & Their Roles\n- **Polysaccharide A from _Bacteroides fragilis_**: This has a role in promoting Treg cell maturation and inhibiting pro-inflammatory cytokine expression (e.g., TNF). \n\n- **Prevotella spp.**: Increased prevalence of _Prevotella copri_ in newly diagnosed RA patients suggests a pro-inflammatory potential. It may contribute to disease through gut permeability issues or by activating immune pathways that drive RA pathology (e.g., through citrullination of proteins).\n\n- **Collinsella spp.**: This bacterium, when administered in mice, increased susceptibility to collagen-induced arthritis, highlighting the potential for certain gut microbes to drive inflammatory conditions linked to RA.\n\n### Metabolic Disruptions and Disease Pathophysiology\n- The research suggests that dysbiosis, defined by an imbalance of gut bacteria\u2014such as the reduction of beneficial bacteria (e.g., _Bacteroides_ and _Bifidobacterium_) and the increase of others (such as _Prevotella_)\u2014affects metabolic pathways essential for immune modulation. This dysregulation can influence the secretion of SCFAs like butyrate, which have roles in immune function and inflammation.\n\n### Conclusion\nThe alterations in the gut microbiome associated with Rheumatoid Arthritis seem to induce immune dysregulation via modifications in immune cell populations, particularly impacting Treg and Th17 cells, along with the signaling pathways they engage. Specific bacterial species such as _Bacteroides fragilis_ and _Prevotella copri_ are highlighted for their potential roles in stimulating or suppressing inflammatory pathways relevant to RA. Furthermore, metabolic products from gut bacteria may further influence the pathophysiology of the disease, establishing a clear link between gut health and RA susceptibility.",
    "annotated_entities": [
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 60,
        "end_char": 63,
        "color": "pink"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 238,
        "end_char": 252,
        "color": "red"
      },
      {
        "text": "gut-associated lymphoid tissue",
        "label": "CELL",
        "start_char": 344,
        "end_char": 374,
        "color": "green"
      },
      {
        "text": "germ-free mice",
        "label": "ORGANISM",
        "start_char": 396,
        "end_char": 410,
        "color": "yellow"
      },
      {
        "text": "hypoplastic Peyer",
        "label": "TISSUE",
        "start_char": 419,
        "end_char": 436,
        "color": "blue"
      },
      {
        "text": "immune cells",
        "label": "CELL",
        "start_char": 470,
        "end_char": 482,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 500,
        "end_char": 503,
        "color": "pink"
      },
      {
        "text": "Cells",
        "label": "CELL",
        "start_char": 592,
        "end_char": 597,
        "color": "teal"
      },
      {
        "text": "Bacteroides fragilis",
        "label": "ORGANISM",
        "start_char": 660,
        "end_char": 680,
        "color": "green"
      },
      {
        "text": "Th1",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 714,
        "end_char": 717,
        "color": "teal"
      },
      {
        "text": "Th2 lymphocytes",
        "label": "CELL",
        "start_char": 722,
        "end_char": 737,
        "color": "red"
      },
      {
        "text": "Th17 lymphocytes",
        "label": "CELL",
        "start_char": 785,
        "end_char": 801,
        "color": "pink"
      },
      {
        "text": "Treg lymphocytes",
        "label": "CELL",
        "start_char": 817,
        "end_char": 833,
        "color": "pink"
      },
      {
        "text": "RA patients",
        "label": "CANCER",
        "start_char": 856,
        "end_char": 867,
        "color": "green"
      },
      {
        "text": "Butyrate",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 920,
        "end_char": 928,
        "color": "purple"
      },
      {
        "text": "short-chain fatty acid",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 932,
        "end_char": 954,
        "color": "purple"
      },
      {
        "text": "SCFA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 956,
        "end_char": 960,
        "color": "blue"
      },
      {
        "text": "intestinal",
        "label": "ORGAN",
        "start_char": 974,
        "end_char": 984,
        "color": "teal"
      },
      {
        "text": "Treg",
        "label": "CELL",
        "start_char": 1006,
        "end_char": 1010,
        "color": "teal"
      },
      {
        "text": "Toll-like receptors",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1146,
        "end_char": 1165,
        "color": "purple"
      },
      {
        "text": "TLRs",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1167,
        "end_char": 1171,
        "color": "blue"
      },
      {
        "text": "TLR-2",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1187,
        "end_char": 1192,
        "color": "green"
      },
      {
        "text": "polysaccharide A",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1237,
        "end_char": 1253,
        "color": "pink"
      },
      {
        "text": "Bacteroides fragilis",
        "label": "ORGANISM",
        "start_char": 1260,
        "end_char": 1280,
        "color": "green"
      },
      {
        "text": "Treg cell",
        "label": "CELL",
        "start_char": 1333,
        "end_char": 1342,
        "color": "yellow"
      },
      {
        "text": "Bacteroides fragilis",
        "label": "ORGANISM",
        "start_char": 1560,
        "end_char": 1580,
        "color": "green"
      },
      {
        "text": "Treg cell",
        "label": "CELL",
        "start_char": 1614,
        "end_char": 1623,
        "color": "yellow"
      },
      {
        "text": "TNF",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1694,
        "end_char": 1697,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1875,
        "end_char": 1878,
        "color": "pink"
      },
      {
        "text": "mice",
        "label": "ORGANISM",
        "start_char": 2062,
        "end_char": 2066,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2163,
        "end_char": 2166,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2345,
        "end_char": 2348,
        "color": "pink"
      },
      {
        "text": "Bacteroides",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2411,
        "end_char": 2422,
        "color": "red"
      },
      {
        "text": "Bifidobacterium",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2429,
        "end_char": 2444,
        "color": "blue"
      },
      {
        "text": "Prevotella_)\u2014affects",
        "label": "CELL",
        "start_char": 2484,
        "end_char": 2504,
        "color": "red"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2607,
        "end_char": 2612,
        "color": "orange"
      },
      {
        "text": "butyrate",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2618,
        "end_char": 2626,
        "color": "purple"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 2721,
        "end_char": 2735,
        "color": "red"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2830,
        "end_char": 2841,
        "color": "orange"
      },
      {
        "text": "Treg",
        "label": "CELL",
        "start_char": 2878,
        "end_char": 2882,
        "color": "teal"
      },
      {
        "text": "Th17 cells",
        "label": "CELL",
        "start_char": 2887,
        "end_char": 2897,
        "color": "yellow"
      },
      {
        "text": "Bacteroides fragilis",
        "label": "ORGANISM",
        "start_char": 2982,
        "end_char": 3002,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3174,
        "end_char": 3177,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3279,
        "end_char": 3282,
        "color": "pink"
      }
    ]
  },
  "Row_19_Col_Rifaximin Justification": {
    "original_text": "### Expert Analysis - Therapeutic Alignment and Repurposing Rationale for Rifaximin in Rheumatoid Arthritis\n\n1. **Mechanistic Convergence**\n\n   *Rifaximin's Mechanisms of Action:*\n   - Rifaximin modulates gut microbiota by selectively inhibiting ammonia-producing bacteria in the gastrointestinal tract, which results in reductions of pro-inflammatory cytokines such as TNF\u03b1 and IL-1\u03b2. Its action through binding to bacterial RNA polymerase disrupts protein synthesis, leading to a decrease in bacterial overgrowth and the promotion of beneficial microbial populations like Lactobacillus and Ruminococcaceae.\n   - Key actions include:\n       - Reduction of Pro-Inflammatory Cytokines: Rifaximin [red[reduces levels of TNF\u03b1 and IL-1\u03b2, critical components that drive inflammatory responses.]]   \n       -Promotion of Anti-Inflammatory Cytokines: By enhancing IL-10 production, Rifaximin balances the immune response towards anti-inflammatory pathways.]]\n\n   *Mechanisms in Rheumatoid Arthritis:*\n   - [red[The dysregulation observed in RA includes an imbalance between Th17 and Treg cells, with increased Th17 contributing to aggressive inflammatory responses.]] Bacterial influences on immune modulation, particularly through SCFAs, engage pathways that impact Treg differentiation.\n   - Specific bacterial signals, such as those from _Bacteroides fragilis_, promote Treg cell maturation while inhibiting pro-inflammatory cytokines.   - [red[RA pathology is marked by elevation of cytokines like TNF\u03b1, which Rifaximin directly targets for reduction.]]\n\n   *Mechanistic Alignment:*\n   - There is clear mechanistic overlap. Both the gut microbiome alterations in RA and Rifaximin\u2019s action involve:]]\n       - TNF\u03b1 Reduction: Rifaximin's ability to [red[reduce TNF\u03b1 levels corresponds with the overproduction noted in RA patients.]]\n       - Treg Cell Modulation: While Rifaximin primarily [green[enhances IL-10, its impact on gut microbiota can lead to an indirect promotion of Treg differentiation, aligning with the need for regulatory balance in RA.]]\n       - Inhibition of Dysbiosis: Rifaximin restores microbial balance, potentially addressing dysbiosis in RA that is characterized by increased _Prevotella spp._ and decreased beneficial bacteria.\n\n   Thus, Rifaximin's pharmacologic effects may indeed modulate specific inflammatory and immune pathways involved in RA, suggesting a viable approach for repurposing.\n\n2. **Supporting Clinical or Preclinical Evidence**\n\n   - [purple[Rifaximin has documented success in conditions characterized by dysbiosis, such as hepatic encephalopathy and IBS, which correlate with mechanisms underlying rheumatoid arthritis.]] Notably:\n       - [green[The reduction in TNF\u03b1 and other pro-inflammatory markers following Rifaximin treatment supports its potential to alleviate systemic inflammation.]]\n       - [green[By improving gut health and potentially restoring microbial balance, Rifaximin could address both local and systemic inflammatory responses, exhibiting a pathway toward symptomatic relief in RA.]]\n\n3. **Therapeutic Implications**\n\n   - [green[Rifaximin offers potential therapeutic benefits for rheumatoid arthritis through:]]\n       - [orange[Symptom Relief and Inflammation Control: By modulating gut microbiota and reducing systemic inflammation (e.g., lowering TNF\u03b1), it could alleviate inflammatory symptoms associated with RA.]]\n       - [green[Modulating Gut-Brain Axis Dysfunction: The influence of Rifaximin on gut health may also indirectly improve neurological functions and psychological symptoms, which could coexist with RA.]]\n\n   - **Limitations and Caveats**:\n       - While Rifaximin shows promise, it may not comprehensively address all pathways involved in RA, particularly those beyond gut microbiota modulation. Its efficacy may vary, particularly in patient populations with distinct microbiomal profiles.\n       - As a singular treatment, Rifaximin may not suffice for full disease management, indicating a potential need for adjunct therapies targeting other inflammation pathways or autoimmune factors.\n\nIn summary, Rifaximin presents a compelling candidate for repurposing in rheumatoid arthritis treatment given its mechanism of action aligning with key inflammatory processes and immune modulation observed in RA.",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 74,
        "end_char": 83,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 145,
        "end_char": 154,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 205,
        "end_char": 208,
        "color": "purple"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 280,
        "end_char": 302,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 370,
        "end_char": 374,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 674,
        "end_char": 683,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 685,
        "end_char": 694,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 718,
        "end_char": 722,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 833,
        "end_char": 842,
        "color": "green"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 857,
        "end_char": 862,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 875,
        "end_char": 884,
        "color": "orange"
      },
      {
        "text": "Th17",
        "label": "CELL",
        "start_char": 1067,
        "end_char": 1071,
        "color": "teal"
      },
      {
        "text": "Treg cells",
        "label": "CELL",
        "start_char": 1076,
        "end_char": 1086,
        "color": "green"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1225,
        "end_char": 1230,
        "color": "purple"
      },
      {
        "text": "Treg",
        "label": "CELL",
        "start_char": 1260,
        "end_char": 1264,
        "color": "pink"
      },
      {
        "text": "Bacteroides fragilis",
        "label": "ORGANISM",
        "start_char": 1335,
        "end_char": 1355,
        "color": "red"
      },
      {
        "text": "Treg cell",
        "label": "CELL",
        "start_char": 1366,
        "end_char": 1375,
        "color": "red"
      },
      {
        "text": "cytokines like TNF\u03b1",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1480,
        "end_char": 1499,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1507,
        "end_char": 1516,
        "color": "orange"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 1630,
        "end_char": 1644,
        "color": "teal"
      },
      {
        "text": "RA",
        "label": "CELL",
        "start_char": 1660,
        "end_char": 1662,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1667,
        "end_char": 1676,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1722,
        "end_char": 1731,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 1757,
        "end_char": 1761,
        "color": "yellow"
      },
      {
        "text": "RA patients",
        "label": "CANCER",
        "start_char": 1814,
        "end_char": 1825,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1866,
        "end_char": 1875,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1923,
        "end_char": 1926,
        "color": "purple"
      },
      {
        "text": "Treg",
        "label": "CELL",
        "start_char": 1975,
        "end_char": 1979,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2086,
        "end_char": 2095,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2261,
        "end_char": 2270,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 2568,
        "end_char": 2575,
        "color": "yellow"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2709,
        "end_char": 2713,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2759,
        "end_char": 2768,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2869,
        "end_char": 2872,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2925,
        "end_char": 2934,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3255,
        "end_char": 3258,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3463,
        "end_char": 3472,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3476,
        "end_char": 3479,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3647,
        "end_char": 3656,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3762,
        "end_char": 3765,
        "color": "purple"
      },
      {
        "text": "patient",
        "label": "ORGANISM",
        "start_char": 3828,
        "end_char": 3835,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3918,
        "end_char": 3927,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4097,
        "end_char": 4106,
        "color": "orange"
      }
    ]
  },
  "Row_20_Col_Disease": {
    "original_text": "Atherosclerosis",
    "annotated_entities": []
  },
  "Row_20_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_20_Col_Disease_Mechanism": {
    "original_text": "The provided research paper offers insights into the mechanisms linking alterations in the gut microbiome to atherosclerosis through several key findings:\n\n1. **Altered Gut Microbial Composition**: The study identified specific bacterial taxa associated with symptomatic atherosclerosis. Patients with atherosclerosis exhibited an enrichment of the genus **Collinsella**, while healthy controls had higher levels of **Eubacterium** and **Roseburia**. This alteration in microbial composition is indicative of gut dysbiosis, which may influence disease pathology.\n\n2. **Immune Modulation via Peptidoglycan Biosynthesis**: The patient metagenomes were notably enriched in genes related to **peptidoglycan biosynthesis**. Increased production of peptidoglycan\u2014a component of bacterial cell walls\u2014may contribute to the activation of the innate immune system. This mechanism potentially primes immune responses and enhances neutrophil function, both of which are relevant to the inflammation observed in atherosclerosis. The study suggests that this pathway may play a role in exacerbating atherosclerotic processes.\n\n3. **Functional Capacity and Inflammatory Markers**: There was a functional characterization showing that microbial communities from atherosclerosis patients were enriched in metabolic functions associated with inflammation. The study highlighted a negative correlation between levels of certain beneficial gut microbes (e.g., butyrate-producing bacteria) and inflammatory markers like **high-sensitivity C-reactive protein (hsCRP)**, which is often elevated in cardiovascular diseases. The presence of these beneficial microbes is associated with inflammation reduction.\n\n4. **Metabolic Disruptions**: The functional analysis indicated differential abundance of various metabolic pathways between patients and controls. For example, the controls showed enrichment in genes related to **phytoene dehydrogenase**, an enzyme linked to carotenoid metabolism, which is associated with antioxidant production. This parameter suggests that patients had reduced capacity for producing beneficial metabolites such as carotenoids, which may help mitigate cardiovascular conditions.\n\n5. **Systemic Effects and Metabolites**: The study also implied potential systemic effects of gut dysbiosis connected to atherosclerosis through metabolites. It emphasizes that altered microbial metabolism may lead to an imbalance in metabolites including carotenoids like **\u03b2-carotene**, which showed reduced serum levels in patients, indicating the possibility that gut micrbiota-derived metabolites might influence atherosclerosis progression.\n\nOverall, the findings suggest that specific alterations in the gut microbiome composition, along with functional changes involving peptidoglycan synthesis and metabolism of beneficial compounds, contribute to the inflammatory processes associated with atherosclerosis. \n\n**Key Points**:\n- **Collinsella**: Enriched in atherosclerosis patients.\n- **Peptidoglycan biosynthesis**: Potential mechanism for immune activation and inflammation.\n- **Inflammatory markers**: Correlation with butyrate-producing bacteria and hsCRP.\n- **Phytoene dehydrogenase**: Enriched in controls, linked to carotenoid metabolism.\n- **Metabolites like \u03b2-carotene**: Reduced levels in patients, indicating a deficit in protective metabolites. \n\nThese mechanisms illustrate how gut microbiome changes can influence inflammatory pathways and metabolic disruptions relevant to atherosclerosis.",
    "annotated_entities": [
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 91,
        "end_char": 105,
        "color": "blue"
      },
      {
        "text": "Patients",
        "label": "ORGANISM",
        "start_char": 288,
        "end_char": 296,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 509,
        "end_char": 512,
        "color": "red"
      },
      {
        "text": "Peptidoglycan",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 591,
        "end_char": 604,
        "color": "red"
      },
      {
        "text": "patient",
        "label": "ORGANISM",
        "start_char": 625,
        "end_char": 632,
        "color": "purple"
      },
      {
        "text": "peptidoglycan",
        "label": "AMINO_ACID",
        "start_char": 743,
        "end_char": 756,
        "color": "red"
      },
      {
        "text": "bacterial cell walls",
        "label": "CELL",
        "start_char": 772,
        "end_char": 792,
        "color": "green"
      },
      {
        "text": "neutrophil",
        "label": "CELL",
        "start_char": 919,
        "end_char": 929,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 1262,
        "end_char": 1270,
        "color": "yellow"
      },
      {
        "text": "gut microbes",
        "label": "CANCER",
        "start_char": 1420,
        "end_char": 1432,
        "color": "green"
      },
      {
        "text": "butyrate-producing bacteria",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1440,
        "end_char": 1467,
        "color": "orange"
      },
      {
        "text": "cardiovascular",
        "label": "ORGAN",
        "start_char": 1575,
        "end_char": 1589,
        "color": "purple"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 1811,
        "end_char": 1819,
        "color": "yellow"
      },
      {
        "text": "*phytoene dehydrogenase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1899,
        "end_char": 1922,
        "color": "red"
      },
      {
        "text": "carotenoid",
        "label": "ORGANISM_SUBSTANCE",
        "start_char": 1946,
        "end_char": 1956,
        "color": "teal"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 2047,
        "end_char": 2055,
        "color": "yellow"
      },
      {
        "text": "carotenoids",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2122,
        "end_char": 2133,
        "color": "yellow"
      },
      {
        "text": "cardiovascular",
        "label": "ORGAN",
        "start_char": 2159,
        "end_char": 2173,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2281,
        "end_char": 2284,
        "color": "red"
      },
      {
        "text": "carotenoids like *",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2443,
        "end_char": 2461,
        "color": "pink"
      },
      {
        "text": "serum",
        "label": "ORGANISM_SUBSTANCE",
        "start_char": 2497,
        "end_char": 2502,
        "color": "green"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 2513,
        "end_char": 2521,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2555,
        "end_char": 2558,
        "color": "red"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 2698,
        "end_char": 2712,
        "color": "blue"
      },
      {
        "text": "peptidoglycan",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2766,
        "end_char": 2779,
        "color": "red"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 2969,
        "end_char": 2977,
        "color": "yellow"
      },
      {
        "text": "Peptidoglycan",
        "label": "AMINO_ACID",
        "start_char": 2983,
        "end_char": 2996,
        "color": "red"
      },
      {
        "text": "butyrate-producing",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3118,
        "end_char": 3136,
        "color": "blue"
      },
      {
        "text": "carotenoid",
        "label": "ORGANISM_SUBSTANCE",
        "start_char": 3219,
        "end_char": 3229,
        "color": "teal"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3295,
        "end_char": 3303,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3387,
        "end_char": 3390,
        "color": "red"
      }
    ]
  },
  "Row_20_Col_Rifaximin Justification": {
    "original_text": "**Expert Analysis - Therapeutic Alignment and Repurposing Rationale**\n\n**1. Mechanistic Convergence**\n\nThe mechanisms driving atherosclerosis are closely tied to immune response activation, inflammation, and disruptions in gut microbiota composition. Notably, the following mechanisms are highlighted in the atherosclerosis context:\n\n- **Altered Gut Microbial Composition**: Specifically, the enrichment of the genus **Collinsella** and reduced levels of beneficial gut bacteria indicate gut dysbiosis. This dysbiosis correlates with systemic inflammation and the pathogenesis of atherosclerosis.\n\n- **Immune Modulation via Peptidoglycan Biosynthesis**: Increased peptidoglycan biosynthesis can prime the innate immune system and enhance neutrophil function, which is relevant for inflammation typically observed in atherosclerosis.\n\n- **Inflammatory Markers**: A negative correlation exists between levels of butyrate-producing bacteria and **hsCRP**, a key inflammatory marker elevated in cardiovascular diseases. Lower levels of beneficial microbes that produce metabolites like butyrate correlate with higher levels of systemic inflammation.\n\n- **Metabolic Disruptions**: The reduction in carotenoid metabolism, indicated by differential abundance of genes, suggests impaired production of protective metabolites, which could contribute to atherosclerosis progression.\n\nAnalyzing Rifaximin's mechanism of action:\n\n- **Modulation of Gut Microbiota**: Rifaximin alters gut microbiota composition, promoting beneficial genera while suppressing pathogenic bacteria, which aligns with restoring microbial balance\u2014crucial for reducing inflammation.\n\n- **Reduction in Pro-Inflammatory Cytokines**: Rifaximin significantly decreases levels of pro-inflammatory cytokines such as **TNF-\u03b1** and **IL-1\u03b2**. These cytokines are central to the inflammation observed in atherosclerosis. By reducing such pro-inflammatory markers, Rifaximin may potentially inhibit the inflammatory pathways that contribute to the disease\u2019s progression.\n\n- **Enhanced Profile of Anti-Inflammatory Cytokines**: Rifaximin promotes **IL-10**, an anti-inflammatory cytokine, which can help in reducing overall systemic inflammation.\n\nIn summary, there is direct mechanistic alignment between Rifaximin's effects and the inflammatory pathways in atherosclerosis. Rifaximin\u2019s ability to modulate gut microbiota and exert anti-inflammatory effects indicates potential therapeutic benefit in addressing inflammatory drivers associated with atherosclerosis.\n\n**2. Supporting Clinical or Preclinical Evidence**\n\nThe synthesis of data illustrates Rifaximin's capacity for positively modifying gut microbiota and reducing inflammatory markers:\n\n- **Modulation of Microbiota**: The drug effectively decreases ammonia-producing bacteria while promoting beneficial genera, reminiscent of alterations seen in atherosclerosis that point to gut dysbiosis.\n\n- **Reduction of Inflammatory Markers**: Rifaximin\u2019s documented reduction of TNF-\u03b1 and other inflammatory mediators provides a direct link to the inflammatory environment observed in atherosclerosis. Improving gut health and reducing systemic inflammation can have significant downstream effects on atherosclerotic processes.\n\n- **Potential Neurological and Systemic Benefits**: While primarily targeting gut conditions, Rifaximin's impact on cognitive function in HE suggests a broader systemic effect, which may be beneficial in conditions like atherosclerosis that also engage the gut-brain axis.\n\n**3. Therapeutic Implications**\n\nGiven the insights garnered, Rifaximin could offer partial therapeutic benefits in atherosclerosis:\n\n- **Symptom Relief**: By normalizing gut microbiota and lowering systemic inflammation, Rifaximin may alleviate some symptoms associated with atherosclerosis, potentially leading to improved cardiovascular health.\n\n- **Modulation of Gut-Brain Axis Dysfunction**: The drug's effects on the gut-brain axis may provide secondary benefits, particularly in atherosclerosis-related cognitive decline or stress-induced vascular responses.\n\nHowever, some limitations should be noted:\n\n- **Incomplete Pathway Targeting**: While Rifaximin addresses several inflammatory pathways, it may not encompass all mechanisms driving atherosclerosis, suggesting that adjunct therapies may be necessary for comprehensive management.\n\n- **Scope of Symptom Improvement**: The potential scope for symptom alleviation may vary among individuals, especially those with more severe dysbiosis or advanced atherosclerotic disease.\n\nIn conclusion, Rifaximin presents a promising avenue for repurposing in the context of atherosclerosis, with specific mechanisms and clinical observations indicating its viability as a modulator of gut health and systemic inflammation.",
    "annotated_entities": [
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 466,
        "end_char": 469,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 488,
        "end_char": 491,
        "color": "purple"
      },
      {
        "text": "Peptidoglycan",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 624,
        "end_char": 637,
        "color": "green"
      },
      {
        "text": "peptidoglycan",
        "label": "AMINO_ACID",
        "start_char": 664,
        "end_char": 677,
        "color": "green"
      },
      {
        "text": "neutrophil",
        "label": "CELL",
        "start_char": 738,
        "end_char": 748,
        "color": "pink"
      },
      {
        "text": "butyrate-producing",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 910,
        "end_char": 928,
        "color": "red"
      },
      {
        "text": "cardiovascular",
        "label": "ORGAN",
        "start_char": 991,
        "end_char": 1005,
        "color": "green"
      },
      {
        "text": "carotenoid",
        "label": "ORGANISM_SUBSTANCE",
        "start_char": 1193,
        "end_char": 1203,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1384,
        "end_char": 1393,
        "color": "blue"
      },
      {
        "text": "Gut Microbiota**:",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1436,
        "end_char": 1453,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1454,
        "end_char": 1463,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1471,
        "end_char": 1474,
        "color": "purple"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1682,
        "end_char": 1691,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1695,
        "end_char": 1704,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1919,
        "end_char": 1928,
        "color": "blue"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2068,
        "end_char": 2077,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2081,
        "end_char": 2090,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2259,
        "end_char": 2268,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2329,
        "end_char": 2338,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2361,
        "end_char": 2364,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2607,
        "end_char": 2616,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2653,
        "end_char": 2656,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2894,
        "end_char": 2897,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2951,
        "end_char": 2960,
        "color": "blue"
      },
      {
        "text": "TNF-\u03b1",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2992,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3120,
        "end_char": 3123,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3315,
        "end_char": 3318,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3331,
        "end_char": 3340,
        "color": "blue"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3494,
        "end_char": 3503,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3573,
        "end_char": 3582,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3682,
        "end_char": 3685,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3733,
        "end_char": 3742,
        "color": "blue"
      },
      {
        "text": "cardiovascular",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 3836,
        "end_char": 3850,
        "color": "green"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3934,
        "end_char": 3943,
        "color": "yellow"
      },
      {
        "text": "vascular",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 4057,
        "end_char": 4065,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4164,
        "end_char": 4173,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4563,
        "end_char": 4572,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4746,
        "end_char": 4749,
        "color": "purple"
      }
    ]
  },
  "Row_21_Col_Disease": {
    "original_text": "Neuromyelitis Optica Spectrum Disorder",
    "annotated_entities": []
  },
  "Row_21_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_21_Col_Disease_Mechanism": {
    "original_text": "The research paper titled \"Clostridium bolteae is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4\" provides significant insights into the mechanisms linking gut microbiome alterations with Neuromyelitis Optica Spectrum Disorder (NMOSD), particularly through the elevation of the gut bacterium Clostridium bolteae and its immunological implications.\n\n### Key Mechanisms Identified:\n\n1. **Microbiome-Induced Immune Modulation**:\n   - **Specific Gut Bacteria Influence**: The study identifies Clostridium bolteae as significantly elevated in patients with AQP4-IgG+ NMOSD (p = 0.00007). This bacterium shares sequence similarity with aquaporin-4 (AQP4), a protein implicated in the pathophysiology of NMOSD. The alignment of C. bolteae's peptide with AQP4 suggests a potential for molecular mimicry, potentially triggering an autoimmune response by activating AQP4-specific T cells.\n   - **Gene Expression Correlation**: The presence of C. bolteae correlates positively with the upregulation of several immune-related genes (Rho \u2265 0.5, p < 0.05), particularly those involved in inflammatory responses (e.g., CD70, IFI35, MAPK11). This association indicates that alterations in the gut microbiome may modulate immune cell functionality, particularly in CD4+ T cells.\n\n2. **Inflammatory Pathways**:\n   - The study discusses gene expression changes that are relevant to inflammatory pathways associated with NMOSD, including T cell differentiation pathways such as TH1, TH2, and TH17. These pathways are critical in the autoimmune process, where gut-derived microbial changes may impact the systemic immune response through activation of these pathways.\n\n3. **Compositional Differences**:\n   - The paper details significant compositional changes in the gut microbiota of NMOSD patients compared to healthy controls, highlighting an increased abundance of several bacterial genera in NMOSD, particularly Clostridium, Megamonas, and Enterobacteriaceae. This dysbiosis suggests a shift in the microbial community that could impact immune modulation.\n\n4. **Gut-Organ Crosstalk**:\n   - Although not explicitly detailed in the excerpt, the presence of metabolites or bacterial components from the gut (such as from the altered microbiome) likely influences systemic inflammation and may affect distant organs (including the central nervous system) by either directly traveling through the bloodstream or by impacting metabolic pathways relevant to health and disease.\n\n5. **Biological Mechanism & Molecular Pathways**:\n   - The homology between C. bolteae and AQP4 indicates that gut-derived microbial changes may mechanistically alter host physiology through direct immune activation via molecular mimicry. The subsequent inflammatory response could contribute to the pathophysiology of NMOSD.\n\n### Summary:\nThe research highlights **Clostridium bolteae** as an **important microbiome-derived factor** linked to **immune modulation** and inflammation in **Neuromyelitis Optica Spectrum Disorder**. The **sequence similarity with AQP4** suggests a potential mechanism involving **molecular mimicry**, leading to **autoimmune activation** in susceptible individuals. The observed **correlations with immune gene expression** indicate that gut microbiome alterations might influence systemic immunity, thus playing a crucial role in the pathogenesis of NMOSD through **dysbiosis** and **inflammation**.",
    "annotated_entities": [
      {
        "text": "Clostridium bolteae",
        "label": "ORGANISM",
        "start_char": 27,
        "end_char": 46,
        "color": "pink"
      },
      {
        "text": "AQP4",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 146,
        "end_char": 150,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 210,
        "end_char": 213,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 332,
        "end_char": 335,
        "color": "red"
      },
      {
        "text": "Clostridium bolteae",
        "label": "ORGANISM",
        "start_char": 543,
        "end_char": 562,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 592,
        "end_char": 600,
        "color": "pink"
      },
      {
        "text": "aquaporin-4",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 684,
        "end_char": 695,
        "color": "blue"
      },
      {
        "text": "AQP4",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 697,
        "end_char": 701,
        "color": "red"
      },
      {
        "text": "C. bolteae's peptide",
        "label": "ORGANISM",
        "start_char": 775,
        "end_char": 795,
        "color": "purple"
      },
      {
        "text": "AQP4",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 801,
        "end_char": 805,
        "color": "red"
      },
      {
        "text": "AQP4-specific T cells",
        "label": "CELL",
        "start_char": 910,
        "end_char": 931,
        "color": "green"
      },
      {
        "text": "C. bolteae",
        "label": "ORGANISM",
        "start_char": 987,
        "end_char": 997,
        "color": "orange"
      },
      {
        "text": "Rho",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1075,
        "end_char": 1078,
        "color": "red"
      },
      {
        "text": "CD70",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1158,
        "end_char": 1162,
        "color": "yellow"
      },
      {
        "text": "IFI35",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1164,
        "end_char": 1169,
        "color": "orange"
      },
      {
        "text": "MAPK11",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1171,
        "end_char": 1177,
        "color": "teal"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 1231,
        "end_char": 1245,
        "color": "green"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 1259,
        "end_char": 1270,
        "color": "purple"
      },
      {
        "text": "CD4+",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1302,
        "end_char": 1306,
        "color": "teal"
      },
      {
        "text": "T cell",
        "label": "CELL",
        "start_char": 1472,
        "end_char": 1478,
        "color": "green"
      },
      {
        "text": "TH1",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1512,
        "end_char": 1515,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1800,
        "end_char": 1803,
        "color": "red"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 1824,
        "end_char": 1832,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2238,
        "end_char": 2241,
        "color": "red"
      },
      {
        "text": "organs",
        "label": "ORGAN",
        "start_char": 2343,
        "end_char": 2349,
        "color": "yellow"
      },
      {
        "text": "C. bolteae",
        "label": "ORGANISM",
        "start_char": 2586,
        "end_char": 2596,
        "color": "orange"
      },
      {
        "text": "AQP4",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2601,
        "end_char": 2605,
        "color": "red"
      },
      {
        "text": "gut-derived",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2621,
        "end_char": 2632,
        "color": "blue"
      },
      {
        "text": "Clostridium bolteae",
        "label": "ORGANISM",
        "start_char": 2876,
        "end_char": 2895,
        "color": "pink"
      },
      {
        "text": "AQP4",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3071,
        "end_char": 3075,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3279,
        "end_char": 3282,
        "color": "red"
      }
    ]
  },
  "Row_21_Col_Rifaximin Justification": {
    "original_text": "### Expert Analysis - Therapeutic Alignment and Repurposing Rationale\n\n#### 1. Mechanistic Convergence\n\n**Immune Modulation in Neuromyelitis Optica Spectrum Disorder (NMOSD)**:\n- The identified mechanisms in NMOSD, particularly involving **Clostridium bolteae**, emphasize a **gut microbiome-induced immune modulation**. The elevation of this bacterium correlates with **autoimmune responses** due to its sequence similarity with **aquaporin-4 (AQP4)**, implicating a potential for **molecular mimicry** that activates **AQP4-specific T cells**. \n- Additionally, gene expression changes in inflammatory pathways, including **upregulation of CD70 and MAPK11**, point to enhanced **T cell differentiation**, particularly in **TH1** and **TH17** pathways. These pathways play a crucial role in orchestrating inflammation and autoimmune processes.\n\n**Comparison with Rifaximin\u2019s Mechanisms**:\n- Rifaximin compromises the **gut microbiota** by selectively targeting **ammonia-producing bacteria**, influencing the overall microbial composition, which could potentially reduce the abundance of pathogenic strains like **Clostridium bolteae**. By fostering the growth of beneficial bacteria such as **Lactobacillus**, Rifaximin may help restore gut microbial balance, facilitating **immune homeostasis**.\n- Through its actions on pro-inflammatory cytokines, Rifaximin has been shown to **reduce TNF\u03b1, IL-1\u03b2**, and **IL-17** levels. Specifically, the reduction of these cytokines aligns with the **cytokine elevation** observed in NMOSD, suggesting that Rifaximin could effectively target an inflammatory milieu that is detrimental to NMOSD patients.\n- Furthermore, Rifaximin enhances the production of the **anti-inflammatory cytokine IL-10**, which could counteract the pro-inflammatory responses triggered by the gut microbiome alterations linked to NMOSD.\n\nIn conclusion, there exists a **strong mechanistic overlap** between Rifaximin's anti-inflammatory effects and the pathological autoimmune mechanisms in NMOSD. Rifaximin's capacity to modulate key immune functions and curb inflammation positions it as a potential therapeutic candidate in NMOSD.\n\n#### 2. Supporting Clinical or Preclinical Evidence\n\nRifaximin has established clinical efficacy in conditions involving **gut dysfunction and inflammation**, such as **hepatic encephalopathy (HE)** and **irritable bowel syndrome (IBS)**, both of which demonstrate a notable relationship with the gut-brain axis. \n\nThe data suggests the following:\n- **Modulation of Gut Microbiota**: Rifaximin demonstrates a consistent ability to alter gut microbiota profiles, reducing pathogen abundance while promoting beneficial taxa. This aligns with the dysbiosis identified in NMOSD, particularly with the increase in **Clostridium** species.\n- **Reduction of Inflammatory Markers**: Rifaximin's ability to lower systemic levels of inflammatory mediators (like **TNF\u03b1**) correlates with improvements in gut health and cognitive function in patients with HE, which could potentially translate to similar benefits in NMOSD.\n\nWhile direct clinical evidence in NMOSD may lack rigor, the parallels drawn from conditions involving autoimmune and neuroinflammatory components\u2014the efficacy observed in managing cognitive and systemic inflammation hint towards Rifaximin holding promise in NMOSD symptomatology.\n\n#### 3. Therapeutic Implications\n\nGiven the outlined mechanisms and supporting evidence, Rifaximin could offer **partial therapeutic benefit** in NMOSD:\n- **Symptom Relief**: By targeting gut dysbiosis and reducing inflammatory cytokines, Rifaximin may alleviate some systemic symptoms associated with NMOSD, such as fatigue and cognitive issues, leading to overall improved quality of life.\n- **Gut-Brain Axis Modulation**: Given Rifaximin\u2019s role in lowering ammonia levels and reducing gut-derived neuroinflammation, it could indirectly mitigate the impact of gut health on neurological function, which is relevant in NMOSD.\n- **Reduction of Systemic Inflammation**: Rifaximin\u2019s ability to enhance IL-10 and reduce pro-inflammatory cytokines aligns well with the need to manage inflammatory responses in NMOSD.\n\n**Limitations**:\n- Rifaximin may not comprehensively target all pathological pathways involved in NMOSD, notably the **autoantibody production** or complete alteration in T cell dynamics, which may necessitate **adjunct therapies**.\n- The variability of individual gut microbiota may also influence the efficacy of Rifaximin, suggesting that patient-specific profiling could be warranted to predict treatment outcomes.\n\n### Conclusion\n\nRifaximin presents a **mechanistically sound** and **potentially effective** repurposing opportunity for Neuromyelitis Optica Spectrum Disorder. Its abilities to modulate gut microbiota, reduce inflammatory cytokine levels, and enhance anti-inflammatory responses touch on critical pathophysiological drivers of NMOSD. While it stands to provide partial symptomatic relief and help restore balance within the gut-brain axis, clinical validation through targeted studies in NMOSD is recommended to solidify its therapeutic position.",
    "annotated_entities": [
      {
        "text": "Clostridium bolteae",
        "label": "ORGANISM",
        "start_char": 240,
        "end_char": 259,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 277,
        "end_char": 280,
        "color": "yellow"
      },
      {
        "text": "aquaporin-4",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 432,
        "end_char": 443,
        "color": "blue"
      },
      {
        "text": "AQP4",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 445,
        "end_char": 449,
        "color": "green"
      },
      {
        "text": "CD70",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 641,
        "end_char": 645,
        "color": "purple"
      },
      {
        "text": "MAPK11",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 650,
        "end_char": 656,
        "color": "teal"
      },
      {
        "text": "T cell",
        "label": "CELL",
        "start_char": 680,
        "end_char": 686,
        "color": "red"
      },
      {
        "text": "TH1",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 724,
        "end_char": 727,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 863,
        "end_char": 872,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 919,
        "end_char": 922,
        "color": "yellow"
      },
      {
        "text": "Lactobacillus",
        "label": "AMINO_ACID",
        "start_char": 1194,
        "end_char": 1207,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1211,
        "end_char": 1220,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1238,
        "end_char": 1241,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1351,
        "end_char": 1360,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 1388,
        "end_char": 1392,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1546,
        "end_char": 1555,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1658,
        "end_char": 1667,
        "color": "pink"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 1808,
        "end_char": 1822,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1922,
        "end_char": 1931,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2013,
        "end_char": 2022,
        "color": "pink"
      },
      {
        "text": "immune",
        "label": "CANCER",
        "start_char": 2050,
        "end_char": 2056,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2203,
        "end_char": 2212,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2273,
        "end_char": 2276,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 2319,
        "end_char": 2326,
        "color": "blue"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 2365,
        "end_char": 2370,
        "color": "orange"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2447,
        "end_char": 2456,
        "color": "green"
      },
      {
        "text": "Gut Microbiota**:",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2516,
        "end_char": 2533,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2534,
        "end_char": 2543,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2587,
        "end_char": 2590,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2825,
        "end_char": 2834,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2944,
        "end_char": 2947,
        "color": "yellow"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 2981,
        "end_char": 2989,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3293,
        "end_char": 3302,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3434,
        "end_char": 3443,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3533,
        "end_char": 3536,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3584,
        "end_char": 3593,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3776,
        "end_char": 3785,
        "color": "pink"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3805,
        "end_char": 3812,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3907,
        "end_char": 3910,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4014,
        "end_char": 4023,
        "color": "pink"
      },
      {
        "text": "T cell",
        "label": "CELL",
        "start_char": 4330,
        "end_char": 4336,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4424,
        "end_char": 4427,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4474,
        "end_char": 4483,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4595,
        "end_char": 4604,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4766,
        "end_char": 4769,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 5004,
        "end_char": 5013,
        "color": "green"
      }
    ]
  },
  "Row_22_Col_Disease": {
    "original_text": "Alzheimer's disease",
    "annotated_entities": []
  },
  "Row_22_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_22_Col_Disease_Mechanism": {
    "original_text": "The provided research paper discusses the association between Helicobacter pylori infection and various health outcomes, including Alzheimer's disease (AD). It outlines several proposed mechanisms by which gut microbiome alterations could link to the risk and pathophysiology of AD.\n\n1. **Vitamin B12 Deficiency**: H. pylori infection induces gastric alterations that lead to vitamin B12 deficiency. This deficiency can cause elevated levels of homocysteine, an amino acid that has been associated with cognitive impairment and dementia. Thus, the altered gut microbiome due to H. pylori can influence cognitive health through metabolic disruptions.\n\n2. **Hyperphosphorylation of TAU Protein**: There is a hypothesis that H. pylori infection could cause abnormal hyperphosphorylation of TAU protein. Hyperphosphorylated TAU is known to be involved in neurodegenerative processes related to Alzheimer's disease. This suggests a mechanism whereby changes in gut microbiome due to bacterial infection might influence protein signaling pathways that are critical in neuronal health.\n\n3. **Influence on Genetic Risk Factors**: The article mentions that H. pylori may positively influence ApoE polymorphism, which is a well-established genetic risk factor for AD. This interaction suggests that the gut microbiome, through H. pylori, might impact genetic pathways that govern susceptibility to neurodegenerative changes.\n\n4. **Neuroinflammation**: While the paper primarily focuses on the direct mechanisms of vitamin deficiency and protein alterations, systemic inflammation induced by H. pylori could also play a role in the pathogenesis of AD. Chronic inflammation is increasingly recognized as a contributor to the neurodegenerative process, although specific inflammatory pathways connected to the gut microbiome changes in the context of AD are not detailed in the provided text.\n\n5. **Potential Bacterial Reach to the Brain**: The paper posits that H. pylori could potentially access the brain through the olfactory bulb, suggesting a mechanism where alterations in gut microbiota can facilitate the translocation of bacteria or their products to the central nervous system, inducing neuroinflammatory responses.\n\nIn summary, the alterations in the gut microbiome, specifically due to H. pylori infection, link to Alzheimer's disease through mechanisms involving **vitamin B12 deficiency**, **hyperphosphorylation of TAU**, interactions with **genetic risk factors** such as **ApoE**, and potential pathways for **neuroinflammation**. These insights highlight the complex interplay between gut health and neurological outcomes, underpinning the relevance of gut microbiome studies in understanding Alzheimer's disease pathology.",
    "annotated_entities": [
      {
        "text": "Helicobacter pylori",
        "label": "ORGANISM",
        "start_char": 62,
        "end_char": 81,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 206,
        "end_char": 209,
        "color": "yellow"
      },
      {
        "text": "Vitamin B12",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 289,
        "end_char": 300,
        "color": "red"
      },
      {
        "text": "H. pylori",
        "label": "ORGANISM",
        "start_char": 315,
        "end_char": 324,
        "color": "red"
      },
      {
        "text": "gastric",
        "label": "ORGAN",
        "start_char": 343,
        "end_char": 350,
        "color": "teal"
      },
      {
        "text": "vitamin B12",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 376,
        "end_char": 387,
        "color": "red"
      },
      {
        "text": "homocysteine",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 445,
        "end_char": 457,
        "color": "blue"
      },
      {
        "text": "amino acid",
        "label": "AMINO_ACID",
        "start_char": 462,
        "end_char": 472,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 556,
        "end_char": 559,
        "color": "yellow"
      },
      {
        "text": "H. pylori",
        "label": "ORGANISM",
        "start_char": 578,
        "end_char": 587,
        "color": "red"
      },
      {
        "text": "TAU",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 680,
        "end_char": 683,
        "color": "teal"
      },
      {
        "text": "H. pylori",
        "label": "ORGANISM",
        "start_char": 722,
        "end_char": 731,
        "color": "red"
      },
      {
        "text": "TAU",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 787,
        "end_char": 790,
        "color": "teal"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 956,
        "end_char": 970,
        "color": "pink"
      },
      {
        "text": "neuronal",
        "label": "CELL",
        "start_char": 1062,
        "end_char": 1070,
        "color": "orange"
      },
      {
        "text": "H. pylori",
        "label": "ORGANISM",
        "start_char": 1148,
        "end_char": 1157,
        "color": "red"
      },
      {
        "text": "ApoE",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1183,
        "end_char": 1187,
        "color": "blue"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 1293,
        "end_char": 1307,
        "color": "pink"
      },
      {
        "text": "H. pylori",
        "label": "ORGANISM",
        "start_char": 1317,
        "end_char": 1326,
        "color": "red"
      },
      {
        "text": "vitamin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1504,
        "end_char": 1511,
        "color": "yellow"
      },
      {
        "text": "H. pylori",
        "label": "ORGANISM",
        "start_char": 1581,
        "end_char": 1590,
        "color": "red"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 1797,
        "end_char": 1811,
        "color": "pink"
      },
      {
        "text": "AD",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 1838,
        "end_char": 1840,
        "color": "red"
      },
      {
        "text": "Brain",
        "label": "ORGAN",
        "start_char": 1919,
        "end_char": 1924,
        "color": "purple"
      },
      {
        "text": "H. pylori",
        "label": "ORGANISM",
        "start_char": 1950,
        "end_char": 1959,
        "color": "red"
      },
      {
        "text": "brain",
        "label": "ORGAN",
        "start_char": 1989,
        "end_char": 1994,
        "color": "purple"
      },
      {
        "text": "olfactory bulb",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 2007,
        "end_char": 2021,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2067,
        "end_char": 2070,
        "color": "yellow"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 2250,
        "end_char": 2264,
        "color": "pink"
      },
      {
        "text": "H. pylori",
        "label": "ORGANISM",
        "start_char": 2286,
        "end_char": 2295,
        "color": "red"
      },
      {
        "text": "vitamin B12",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2366,
        "end_char": 2377,
        "color": "red"
      },
      {
        "text": "TAU",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2418,
        "end_char": 2421,
        "color": "teal"
      },
      {
        "text": "ApoE",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2478,
        "end_char": 2482,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2591,
        "end_char": 2594,
        "color": "yellow"
      },
      {
        "text": "gut microbiome",
        "label": "CANCER",
        "start_char": 2659,
        "end_char": 2673,
        "color": "pink"
      }
    ]
  },
  "Row_22_Col_Rifaximin Justification": {
    "original_text": "### Expert Analysis - Therapeutic Alignment and Repurposing Rationale\n\n1. **Mechanistic Convergence**\n\n#### Mechanisms in Alzheimer\u2019s Disease:\n- **Vitamin B12 Deficiency**: H. pylori infection can lead to gastric alterations that cause vitamin B12 deficiency. This deficiency results in elevated homocysteine levels, which are associated with cognitive impairment. \n- **Hyperphosphorylation of TAU Protein**: H. pylori may contribute to the abnormal hyperphosphorylation of TAU, a process linked to neurodegeneration in AD.\n- **Genetic Risk Factors**: H. pylori's influence on ApoE polymorphism connects gut health with neurodegenerative susceptibility.\n- **Neuroinflammation**: Chronic inflammation, potentially induced by H. pylori, is implicated in AD's pathogenesis. \n- **Potential Bacterial Translocation**: H. pylori may access the brain, instigating neuroinflammatory responses.\n\n#### Rifaximin\u2019s Mechanisms of Action:\n- **Cytokine Modulation**: Rifaximin reduces pro-inflammatory cytokines including TNF\u03b1 and IL-1\u03b2, key mediators of inflammation, which may directly correlate with systemic inflammation relevant to AD.\n- **Microbial Modulation**: Rifaximin selectively targets ammonia-producing bacteria in the gut, which can influence the overall microbiota composition. The increase in beneficial bacteria post-treatment could potentially mitigate some pathogenic microbiome alterations connected to AD.\n- **Decreased Ammonia Production**: By reducing bacteria associated with ammonia production, Rifaximin may indirectly lessen factors that exacerbate neuroinflammation and cognitive dysfunction associated with AD.\n\n#### Assessment of Overlap:\nThe inflammatory pathways involved in AD\u2014specifically neuroinflammation characterized by elevated levels of pro-inflammatory cytokines\u2014align with Rifaximin's ability to modulate these pathways. By reducing TNF\u03b1 and IL-1\u03b2, Rifaximin potentially counters some of the inflammatory processes that contribute to AD, creating a plausible mechanistic overlap. Additionally, the influence of gut health, mediated through Rifaximin\u2019s modulation of gut microbiota, could address some alterations associated with the disease pathology.\n\nOverall, **there is a direct mechanistic alignment between Rifaximin\u2019s pharmacologic effects**\u2014particularly its capacity to modulate cytokines and alter microbiota\u2014and the pathophysiological drivers of Alzheimer's disease, underscoring its repurposing potential.\n\n2. **Supporting Clinical or Preclinical Evidence**\nThe existing data show that Rifaximin achieves significant therapeutic effects in other contexts such as hepatic encephalopathy and IBS, primarily through:\n- **Microbiota Modulation**: Rifaximin alters the gut microbiome, enriching beneficial bacterial genera, which may also influence cognitive health through improved intestinal flora balance.\n- **Reduction of Inflammatory Markers**: The demonstrated reduction in pro-inflammatory cytokines provides a pathway for potential systemic benefits, which may extend to conditions like Alzheimer's disease, where inflammation plays a critical role.\n- **Cognitive Improvement**: Evidence from hepatic encephalopathy indicates that cognitive function improves with reduced ammonia levels, suggesting a mechanism that could also apply to AD, as both conditions involve neuroinflammation and cognitive decline.\n\n3. **Therapeutic Implications**\nRifaximin could present potential therapeutic benefits in Alzheimer's disease, including:\n- **Symptom Relief**: By mitigating inflammation and improving gut health, Rifaximin might help alleviate some cognitive symptoms associated with AD.\n- **Modulation of Gut-Brain Axis Dysfunction**: Interventions aimed at restoring gut microbiota may have positive downstream effects on neurological function, making Rifaximin a candidate for improving gut-brain connectivity.\n- **Reduction in Systemic Inflammation**: As Rifaximin shows potential in reducing inflammatory biomarkers, it could lead to less neuroinflammation in the context of Alzheimer's pathology.\n\n**Limitations/Caveats**:\n- While Rifaximin may address some overarching inflammatory and microbial concerns in AD, it may not fully target all pathways involved in the disease's progression. Consequently, Rifaximin\u2019s benefits may be more supportive rather than curative.\n- The need for adjunct therapies or combination approaches may also be necessary to comprehensively address the multifaceted nature of Alzheimer's disease.\n\n### Conclusion\nGiven the distinct mechanistic overlaps and promising therapeutic implications, Rifaximin presents a compelling case for repurposing in Alzheimer's disease through modulation of gut health and systemic inflammation. Key actions include cytokine regulation, microbiota modulation, and potential cognitive benefits, reinforcing its viability as a treatment option worth exploring further.",
    "annotated_entities": [
      {
        "text": "Vitamin B12",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 147,
        "end_char": 158,
        "color": "red"
      },
      {
        "text": "H. pylori",
        "label": "ORGANISM",
        "start_char": 173,
        "end_char": 182,
        "color": "red"
      },
      {
        "text": "gastric",
        "label": "ORGAN",
        "start_char": 205,
        "end_char": 212,
        "color": "purple"
      },
      {
        "text": "vitamin B12",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 236,
        "end_char": 247,
        "color": "red"
      },
      {
        "text": "homocysteine",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 296,
        "end_char": 308,
        "color": "blue"
      },
      {
        "text": "TAU",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 394,
        "end_char": 397,
        "color": "teal"
      },
      {
        "text": "H. pylori",
        "label": "ORGANISM",
        "start_char": 409,
        "end_char": 418,
        "color": "red"
      },
      {
        "text": "TAU",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 474,
        "end_char": 477,
        "color": "teal"
      },
      {
        "text": "H. pylori",
        "label": "ORGANISM",
        "start_char": 552,
        "end_char": 561,
        "color": "red"
      },
      {
        "text": "ApoE",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 577,
        "end_char": 581,
        "color": "blue"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 604,
        "end_char": 607,
        "color": "teal"
      },
      {
        "text": "H. pylori",
        "label": "ORGANISM",
        "start_char": 724,
        "end_char": 733,
        "color": "red"
      },
      {
        "text": "H. pylori",
        "label": "ORGANISM",
        "start_char": 813,
        "end_char": 822,
        "color": "red"
      },
      {
        "text": "brain",
        "label": "ORGAN",
        "start_char": 838,
        "end_char": 843,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 892,
        "end_char": 901,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 953,
        "end_char": 962,
        "color": "purple"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 1008,
        "end_char": 1012,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1155,
        "end_char": 1164,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1219,
        "end_char": 1222,
        "color": "teal"
      },
      {
        "text": "Ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1428,
        "end_char": 1435,
        "color": "green"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1487,
        "end_char": 1494,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1507,
        "end_char": 1516,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1802,
        "end_char": 1811,
        "color": "purple"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 1862,
        "end_char": 1866,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1878,
        "end_char": 1887,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2040,
        "end_char": 2043,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2069,
        "end_char": 2078,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2095,
        "end_char": 2098,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2241,
        "end_char": 2250,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2525,
        "end_char": 2534,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 2602,
        "end_char": 2609,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2682,
        "end_char": 2691,
        "color": "purple"
      },
      {
        "text": "gut microbiome",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 2703,
        "end_char": 2717,
        "color": "yellow"
      },
      {
        "text": "intestinal flora",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 2817,
        "end_char": 2833,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3135,
        "end_char": 3142,
        "color": "green"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3214,
        "end_char": 3221,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3383,
        "end_char": 3392,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3536,
        "end_char": 3539,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3548,
        "end_char": 3557,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3704,
        "end_char": 3707,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3789,
        "end_char": 3798,
        "color": "purple"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3825,
        "end_char": 3834,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3894,
        "end_char": 3903,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4072,
        "end_char": 4081,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4244,
        "end_char": 4253,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4562,
        "end_char": 4571,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4660,
        "end_char": 4663,
        "color": "teal"
      }
    ]
  },
  "Row_23_Col_Disease": {
    "original_text": "Migraine",
    "annotated_entities": []
  },
  "Row_23_Col_Drug_Mechanism": {
    "original_text": "Rifaximin is a nonabsorbable, bactericidal rifamycin derivative that acts primarily within the gastrointestinal tract. It exerts its therapeutic effects not only through direct antimicrobial activity but also by modulating gut microbiota, influencing immune responses, and altering cytokine profiles. These multifaceted actions make it effective in managing gastrointestinal and hepatic disorders such as hepatic encephalopathy (HE), irritable bowel syndrome (IBS), and small intestinal bacterial overgrowth (SIBO).\n1. Molecular Mechanism and Antibacterial Activity\nRifaximin acts by binding to the \u03b2-subunit of bacterial RNA polymerase (RpoB), preventing the initiation of transcription and thereby inhibiting bacterial protein synthesis. Its nonabsorbable nature ensures that it exerts its antimicrobial effects locally in the gut, reducing the potential for systemic side effects.\n2. Bacterial Targets and Gut Microbiota Modulation\nRifaximin selectively targets ammonia-producing colonic bacteria, crucial in the pathogenesis of HE, IBS, and SIBO. Key bacterial targets include:\n\u2022\tStreptococcus salivarius (urease-positive strains): Reduced in HE patients, leading to decreased urease activity and lower systemic ammonia levels.\n\u2022\tVeillonellaceae family: Suppressed by rifaximin, leading to reduced colonic ammonia production.\n\u2022\tRuminococcus gnavus: Sensitivity to rifaximin is influenced by conjugated bile acids.\n\u2022\tRuminococcaceae and Lachnospiraceae: These beneficial bacteria increase in abundance following rifaximin treatment, contributing to its anti-inflammatory effects.\nGut Microbiota and Biomarkers:\n\u2022\tAmmonia: A key biomarker of HE, its systemic levels decrease following rifaximin treatment, correlating with improved cognitive function.\n\u2022\tMicrobial Composition: Rifaximin increases beneficial genera like Lactobacillus and Ruminococcaceae, while reducing pathogenic and inflammatory bacteria, contributing to improved gut health and function.\n3. Cytokine Modulation and Immune Responses\nRifaximin significantly influences immune responses by modulating levels of key cytokines involved in inflammation, immunity, and gut homeostasis. These include:\nPro-Inflammatory Cytokines:\n\u2022\tTNF\u03b1 (Tumor Necrosis Factor-alpha): Rifaximin reduces TNF\u03b1 levels, which is a central mediator of inflammation, particularly in liver cirrhosis, IBS, and SIBO. Elevated TNF\u03b1 is often associated with gut inflammation and liver dysfunction.\n\u2022\tIL-1\u03b2 (Interleukin-1 beta): IL-1\u03b2 is a pro-inflammatory cytokine involved in immune cell recruitment and inflammation. Rifaximin has been shown to reduce IL-1\u03b2 levels in various inflammatory conditions, particularly in the gut and liver.\n\u2022\tIL-17 (Interleukin-17): IL-17 is a key cytokine in autoimmune responses and chronic inflammation. Rifaximin\u2019s ability to reduce IL-17 is critical in preventing tissue damage and chronic inflammatory conditions like IBS and liver cirrhosis.\n\u2022\tINF\u03b3 (Interferon-gamma): INF\u03b3 plays a role in immune activation and T-cell differentiation. Rifaximin has been shown to modulate INF\u03b3 production, potentially reducing the inflammatory burden in the gut and liver, particularly in patients with chronic liver disease.\nAnti-Inflammatory Cytokines:\n\u2022\tIL-10: Rifaximin promotes the production of IL-10, an anti-inflammatory cytokine, which is crucial for maintaining immune tolerance and balancing the inflammatory response in the gut.\nMetabolite Interactions\n Rifaximin, by enhancing the production of beneficial gut bacteria, can increase the levels of SCFAs. These SCFAs have been implicated in reducing inflammation, suggesting a potential mechanism for symptom relief in migraine patients.\n4. Effects on Gut-Brain Axis and Neurological Function\nRifaximin\u2019s impact extends beyond the gut, particularly in conditions like hepatic encephalopathy (HE), where its neuroprotective effects are well-documented:\n\u2022\tCognitive Improvement: By reducing ammonia-producing bacteria in the gut, rifaximin decreases systemic ammonia levels, which are neurotoxic and contribute to cognitive dysfunction in cirrhotic patients.\n\u2022\tNeuroinflammation: Rifaximin\u2019s ability to reduce pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, and IL-6 contributes to reduced neuroinflammation, potentially improving mood and cognitive function in conditions like HE and stress-induced gut disorders.\n5. Modulating Factors and Therapeutic Efficacy\n\u2022\tBile Acids: Conjugated bile acids like taurodeoxycholic acid (TDCA) enhance rifaximin\u2019s antibacterial activity by increasing the sensitivity of certain bacteria (e.g., R. gnavus) to the drug, improving its efficacy.\n\u2022\tPatient Response Variability: Rifaximin\u2019s efficacy can vary based on the individual\u2019s gut microbiota composition. Responders show significant reductions in urease-producing bacteria and ammonia levels, whereas non-responders may harbor alternative ammonia-producing species, leading to a reduced therapeutic effect.\n6. Clinical Applications and Therapeutic Outcomes\nRifaximin\u2019s multifaceted mechanism of action makes it highly effective in treating various gastrointestinal and hepatic conditions:\n\u2022\tHepatic Encephalopathy (HE): Rifaximin reduces ammonia-producing bacteria, leading to lower ammonia levels and improved cognitive function in patients with cirrhosis.\n\u2022\tIrritable Bowel Syndrome (IBS): Rifaximin alters the gut microbiota, reducing pathogenic bacteria and promoting beneficial species, which leads to symptom relief in IBS patients, particularly those with bloating and abdominal discomfort.\n\u2022\tSmall Intestinal Bacterial Overgrowth (SIBO): In SIBO, rifaximin helps reduce bacterial overgrowth in the small intestine, leading to symptomatic improvement and gut health restoration.\n\u2022\tStress-Induced Gut Disorders: In experimental models, rifaximin prevents mucosal inflammation, visceral hypersensitivity, and barrier dysfunction, which may have therapeutic potential for stress-related gut disorders.\nConclusion:\nRifaximin\u2019s multifaceted mechanism of action involves its direct antimicrobial effect and its ability to modulate immune responses, including the reduction of key pro-inflammatory cytokines such as TNF\u03b1, IL-1\u03b2, IL-17, and INF\u03b3. Its ability to reduce ammonia levels, modulate gut microbiota, and alter cytokine profiles contributes to its effectiveness in treating conditions like hepatic encephalopathy, IBS, SIBO, and stress-induced gut disorders. These actions underscore its potential as a gut microenvironment modulator, offering broad therapeutic benefits for gut-brain axis-related diseases.\n ",
    "annotated_entities": [
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 0,
        "end_char": 9,
        "color": "pink"
      },
      {
        "text": "gastrointestinal tract",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 95,
        "end_char": 117,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 223,
        "end_char": 226,
        "color": "yellow"
      },
      {
        "text": "gastrointestinal",
        "label": "ORGAN",
        "start_char": 358,
        "end_char": 374,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 379,
        "end_char": 386,
        "color": "orange"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 405,
        "end_char": 412,
        "color": "orange"
      },
      {
        "text": "bowel",
        "label": "ORGAN",
        "start_char": 444,
        "end_char": 449,
        "color": "yellow"
      },
      {
        "text": "small intestinal",
        "label": "ORGAN",
        "start_char": 470,
        "end_char": 486,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 566,
        "end_char": 575,
        "color": "pink"
      },
      {
        "text": "RNA polymerase",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 622,
        "end_char": 636,
        "color": "red"
      },
      {
        "text": "RpoB",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 638,
        "end_char": 642,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 829,
        "end_char": 832,
        "color": "yellow"
      },
      {
        "text": "Gut Microbiota",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 909,
        "end_char": 923,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 935,
        "end_char": 944,
        "color": "pink"
      },
      {
        "text": "colonic",
        "label": "ORGAN",
        "start_char": 983,
        "end_char": 990,
        "color": "red"
      },
      {
        "text": "HE",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1032,
        "end_char": 1034,
        "color": "green"
      },
      {
        "text": "urease-positive",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1110,
        "end_char": 1125,
        "color": "blue"
      },
      {
        "text": "HE patients",
        "label": "ORGANISM",
        "start_char": 1147,
        "end_char": 1158,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1272,
        "end_char": 1281,
        "color": "pink"
      },
      {
        "text": "colonic ammonia",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 1302,
        "end_char": 1317,
        "color": "green"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1368,
        "end_char": 1377,
        "color": "pink"
      },
      {
        "text": "bile",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1406,
        "end_char": 1410,
        "color": "blue"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1515,
        "end_char": 1524,
        "color": "pink"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1687,
        "end_char": 1696,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1779,
        "end_char": 1788,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1935,
        "end_char": 1938,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2004,
        "end_char": 2013,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2134,
        "end_char": 2137,
        "color": "yellow"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2183,
        "end_char": 2192,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2196,
        "end_char": 2200,
        "color": "red"
      },
      {
        "text": "Tumor Necrosis Factor-alpha",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2202,
        "end_char": 2229,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2232,
        "end_char": 2241,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2250,
        "end_char": 2254,
        "color": "red"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2324,
        "end_char": 2329,
        "color": "orange"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 2365,
        "end_char": 2369,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2395,
        "end_char": 2398,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2416,
        "end_char": 2421,
        "color": "orange"
      },
      {
        "text": "Interleukin-1 beta",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2444,
        "end_char": 2462,
        "color": "blue"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 2514,
        "end_char": 2525,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2556,
        "end_char": 2565,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2660,
        "end_char": 2663,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2668,
        "end_char": 2673,
        "color": "orange"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2677,
        "end_char": 2682,
        "color": "yellow"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2701,
        "end_char": 2706,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2775,
        "end_char": 2784,
        "color": "pink"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2805,
        "end_char": 2810,
        "color": "yellow"
      },
      {
        "text": "tissue",
        "label": "TISSUE",
        "start_char": 2837,
        "end_char": 2843,
        "color": "pink"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 2900,
        "end_char": 2905,
        "color": "orange"
      },
      {
        "text": "INF\u03b3",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2919,
        "end_char": 2923,
        "color": "red"
      },
      {
        "text": "Interferon-gamma):",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 2925,
        "end_char": 2943,
        "color": "green"
      },
      {
        "text": "T-cell",
        "label": "CELL",
        "start_char": 2987,
        "end_char": 2993,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3011,
        "end_char": 3020,
        "color": "pink"
      },
      {
        "text": "INF\u03b3",
        "label": "CELL",
        "start_char": 3048,
        "end_char": 3052,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3117,
        "end_char": 3120,
        "color": "yellow"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3125,
        "end_char": 3130,
        "color": "orange"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 3148,
        "end_char": 3156,
        "color": "teal"
      },
      {
        "text": "liver",
        "label": "ORGAN",
        "start_char": 3170,
        "end_char": 3175,
        "color": "orange"
      },
      {
        "text": "Cytokines",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3203,
        "end_char": 3212,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3223,
        "end_char": 3232,
        "color": "pink"
      },
      {
        "text": "IL-10",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3260,
        "end_char": 3265,
        "color": "teal"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3395,
        "end_char": 3398,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3425,
        "end_char": 3434,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3478,
        "end_char": 3481,
        "color": "yellow"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3519,
        "end_char": 3524,
        "color": "blue"
      },
      {
        "text": "SCFAs",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3532,
        "end_char": 3537,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3714,
        "end_char": 3723,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3752,
        "end_char": 3755,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 3789,
        "end_char": 3796,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3944,
        "end_char": 3947,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3949,
        "end_char": 3958,
        "color": "pink"
      },
      {
        "text": "cirrhotic patients",
        "label": "CANCER",
        "start_char": 4058,
        "end_char": 4076,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4099,
        "end_char": 4108,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 4164,
        "end_char": 4168,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4319,
        "end_char": 4322,
        "color": "yellow"
      },
      {
        "text": "Bile Acids",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 4383,
        "end_char": 4393,
        "color": "orange"
      },
      {
        "text": "Conjugated bile acids like taurodeoxycholic acid",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4395,
        "end_char": 4443,
        "color": "blue"
      },
      {
        "text": "TDCA",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4445,
        "end_char": 4449,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4459,
        "end_char": 4468,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4631,
        "end_char": 4640,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 4687,
        "end_char": 4690,
        "color": "yellow"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4787,
        "end_char": 4794,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 4967,
        "end_char": 4976,
        "color": "pink"
      },
      {
        "text": "gastrointestinal",
        "label": "CANCER",
        "start_char": 5058,
        "end_char": 5074,
        "color": "purple"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 5079,
        "end_char": 5086,
        "color": "orange"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5130,
        "end_char": 5139,
        "color": "pink"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 5243,
        "end_char": 5251,
        "color": "teal"
      },
      {
        "text": "Bowel",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5280,
        "end_char": 5285,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5302,
        "end_char": 5311,
        "color": "pink"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5323,
        "end_char": 5326,
        "color": "yellow"
      },
      {
        "text": "IBS patients",
        "label": "CANCER",
        "start_char": 5435,
        "end_char": 5447,
        "color": "purple"
      },
      {
        "text": "bloating",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5473,
        "end_char": 5481,
        "color": "purple"
      },
      {
        "text": "abdominal",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5486,
        "end_char": 5495,
        "color": "red"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5565,
        "end_char": 5574,
        "color": "pink"
      },
      {
        "text": "small intestine",
        "label": "ORGAN",
        "start_char": 5616,
        "end_char": 5631,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5672,
        "end_char": 5675,
        "color": "yellow"
      },
      {
        "text": "rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5752,
        "end_char": 5761,
        "color": "pink"
      },
      {
        "text": "mucosal",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 5771,
        "end_char": 5778,
        "color": "purple"
      },
      {
        "text": "visceral",
        "label": "TISSUE",
        "start_char": 5793,
        "end_char": 5801,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 5901,
        "end_char": 5904,
        "color": "yellow"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 5928,
        "end_char": 5937,
        "color": "pink"
      },
      {
        "text": "TNF\u03b1",
        "label": "CELL",
        "start_char": 6126,
        "end_char": 6130,
        "color": "red"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6139,
        "end_char": 6144,
        "color": "yellow"
      },
      {
        "text": "INF\u03b3",
        "label": "CELLULAR_COMPONENT",
        "start_char": 6150,
        "end_char": 6154,
        "color": "red"
      },
      {
        "text": "ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 6178,
        "end_char": 6185,
        "color": "green"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6203,
        "end_char": 6206,
        "color": "yellow"
      },
      {
        "text": "hepatic",
        "label": "ORGAN",
        "start_char": 6308,
        "end_char": 6315,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6362,
        "end_char": 6365,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 6421,
        "end_char": 6424,
        "color": "yellow"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 6493,
        "end_char": 6502,
        "color": "red"
      }
    ]
  },
  "Row_23_Col_Disease_Mechanism": {
    "original_text": "The provided excerpt from the research paper does not contain relevant information regarding the mechanisms linking gut microbiome alterations to Migraine. Consequently, I cannot generate a response based on the specified criteria.",
    "annotated_entities": [
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 116,
        "end_char": 119,
        "color": "red"
      }
    ]
  },
  "Row_23_Col_Rifaximin Justification": {
    "original_text": "### Section 3: Expert Analysis - Therapeutic Alignment and Repurposing Rationale\n\n#### 1. Mechanistic Convergence\nWhile the specific pathophysiological mechanisms of Migraine are not directly detailed, it is well-established that inflammatory mediators and dysregulated immune responses are involved in migraine pathogenesis. Key points include:\n\n- **Inflammatory Mediators**: Migraines often feature the elevation of pro-inflammatory cytokines such as IL-6 and TNF-\u03b1. These cytokines can stimulate trigeminal nerve pathways contributing to migraine attacks.\n- **Immune Cells**: Activation of mast cells, macrophages, and T-lymphocytes can lead to increased inflammation and sensitivity, inducing migraine episodes.\n\n**Comparison with Rifaximin Mechanisms**:\nRifaximin has demonstrated the capability to reduce elevated levels of inflammatory cytokines, notably TNF-\u03b1, IL-1\u03b2, and IL-17, all of which are pertinent in migraine pathology. The drug directly modulates the intestinal microbiota, promoting beneficial bacteria while suppressing pathogenic ones, which can further lead to reduced overall inflammation.\n\n**Mechanistic Overlap**:\n- **Cytokine Modulation**: Rifaximin reduces TNF-\u03b1 levels, thus potentially mitigating one of the pro-inflammatory pathways implicated in migraine.\n- **Immune Pathway Targeting**: By improving gut microbiota composition, Rifaximin may influence systemic inflammation and immune responses, which are relevant to migraine pathophysiology.\n  \n**Conclusion on Mechanistic Alignment**: There is an **indirect** yet potentially beneficial mechanistic alignment between Rifaximin's pharmacological effects and the inflammation-driven aspects of Migraine, particularly concerning the modulation of pro-inflammatory cytokines and immune cell activity.\n\n#### 2. Supporting Clinical or Preclinical Evidence\nWhile direct studies on Rifaximin\u2019s effects on migraines may not be explicitly provided in the context, the substantial evidence regarding Rifaximin\u2019s anti-inflammatory and gut microbiota-modulating effects can be extrapolated to the context of migraine management. \n\n- **Microbiota Modulation**: The drug's ability to increase beneficial genera like Lactobacillus can indirectly influence systemic inflammation markers.\n- **Reduction of Inflammatory Markers**: Observational outcomes highlight that reductions in gut-derived ammonia and modulated cytokine profiles correlate with improved cognitive and systemic symptoms, potentially relevant to the dysregulated immune system seen in migraine sufferers.\n\n#### 3. Therapeutic Implications\nGiven Rifaximin's known therapeutic properties, it could provide partial therapeutic benefits for migraine patients, particularly those demonstrating signs of gut dysbiosis or chronic systemic inflammation. Key considerations include:\n\n- **Symptom Relief**: Rifaximin may contribute to symptom relief by addressing gut inflammation and enhancing overall gut health.\n- **Gut-Brain Axis Modulation**: Its effects on gut microbiota and systemic inflammation may offer a novel pathway to alleviate migraine symptoms through gut-brain axis modulation.\n\n**Limitations/Caveats**:\n- **Scope of Improvement**: While Rifaximin may provide symptom relief, it might not fully address the multifaceted nature of migraine triggers, such as hormonal changes, diet, and other environmental factors.\n- **Adjunct Therapy Necessity**: Rifaximin would likely need to be part of a broader treatment protocol, focusing on comprehensive migraine management alongside lifestyle modifications and other pharmacological interventions.\n\nIn summary, the evidence suggests that **Rifaximin has a viable potential as a repurposed therapy for Migraine**, primarily through its actions on inflammatory cytokines and gut microbiota modulation, making it an intriguing candidate for further investigation in this therapeutic context.",
    "annotated_entities": [
      {
        "text": "IL-6",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 453,
        "end_char": 457,
        "color": "purple"
      },
      {
        "text": "trigeminal nerve",
        "label": "MULTI_TISSUE_STRUCTURE",
        "start_char": 499,
        "end_char": 515,
        "color": "pink"
      },
      {
        "text": "Immune Cells",
        "label": "CELL",
        "start_char": 563,
        "end_char": 575,
        "color": "yellow"
      },
      {
        "text": "mast cells",
        "label": "CELL",
        "start_char": 593,
        "end_char": 603,
        "color": "green"
      },
      {
        "text": "macrophages",
        "label": "CELL",
        "start_char": 605,
        "end_char": 616,
        "color": "red"
      },
      {
        "text": "T-lymphocytes",
        "label": "CELL",
        "start_char": 622,
        "end_char": 635,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 735,
        "end_char": 744,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 759,
        "end_char": 768,
        "color": "purple"
      },
      {
        "text": "IL-17",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 880,
        "end_char": 885,
        "color": "orange"
      },
      {
        "text": "intestinal",
        "label": "ORGAN",
        "start_char": 969,
        "end_char": 979,
        "color": "pink"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1166,
        "end_char": 1175,
        "color": "purple"
      },
      {
        "text": "TNF-\u03b1",
        "label": "CELL",
        "start_char": 1184,
        "end_char": 1189,
        "color": "yellow"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 1332,
        "end_char": 1335,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1360,
        "end_char": 1369,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1602,
        "end_char": 1611,
        "color": "purple"
      },
      {
        "text": "immune cell",
        "label": "CELL",
        "start_char": 1760,
        "end_char": 1771,
        "color": "teal"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1859,
        "end_char": 1868,
        "color": "purple"
      },
      {
        "text": "migraines",
        "label": "PATHOLOGICAL_FORMATION",
        "start_char": 1882,
        "end_char": 1891,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 1974,
        "end_char": 1983,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2008,
        "end_char": 2011,
        "color": "red"
      },
      {
        "text": "gut-derived ammonia",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2349,
        "end_char": 2368,
        "color": "blue"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2581,
        "end_char": 2590,
        "color": "purple"
      },
      {
        "text": "patients",
        "label": "ORGANISM",
        "start_char": 2682,
        "end_char": 2690,
        "color": "orange"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2734,
        "end_char": 2737,
        "color": "red"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 2833,
        "end_char": 2842,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2890,
        "end_char": 2893,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2929,
        "end_char": 2932,
        "color": "red"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 2989,
        "end_char": 2992,
        "color": "red"
      },
      {
        "text": "gut-brain",
        "label": "GENE_OR_GENE_PRODUCT",
        "start_char": 3095,
        "end_char": 3104,
        "color": "green"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3182,
        "end_char": 3191,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3391,
        "end_char": 3400,
        "color": "purple"
      },
      {
        "text": "Rifaximin",
        "label": "SIMPLE_CHEMICAL",
        "start_char": 3626,
        "end_char": 3635,
        "color": "purple"
      },
      {
        "text": "gut",
        "label": "ORGANISM_SUBDIVISION",
        "start_char": 3759,
        "end_char": 3762,
        "color": "red"
      }
    ]
  }
}